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STRUCTURE AND OBJECTIVES 
The aim of this work was to develop one-step procedures to identify and quantify the low 
molecular weight compound and drug of abuse gamma-hydroxybutyric acid (GHB) in various 
biological matrices using gas chromatography coupled to mass spectrometry (GC-MS). Since GHB 
requires derivatization prior to GC-MS, we aimed to minimize the resulting work-load by 
introducing direct derivatization procedures.  
The first chapter of PART I, Chapter I.A, gives a brief general overview concerning GHB. Its 
chemical properties, metabolization, use, abuse, effects, adverse effects and current legal status 
are discussed. Chapter I.B provides a detailed overview of state-of-the-art techniques used for 
GHB determination in biofluids.  
The second part (PART II) of this thesis describes the development of a GC-MS method for the 
determination of GHB in dried blood spots (DBS) using “on spot” derivatization. Although GHB is 
clinically used for treating narcolepsy associated with cataplexy (Xyrem®), it is especially notorious 
for its abuse as a club and date-rape drug. Given its rapid metabolism, its endogenous presence 
and the possibility of ex vivo formation, proving GHB misuse remains a challenge. The use of dried 
blood spots (DBS) may represent a new, minimally invasive way of sampling and storing blood 
from patients, abusers or victims. Amongst the advantages of DBS are the ease of sample handling 
and stabilization of many compounds, thereby improving long-term storage of samples. The latter 
is of interest for GHB since de novo formation of GHB in whole blood samples has been reported. 
First, an overview of the use of DBS in toxicology is given, with a focus on the determination of 
drugs of abuse (Chapter II.A). Derivatization procedures applied in DBS analysis are reviewed in 
Chapter II.B. In Chapter II.C, the determination of GHB in DBS using “on spot” derivatization and 
GC-MS is presented. First, the optimization of the GC-MS method is presented (II.C.1). Next, the 
development of a procedure for the determination of GHB in 50 µl-DBS is described. The complete 
DBS was excised for analysis, a useful approach in cases where a fixed sample volume can be easily 
spotted on a DBS card using capillary pipettes (II.C.2). Results indicated the applicability of the DBS 
method in routine toxicological analysis. However, as we also wished to collect capillary DBS from 
patients in a real-life setting, a more convenient approach was the direct collection of drops of 
capillary blood on a DBS card followed by punching out a fixed area (a 6-mm diameter punch). 
Therefore, the original method was adjusted since no longer a fixed volume, but a fixed area was 
analyzed (II.C.3). Not only the sample preparation steps were re-evaluated, but also the impact of 
additional parameters needed to be evaluated such as the influence of hematocrit, of the blood 
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spot volume and of punch localization on the measured concentration. Finally, following 
validation, the applicability of the DBS method was demonstrated by analyzing venous whole 
blood, venous DBS and capillary DBS collected simultaneously from suspected GHB-intoxicated 
patients and by comparing the obtained GHB concentrations. Furthermore, a proof-of-concept 
study was performed to evaluate the feasibility of DBS sampling in a real-life setting. Therefore, 
narcoleptic patients who used Xyrem® (sodium oxybate, the sodium salt of GHB) on a regular basis 
at night-time, were asked to collect capillary DBS during a maximum of 7 consecutive days. Results 
of this study are presented in II.C.4.   
A third part of this work (PART III) deals with the use of headspace-trap (HS-trap) as injection 
technique for the GC-MS-based determination of GHB in various biofluids following “in-vial” 
derivatization. Similar to “on spot” derivatization, “in-vial” derivatization implies the direct 
addition of derivatization reagents to the biological matrix, here a small volume (100 µl) of 
biofluid, rather than a DBS. Combining “in-vial” derivatization with HS may lead to an extension of 
the application range of the HS technique to non-volatile compounds. In addition, the use of a trap 
enables the sampling of a larger HS fraction as compared to other available techniques, allowing 
small sample volumes to be analyzed, while still providing enough sensitivity. An overview of HS 
techniques with a focus on HS-trap and its applications found in literature is given in Chapter III.A. 
Method development, including the choice of a suitable derivatization reagent and the 
optimization of HS and trap parameters, is subsequently presented in Chapter III.B. This chapter 
also contains validation data and method application involving the analysis of samples from 
suspected GHB-intoxicated patients.  
A general conclusion with future perspectives is given in the final part (PART IV). 
 
 
 
 
 
PART I 
GAMMA-HYDROXYBUTYRIC ACID  
 
In Chapter I.A, a brief general introduction on gamma-
hydroxybutyric acid (GHB) is given, starting with its chemical 
and pharmacokinetic properties, as well as a brief description of 
its precursors gamma-butyrolactone (GBL) and 1,4-butanediol 
(1,4-BD). Furthermore, its general use/abuse and the 
effects/adverse effects of a GHB intake are described, together 
with a description of the onset of a GHB intoxication and the 
current legislation. A detailed overview of state-of-the-art 
techniques published since the nineties to determine GHB in 
various biological fluids is presented in Chapter I.B, where both 
screening and confirmation methods are summarized.  
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I.A.1 FOREWORD 
Gamma-hydroxybutyric acid (GHB) or 4-hydroxybutanoic acid, a short chain fatty acid (pKa 4.6-4.8) 
with two polar substituent groups (hydroxyl- and carboxylgroup), was synthesized in the early 
sixties as a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) that 
could cross the blood-brain barrier [1,2]. GHB was also found to be endogenously present in 
humans as a minor precursor and metabolite of GABA. Its role as endogenous compound remains 
unclear; it probably acts as neuromodulator or neurotransmitter through GABAb receptors and 
GHB specific receptors in the brain [3]. GHB can also be formed in humans from the precursors 
gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) (Fig. I.A.1) [4,5]. 
 
 
                                                    
Fig. I.A.1 Structures of GHB (a), GBL (b) GABA (c) and 1,4-BD (d) 
 
 
Although GHB is clinically used for e.g. treating narcolepsy associated with cataplexy (Xyrem®), it is 
especially notorious for its abuse as a club and date-rape drug. GHB and its precursors are often 
misused in combination with other drugs such as alcohol, cannabis and other club drugs such as 
3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy) and ketamine [5]. The range 
between oral ingestion of high recreational doses leading to desired effects and an overdose is 
narrow, quite commonly resulting in acute intoxications in humans [5]. 
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I.A.2 PHARMACOKINETIC PROPERTIES AND PRECURSORS 
As shown in Fig. I.A.2 -which gives an overview of the metabolization pathways of GHB- GBL, easily 
available as an industrial solvent, is rapidly converted to GHB via serum lactonases following 
ingestion. A half-life (T1/2) of 1 min has been observed in rats [5,6]. Moreover, studies suggest a 
higher Cmax and faster Tmax when an equimolar dose to GHB is ingested [7]. In vitro conversion of 
GBL to GHB has also been observed, an equilibrium influenced by pH and temperature (Fig. I.A.3) 
[8].  
 
Furthermore, 1,4-BD, also used as industrial solvent and during synthesis of other industrial 
chemicals, can also be ingested orally for recreational use because of its in vivo conversion to GHB 
[3,9]. It has been suggested that 1,4-BD is first transformed to gamma-hydroxybutyraldehyde via 
alcohol dehydrogenase, which is next converted to GHB via acetaldehyde dehydrogenase. An 
average elimination T1/2 of 39.3 ± 11 min has been observed in a study giving volunteers 25 mg/kg 
1,4-BD [3,7]. Simultaneous ingestion of ethanol competes with the biotransformation of 1,4-BD, 
thereby slowing down its metabolization and prolonging the effects.  
 
GHB is both a metabolite and precursor of GABA. Via mitochondrial GABA transaminase and 
cytosolic succinic semialdehyde (SSA) reductase GABA can be converted to GHB. In the primary 
pathway of elimination, GHB is converted to SSA via GHB dehydrogenase. Next, SSA is converted to 
GABA or it may enter the Krebs cycle through the formation of succinate. A rare inherited 
metabolic disorder, succinic semi-aldehyde dehydrogenase (SSADH) deficiency, is characterized by 
the presence of elevated GHB-concentrations in plasma and urine [4,10]. Alternatively, GHB can be 
oxidized (β-oxidation) to e.g. 3,4-dihydroxybutyrate, which can be further oxidized to acetyl CoA, 
which also enters the Krebs cycle. Since GHB is almost completely converted to H2O, CO2 and 
energy, only 2 to 5 % of a dose is excreted unchanged in urine. No active metabolites have been 
identified. Recently, a new metabolite of GHB, GHB-glucuronide, has been reported to be present 
in urine samples [4,11,12].  
 
Following oral ingestion, GHB has a short T1/2 ranging from 30 min to less than 1 h, consistent with 
rapid gastro-intestinal absorption and elimination from the body. Depending on the dose, 
elimination mechanisms may be saturated, influencing the T1/2. Less than 1 % is bound to plasma 
proteins [3,5,13]. 
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Fig.I.A.2 Overview of the metabolization pathway of GHB 
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Fig. I.A.3 Interconversion of GHB and GBL in vitro 
 
 
I.A.3 USE, ABUSE AND INTOXICATION 
The sodium salt of GHB, sodium oxybate, has been used therapeutically as an anaesthetic, but this 
use has been abandoned in most countries because of side effects such as seizures and amnesia 
[14]. Furthermore, GHB/GBL containing supplements were sold to increase body muscles - since it 
is assumed that GHB stimulates growth-hormone release - and to improve sleep, but these 
supplements have been withdrawn from the market since the late nineties after reports of abuse 
and side effects. Nonetheless, sodium oxybate is currently being used in the treatment of 
narcolepsy with cataplexy and excessive daytime sleepiness (Xyrem®) and of alcohol (Alcover®, 
Italy) as well as opiate withdrawal [15].  
 
In addition, illegal GHB and its precursors, GBL and 1,4-BD, have become popular amongst 
clubbers because of their stimulating effects. The club drug is known under street names such as 
liquid ecstasy, Georgia Home Boy, Grievous Bodily Harm, soap, scoop and salty water [6]. GHB and 
its precursors are most commonly available as solutions, in small vials or mixed in bottles with e.g. 
water, from which typically a capful is ingested orally per dose [4]. GHB abuse has also been 
reported in drug facilitated sexual assaults (DFSA), because of its strong sedative and amnesic 
effects. The possibility to render a victim unconscious is enabled by the chemical properties of 
GHB, being a colourless liquid which can be easily mixed with other liquids [16,17].  
 
A dose typically ingested for abuse ranges from 2 to 6 g GHB, corresponding to 25 to 75 mg/ kg 
body weight (b.w.) [5]. Euphoria, relaxation, increased sociability, and decreased psychomotor 
skills are amongst the effects experienced when using GHB, showing similarity with the effects 
reported for moderate alcohol intoxication [5]. More in particular, effects reported following 
recreational use of GHB and its precursors are dual, i.e. both sedative and stimulatory, depending 
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on the dose. An individual dose of 1.0 to 2.0 g that is ingested orally results in effects like 
relaxation and euphoria, while doses of 2.5 to 3.0 g lead to side-effects such as nausea and 
vomiting (mild intoxication, see below). Higher doses (3.0 to 4.0 g) result in loss of consciousness, a 
dose of more than 4 g resulting in respiratory depression and coma (severe acute intoxication, see 
below) [18]. 
 
GHB has a steep dose-response curve, with a narrow margin between therapeutic or desired and 
toxic effects [5,19,20]. A mild intoxication is characterized by nausea, dizziness and difficulty in 
focussing the eyes, while vomiting, extreme dizziness, disorientation, amnesia and 
unconsciousness may be experienced from an severe acute intoxication [5]. Finally, side effects of 
a severe intoxication may evolve to convulsions, coma, and death. Fatal incidents have been 
reported due to the use of GHB alone or in combination with other drugs such as alcohol and 
MDMA [19]. 
 
First reports of abuse appeared in the early 1990s [20,21]. Since the late 1990s, early 2000s, the 
incidence of GHB intoxications has apparently been decreasing worldwide. For example, when 
evaluating GHB exposures reported to the California Poison Control System from 1999 to 2003, a 
decrease has been recorded, which can reflect the true incidence, but may also be due to a 
decrease in adverse events without a decrease in overall GHB usage or to random variability [21]. 
According to the annual reports of the latest drug situation and trends in the European Union and 
Norway, published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
national estimates of the prevalence of GHB -where they exist- remain low. For example, in the 
UK, 2 % of regular clubbers reported last year use of GHB in an Internet survey [22]. Furthermore, 
GHB screening using automated clinical analyzers has not been routinely available until 2009. In 
addition, due to the rapid elimination of GHB from the human body, delayed sampling may result 
in GHB concentrations below the current cut-off values, thus no longer allowing proof of ingestion 
[23]. Therefore, true case incidence may be underestimated [5]. Moreover, more recent reports 
show that recreational use with limited awareness of the possibility to suddenly fall into a coma 
has resulted again in an increase in GHB intoxications at raves or other dance parties [19,24].  
 
So, although the available epidemiological data has its limitations, general use may be relatively 
low compared to other drugs of abuse such as cannabis, amphetamines and cocaine, while a 
higher use has been seen in subpopulations (e.g. men having sex with men), settings and 
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geographical areas [25,26]. Of all commonly used illegal drugs in the Flemish nightlife across four 
survey years from 2003 to 2009, GHB was with only 3.0 % prevalence one of the least commonly 
used drugs, along with ketamine (1.9 %) (Fig. I.A.4). Nonetheless, over this four survey years of a 
survey set up to explore changes in illicit drug use among music festival goers and dance scene 
attendees in Flanders, an increase in the use of GHB has been detected [27]. It is therefore 
recommended to closely monitor the use of GHB, given its potential for overdose, which in 
addition occurs more frequently than for any other club drug, especially when combined with 
alcohol [27-30]. Also, European surveys between 2008 and 2010 estimated a 3.9 to 14.3 % lifetime 
use and last month prevalence use up to 4.3 %, while in The Netherlands a survey among 
partygoers in 2008 and 2009 revealed a 14 % lifetime and 5 % recent use of GHB [29,31,32]. In 
Australia, lifetime use of GHB is reported to be 1 % of people aged 14 years and older [30].  
            
 
Fig.I.A.4 Last-year drug use over 4 survey years from 2003 to 2009 from a survey administered to explore 
changes in illicit drug use among music festival goers and dance scene attendees in Flanders. Every 2 years, a 
sample of party people was selected at 3 clubs, 2 dance events and 2 rock festivals, resulting in a total of 2812 
respondents filling out a self-report questionnaire (Figure taken from Van havere et al.; 2012, [27]). 
 
 
One should consider the possibility of a GHB-intoxication in the case of unexplained coma in the 
absence of a head injury or elevated head pressure. Treatment of GHB overdose is primarily 
supportive, focussing on preservation of respiratory status, with no known antidote available. 
Gastric lavage and induction of emesis are contra-indicated since GHB may cause a rapid loss of 
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consciousness [4]. Also activated charcoal is not recommended to treat GHB intoxication because 
of the extensive metabolism with a rapid absorption of GHB and because intubation is often 
required, possibly contributing to aspiration risk [1]. Benzodiazepines can be used to treat seizures, 
while atropine can be given to manage symptomatic bradycardia [4]. Complete recovery has 
mostly been observed after 6 - 8 h, with a typical abrupt awakening of the patient [33].  
 
Furthermore, frequent ingestion (every 1 to 3 h, around-the-clock) has been shown to cause long-
term problems, including dependence and severe withdrawal symptoms after abrupt 
discontinuation of the use of GHB or its analogues [29]. The development of chronic dependence is 
typically seen following GHB use during minimum 2 to 3 months, with a usage of more than 3 to 4 
times per day. After discontinuation, withdrawal has been seen with clinical features similar to 
those seen with ethanol and/or benzodiazepine withdrawal. Most commonly observed withdrawal 
symptoms include agitation, anxiety, tachycardia, hypertension and delirium. These symptoms 
begin 1 to 6 h after the last dose, can be very severe within the first day and could last for 5 to 15 
days [7,34,35].  Also a prolonged withdrawal state has been reported, lasting 3 to 6 months and 
characterized by e.g. memory loss and insomnia [36]. Wood et al. (2011) recommend to initially 
manage withdrawal patients with benzodiazepines, ideally administered prior to the development 
of the withdrawal symptoms. Second-line management options are baclofen and barbiturates [7].  
 
I.A.4 LEGISLATION  
Since the late 1990s, the Food and Drug Administration (FDA) banned all non-prescription sales of 
GHB and illicit GHB is since 2000 a Schedule I agent (Controlled Substances Act) in the US. The FDA 
has approved in 2002 the use of sodium oxybate for the treatment of narcolepsy with cataplexy 
(Xyrem®), so it has become available on prescription as a Schedule III agent. Also, in 2005, the 
European Medicines Agency (EMA) approved sodium oxybate for the treatment of narcolepsy with 
cataplexy. On the other hand, GBL is a List I controlled chemical, used for the manufacture of a 
controlled substance -GHB-, making its possession, manufacturing, or selling with the intention for 
ingestion illegal. The latter also applies to gamma-valerolactone (GVL) and 1,4-BD. So, the 
congeners of GHB are easily and moreover legally available on e.g. the internet, as long as the use 
is not intended for ingestion [4,21]. In Belgium, the possession, buying and selling of GHB is illegal 
since 1998, when it became listed as a psychotropic substance [37].  
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I.B.1 INTRODUCTION  
Various bioanalytical methods for GHB determination have been reported since the early 1970s [1-
4]. This review will focus primarily on those methods published since the 1990s, when there was 
an emerging need for analytical methods to measure GHB in biological fluids as part of 
toxicological investigations, given the first reports of GHB abuse appearing in the US [5]. Also 
trends, advantages and disadvantages of sample preparation and analytical techniques are 
discussed. First, according to the generally applied strategy in toxicology, the so-called systematic 
toxicological analysis (STA), screening techniques including e.g. colorimetric and enzymatic tests 
will be discussed. These differentiate between (presumably) positive and negative GHB samples. 
Positive GHB results are then confirmed using a second, independent method, mostly involving 
quantitation [6]. This has been achieved mostly by gas chromatography (GC), although also liquid 
chromatography (LC) and capillary zone electrophoresis (CZE) have been applied. 
 
I.B.2 ANALYTES OF INTEREST 
Although in a toxicological context it might be relevant to determine whether GHB positivity is the 
result of the intake of GHB, GBL or 1,4-BD, GHB remains the most important analyte to search for 
in biological fluids, owing to the fast in vivo biotransformation of its precursors [7,8]. Also in 
fatalities involving consumption of large amounts of these precursors, high GHB and only low GBL 
and 1,4-BD levels have been observed [9]. Other compounds that might be of interest to 
determine simultaneously (in the same run) are the positional isomers and isobaric compounds 
alpha- and beta-hydroxybutyric acid (AHB, BHB) (diabetic and post-mortem cases) [10-13], glycols 
(in emergency cases with coma of unknown origin when ingestion of GHB or ethyleneglycol is 
suspected, the latter also causing high anion gap metabolic acidosis) [13-15] and other club drugs  
such as MDMA or ketamine [16], as well as gamma-hydroxyvaleric acid (GHV) or its lactone, GVL 
(reported to be a GHB alternative) [9,17].  
 
It needs to be kept in mind that a quantitative result may be influenced by the in vitro 
interconversion of GHB and GBL in aqueous matrices, the equilibrium depending on pH and 
temperature [18]. Therefore, several methods have evaluated the rate of GHB/GBL conversion 
during sample treatment or analysis, with different outcomes. Overall, three scenarios have been 
described. First, conversion was complete in one direction and was used for GHB determination 
[e.g. 19-21]; secondly, conversion did not occur, so absolute GHB was measured [e.g. 13,14,22]; 
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lastly, conversion occurred but was minimal, with little or no relevance in the forensic or clinical 
setting [e.g. 23,24]. Therefore, the method of analysis needs to be considered when comparing 
existing data from e.g. post-mortem analyses. In methods involving conversion to GBL, slightly 
higher GHB concentrations may be observed (measured as total GBL) than in methods determining 
absolute GHB. This may be due to the conversion of a proportion of the (endogenous) GHB present 
in a post-mortem plasma or urine sample to GBL during storage, depending on sample pH [25,26]. 
Furthermore, if GHB is determined as GBL, samples can be analyzed in duplicate, one with and one 
without acidic treatment to convert GHB to GBL [e.g. 19]. Similarly, total GHB (GHB+GBL) can be 
determined, if actual GBL is converted completely to GHB before analysis [20,21]. 
 
I.B.3 GHB CONCENTRATIONS & BIOLOGICAL MATRICES OF INTEREST 
As mentioned above, the natural presence of GHB results in measurable baseline levels in various 
biological matrices. Studies have been conducted in e.g. urine [e.g. 26-30], plasma [e.g. 29], serum 
[e.g. 30] whole blood [e.g. 10,28,29] and oral fluid [e.g. 31] samples obtained from healthy non-
users. Also data from non-GHB related fatalities [e.g. 25,32], together with concentrations arising 
from exogenous administration have been collected. Ingestion can be intentional - for recreational 
use - or accidental, which both may lead to overdoses or even fatalities, illustrated by several case 
reports [e.g. 33-36].  Physiological concentrations of GHB, situated in the low and sub-microgram-
per-milliliter range, are mostly well below concentrations found in intoxicated patients, where a 
narrow range exists between recreational doses and overdoses. An overlap between highly toxic 
and lethal concentrations has been observed, demonstrating high inter-individual variability 
between measured GHB concentration and effect [37,38]. According to the list of therapeutic and 
toxic concentrations from The International Association of Forensic Toxicologists (TIAFT), a value 
above 280 µg/ml of GHB in plasma may be sufficient to cause death [39]. In addition, in-vitro 
production during storage, especially in post-mortem blood samples, has been reported, further 
complicating the interpretation of a GHB concentration. Therefore, an appropriate storage of 
samples until analysis is required (recommendation: - 20 °C) [37,38]. For more detailed 
information concerning GHB production in post-mortem cases, we refer the interested reader to 
existing literature [25,32,40,41]. 
 
To differentiate between endo- and exogenous concentrations [29], cut-off levels have been 
established. Most authors agree on a 10 µg/ml cut-off level for GHB in ante-mortem urine 
[28,29,42], although suggestions of 5 [43] or 6 [30] µg/ml have been made as well. For ante-
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mortem whole blood, 10 [22,29], 5 [28] or 4 [30] µg/ml has been proposed as a cut-off, while one 
group even proposes 1 µg/ml, if appropriate storage is guaranteed [10]. This implies that screening 
and confirmation methods for GHB in ante-mortem urine, whole blood and plasma preferably 
have a a decision limit or lower limit of quantification (LLOQ) below or equal to 4 or 5 µg/ml. 
Higher cut-off levels have been proposed for post-mortem matrices (20 and 30 for urine, 50 for 
whole blood and 12 µg/ml for vitreous humour) to exclude false positives [15,22,32]. For following 
up GHB concentrations in Xyrem® patients, a wide concentration range may be necessary, 
depending on the timing of sampling (shortly after intake vs. several hours later) [44]. Endogenous 
presence of GHB in various biological matrices not only renders true blank matrices unavailable for 
conducting method validation experiments, it also precludes the use of low calibrators (< 1 µg/ml) 
prepared in authentic matrices [11], and complicates the interpretation of a positive result. 
 
As an alternative to the use of interpretative cut-off concentrations, continuous-flow GC-
combustion-isotopic ratio MS has been used to discriminate between exogenous (i.e. synthetic) 
and endogenous GHB in blood samples. First findings suggest differences in the 
13
C and 
12
C content 
of the endogenous and synthetic form of GHB [45]. However, it is obvious that the cost and 
complexity associated with this high-end technique strongly limits its general applicability. 
 
In addition to the endogenous presence and possible instability during storage, samples must be 
collected as soon as possible after ingestion, due to extensive metabolism of GHB once ingested 
orally (plasma T1/2 less than 1 h) [46-48]. Otherwise, the GHB level will drop in blood and urine to 
endogenous concentrations within 6 to 12 h following intake, no longer allowing to prove intake of 
GHB, possibly leading to an underestimation of the total number of positive cases [22]. Therefore, 
alternative sampling strategies and alternative matrices have been evaluated. These include dried 
blood spots (DBS), i.e. capillary whole blood obtained by fingerprick, facilitating sample collection, 
as well as non-conventional matrices such as sweat and oral fluid. Only moderate results have 
been obtained in the latter two matrices since diffusion of the acidic drug in these has been shown 
to be limited. Following GHB intake (50 mg/kg sodium GHB, n=5), only 1/4 to 1/3 of the 
concentration found in plasma was measured in oral fluid, with an even quicker return to baseline 
values and high oral fluid/plasma inter-variability, while in sweat, GHB concentrations were only 
slightly higher than baseline values [24,48-52]. On the other hand, hair analysis has been shown 
useful to extend the window of detection, because of incorporation of GHB in the hair matrix. A 
case report has described detection even after a single use in a case of DFSA [53]. Also in hair, 
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endogenous GHB is present, often rendering it difficult to draw straightforward conclusions [54].  
Therefore, small segments are analyzed to detect an elevation of the baseline GHB concentration 
owing to exogenous ingestion [54,55].  
 
More than 95 % of an oral dose of GHB is converted to CO2 and H20 as it enters the Krebs cycle via 
succinate, with less than 5 % being excreted ‘unchanged’ in urine [46]. Until recently, no specific 
metabolites of GHB were known. However, Petersen et al. (2013) [56] demonstrated the existence 
of a new metabolite, GHB-glucuronide, in urine, in concentrations ranging from 0.11 to 5.0 µg/ml. 
Although more research such as pharmacokinetic studies following GHB administration are 
required, this compound is theoretically a biomarker of GHB exposure with the potential to extend 
the window of detection in the conventional matrix urine [56].  
 
I.B.4 SCREENING PROCEDURES FOR THE PRESENCE OF GHB IN BIOFLUIDS 
A good screening procedure allows the identification of unknown analytes in a simple, sensitive, 
selective and rapid way, starting from a minimal amount of sample. STA approaches typically 
utilize immuno- and/or enzymatic assays to screen for analytes or categories of compounds, next 
to GC-mass spectrometry (GC-MS) or high performance liquid chromatography- diode array 
detection (HPLC-DAD) for high-throughput screening for simultaneous detection of as many toxic 
compounds as possible. Liquid chromatography-mass spectrometry (LC-MS) or tandem mass 
spectrometry (LC-MS/MS) and high resolution techniques have been used to a lesser extent for 
such comprehensive screening but are becoming of more and more interest nowadays, sometimes 
even replacing the immunological and/or enzymatic tests [6,57,58]. Below, an overview of possible 
screening procedures for GHB is given, starting with colorimetric tests. Given the lack of 
commercially available immunoassays, STA using chemical analyzers did not include GHB until 
2009 [12,22]. Since then, an enzymatic assay adaptable to common analyzers has become 
commercially available (Bühlmann laboratories, Switzerland) [59]. Furthermore, several GC 
methods became available and recently LC-MS/MS-based methods have been reported with the 
focus on high-throughput, so both techniques can therefore also be used as screening tool. A 
screening method preferably has a decision limit (cut-off of the applied assay) at or below the 
exogenous/endogenous cut-off, to allow for a reliable first differentiation between samples 
considered to be GHB-positive or -negative. However, since moderately to severely intoxicated 
GHB patients such as those brought to an emergency department in comatose state will mostly 
display GHB concentrations well above these cut-off levels we also consider in this review methods 
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with decision limits/LLOQs (well) above these cut-offs as screening methods. As with any screening 
test, a positive result should only be considered preliminary and needs to be confirmed using an 
independent, preferentially MS-based, technique such as GC- or LC-MS (/MS).   
 
I.B.4.1 COLORIMETRIC TESTS 
Badcock and Zotti [60] reported a colorimetric test that allows the identification of GHB in human 
urine based on the conversion of GHB to GBL. Briefly, following the addition of concentrated 
sulphuric acid, ammonium sulphate and nitroprusside to 250 µl of urine, an intense and instant 
blue/olive-green colour will appear if GHB is present in the sample [60]. Another colorimetric test, 
a modification of the ferric hydroxamate test for ester detection, only requires 5 min to detect 
GHB in 0.3 to 1 ml urine, the presence of GHB being indicated by purple colouring of the sample 
[61]. Although both colorimetric tests are simple and results can be obtained in less than 10 min, 
the prime disadvantage is the lack of sensitivity, with limits of detection of 100 or even 500 µg/ml 
[60,61].  
 
I.B.4.2 ENZYMATIC ASSAYS 
Enzymatic assays to determine GHB are based on the oxidation of GHB to SSA, a reaction that 
occurs during metabolization in vivo via the enzyme GHB-DH.  
 
I.B.4.2.1 Colorimetric enzymatic assays 
Bravo et al. (2004) [62] developed a solution-endpoint- and a dipstick-assay for the determination 
of GHB in human urine. The identification was possible by coupling the oxidation reaction of GHB, 
via a cloned and isolated GHB-DH, to a reduction reaction of a tetrazolium pro-dye, resulting in the 
formation of a colored product (absorbance at 450 nm). Although these tests are easy to perform, 
providing enough sensitivity remains a critical issue, only ensuring 100 % true positives when a 
minimum of 100 µg/ml of GHB is present in urine. 
   
Another test strip, commercially available by Drugcheck®, can detect GHB in human urine with a 
cut-off level of 10 µg/ml. Results are obtained within 10 min and a colour chart on the test strip 
has to be used for interpretation, next to a test strip for vitamin C, this compound showing cross-
reactivity with the GHB test. Although this GHB test strip is more sensitive, detecting lower GHB 
concentrations, only a preliminary result is provided, without indication of the degree of 
intoxication [63].   
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I.B.4.2.2 Enzymatic kit  
It has become clear from the tests mentioned above that there was an urgent need for a rapid and 
simple screening method to detect GHB in urine and serum samples in a more sensitive and semi-
quantitative way. To this end, an enzymatic kit was commercialized in 2009 [59]. This kit also 
utilizes a recombinant GHB-DH to oxidize GHB to SSA, while the co-factor nicotinamide adenine 
dinucleotide (NAD
+
) is simultaneously reduced to NADH + H
+
, which absorbs at 340 nm. The test is 
adaptable to common clinical chemistry analyzers and requires only 10 µl of sample. 
Quantification is performed using 2 calibrators and 2 quality controls provided by the 
manufacturer, with a working range from 5 to 250 µg/ml. Results are obtained in about 10 minutes 
and interferences as well as cross-reactivities have been evaluated. A 4 % interference of GBL has 
been observed, which is stated to have no relevant implication since GBL is rapidly converted to 
GHB once ingested. Also per 1.06 g/L ethanol, a 3.0 µg/ml linear increase of false-positive GHB 
concentration was observed, so GHB concentrations of 8-20 µg/ml need careful interpretation, 
especially since GHB is commonly ingested with alcoholic beverages. A cut-off level of 10 µg/ml for 
serum and 15 µg/ml for urine has been proposed [64,65].  
 
Grenier et al. (2012) [66] evaluated the use of this enzymatic assay as a screening method in 
forensic matrices including whole blood and vitreous humour. When correlating the results of a 
variety of cases (sexual assaults, impaired drivers and deaths) with a GC-MS reference method, no 
false negatives and few false positives were observed, with post-mortem samples appearing to be 
more prone to testing false positive than ante-mortem samples. Although whole blood required 
protein precipitation with acetonitrile before analysis, analyst time savings can still be substantial 
compared to chromatography-based procedures. In addition, although very efficient GC-MS and 
LC-MS/MS procedures have been developed for GHB, integration with a battery of other tests on 
automated analyzers makes this assay valuable for (clinical) toxicology labs. However, Grenier et al. 
(2012) [66] found that a limitation of this test is that it may not be applicable to alternative 
matrices such as e.g. vitreous humour due to the observed high rate of false positives.  
In summary, this test may be valuable for screening urine and serum samples in an emergency 
setting, for forensic applications and for other screening purposes [65]. 
 
I.B.4.3 OTHER SCREENING TECHNIQUES 
 1
H nuclear magnetic resonance (NMR) spectrometry has been used to detect GHB in urine and 
serum [67], as well as in oral fluid (600 µl) [57]. This technique is non-destructive and has little or 
Chapter I.B Screening and confirmation methods  
 
 
25 
 
no sample preparation requirements, and is therefore less labour-intensive than other techniques. 
Similarly, ion mobility spectrometry (IMS) showed promise as a screening method for GHB and 
related compounds present in urine samples [68]. Via direct injection using a split/splitless 
injection port and thermal desorption, the sample was brought directly into the IMS configuration 
without chromatographic separation, reducing analysis time and resulting in an estimated 
detection limit of 3 µg/ml.  
 
In addition, CZE with indirect ultraviolet (UV) detection is capable of detecting high concentrations 
of GHB in urine samples following a simple 1:4 dilution with water. Calibration curves ranged from 
80 to 1280 µg/ml [69]. For detection, indirect UV absorption using a chromophore in an electrolyte 
solution was necessary because the native molecule GHB has poor UV absorption [70,71]. Small 
adaptations of analytical conditions (co-ion, pH, etc.) further improved method sensitivity and 
selectivity and enabled the analysis of not only urine but also serum samples following 1:8 dilution 
with 3 mM NaOH, completely converting GBL to GHB (calibration curve ranged from 25 to 500 
µg/ml) [72]. Although accurate and precise results may be obtained using CZE, the LLOQ is 
relatively high (ranging from 25 to 80 µg/ml and 5 to 60 µg/ml, dependent on urine density), when 
compared with chromatographic techniques ( LLOQ ranging from 0.1 to 8 µg/ml). Therefore, these 
CZE-based methods are considered to be more suitable as an alternative screening method for a 
GHB overdose, being rapid and simple, rather than as a secondary confirmatory method. 
 
I.B.4.4 CHROMATOGRAPHIC SCREENING TECHNIQUES  
When compared to colorimetric and enzymatic assays, chromatographic assays typically require 
more intensive and time-consuming sample preparation such as derivatization or conversion to 
GBL (see below). For example, Lebeau et al. (2000) [19] opted for a gas chromatography - flame 
ionization detection (GC-FID) screening method using headspace (HS) as injection technique 
following conversion of GHB to GBL, while confirmation of GHB (as GBL) was done by GC-MS. Also, 
in clinical practice, where the aim is to define a medical diagnosis and start a treatment, a non-
specific detection such as GC-FID is sufficient, as stated by Blanchet et al. (2002) [21]. These 
authors determined GHB following derivatization with BF3-butanol.  
 
Similarly, urinary organic acid assays based on silylation and GC-MS, more readily available than 
GHB assays in hospital laboratories, were investigated for their use to detect GHB in urine samples. 
However, if these methods included acidification of the samples during sample treatment, which 
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favours conversion of GHB to GBL, only a small peak of GHB was visible, as can be expected [73]. In 
addition, silylated urea may elute closely to/co-elute with silylated GHB, having in addition similar 
MS properties. Therefore, it may be important to eliminate the urea interference by adding an 
urease treatment step to the sample preparation procedure, enabling the identification of GHB 
with higher confidence [74-76]. 
 
In addition, chromatographic methods used to screen for various compounds including GHB have 
been reported. Rasanen et al. (2010) [77] developed a headspace in-tube extraction GC-MS 
method to screen for hydroxylic methyl-derivatized organic acids, including GHB, in urine and 
extracted whole blood samples. In addition, a GC-MS method for the simultaneous screening in 
urine of 128 date-rape drugs, including GHB, 1,4-BD and GBL (using silylation), has been reported 
by Adamowicz and Kala (2010) [78]. Recently, an LC-MS/MS method has been reported to screen 
for elevated GHB concentrations in DBS obtained from newborns, to diagnose SSADH deficiency, a 
rare inherited metabolic disorder where GHB concentrations are increased because of a deficiency 
of the succinic semi-aldehyde dehydrogenase enzyme, responsible for conversion of SSA to 
succinate [50]. Although not intended for toxicology purposes, this methodology may also be 
applicable to screen DBS for exogenous GHB [79,80].  
 
Next to these screening methods, several authors have reported simplified and rapid procedures 
to determine GHB with high-throughput, leading to the possibility of using actual confirmation 
methods also as a screening tool. Here, we mention only examples of these methods in which 
sample preparation is reduced or minimal. Details can be found in the next section and in Table 
I.B.1. For example, Van hee et al. (2004) [14] determined GHB (and glycols) in low volume plasma 
and urine samples (20 µl) using GC-MS, by adding an excess silylation reagent directly to the 
biological sample. This procedure was recently modified by Meyer et al. (2010) [13], utilizing 
micro-wave assisted derivatization, another approach particularly useful in hospital laboratories of 
emergency departments, as quantitative results for urine samples can be obtained within 30 min 
using one-point calibration. Other examples of procedures with minimal hands-on time are those 
where derivatization reagents are applied directly “on spot”(in the case of DBS) or “in-vial” (in the 
case of HS-sampling) [20,24,49]. More recently, a multi-analyte ultra high performance LC-MS/MS 
(UHPLC-MS/MS) method has been reported, which may also be useful as a screening tool because 
of the easy sample preparation and resulting high-throughput [81].  
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I.B.5 CONFIRMATION METHODS FOR CLINICAL AND FORENSIC CASES 
Methods suitable for the confirmation of a presumed GHB-positive sample have preferably a LLOQ 
below or at the proposed cut-off level, should be selective for GHB and if they deliver quantitative 
results, these should be reliable and accurate. Since it may be necessary to confirm the presence 
of GHB in more complex biological matrices and because more sophisticated chromatographic 
techniques are used, sample preparation becomes more important. Sample work-up is usually 
more complicated than that used for colorimetric or enzymatic methods, which are primarily 
suited for urine and serum. Below, an overview of commonly used sample preparation procedures 
is given, followed by an overview of the used analytical techniques to separate and detect GHB 
(and analogues). Table I.B.1 provides an overview of the different published procedures (at the 
end of this chapter). To evaluate if a given method allows differentiation between exo- and 
endogenous GHB, the calibration range with the quantification limit is included. Also the choice of 
internal standard may influence the data quality and has therefore also been mentioned in the 
table [82]. As shown in the table, several compounds showing similarity with GHB have been used 
as internal standard. In MS-based methods, the use of a deuterated internal standard is 
recommended to compensate for variations during sample preparation, as well as during analysis. 
The deuterated form of GHB, GHB-d6, has been used widely for this purpose; a C-labelled internal 
standard is not commercially available (yet). 
 
I.B.5.1 SAMPLE PREPARATION 
The following techniques have been applied to treat biofluids, either alone but mostly combined: 
dilution, filtration, deproteinization, chemical modification, liquid-liquid extraction (LLE), solid-
phase extraction (SPE), and HS extraction. These sample preparation procedures are often 
regarded as time-consuming and there has been a tendency to reduce manual sample handling by 
introducing new, fully automated techniques. It should be mentioned that the latter implies longer 
method development times and new skill requirements and may not always be implementable in 
smaller laboratories [83]. Furthermore, starting from the more traditional procedures, simplified 
extractionless procedures have been proposed such as dilution and direct derivatization (“on spot” 
and “in-vial”), together with micro-wave assisted derivatization and on-line derivatization 
techniques such as injection port derivatization. Some of these simplifications have been made 
possible due to improved separation and detection techniques such as tandem MS, resulting in 
procedures with minimal hands-on time. In addition, initial sample volume required for analysis 
may be reduced without loss of method sensitivity.  
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I.B.5.1.1 Dilution and filtration of the biological fluid 
Using appropriate separation and detection techniques, simple dilution of urine and serum 
samples, with or without subsequent filtration, may be sufficient as sample preparation [12,81,84]. 
This has been demonstrated by several LC-MS/MS methods, capable of quantifying GHB with 
sufficient sensitivity in these matrices. In addition, possible extraction difficulties arising from the 
hydrophilic nature of GHB are avoided. For example, urine has been diluted 1:20 [12] and 1:1 [81] 
with water, and 1:10 with acidic 10 % MeOH [84] prior to LC-MS/MS analysis. Alternatively, urine 
and serum samples have been diluted 1:4 with a buffer solution prior to CZE analysis with 
contactless conductivity detection (CZE-C
4
D) [85].  
 
Important to note is that sufficient sensitivity has been obtained, as illustrated by Wood et al. 
(2004) [12], who compared method sensitivity (reflected in signal-to-noise (S/N)) of two sample 
pretreatment procedures prior to LC-MS/MS analysis. The first of these procedures consisted of a 
1:20 dilution of urine samples (with deionised water containing internal standard); the second 
sample clean-up was based on a more time-demanding SPE extraction (OASIS® cartridges). 
Although an approximately 2-fold increase in sensitivity was observed when using the SPE 
cartridges, the authors were still able to use the simpler dilution method as it readily enabled 
measurement of endogenous GHB levels. 
 
Although this dilute-and-shoot approach is simple and convenient, with minimal hands-on time, 
assessment of matrix effects is strongly advised, as in any LC-MS/MS-based procedure, because 
matrix components may strongly influence the ionization of GHB in the MS source. To compensate 
for any effect owing to the matrix, a stable isotopically-labelled internal standard should be 
included in the procedure [12]. Assuming a similar degree of alteration of the response of this 
internal standard, matrix effects can be compensated for.  
 
In addition, samples have been diluted to reduce the influence of the original matrix during sample 
treatment and analysis. For example, the effect of the matrix during solid-phase micro-extraction 
(SPME) may be reduced by diluting the original sample [16,86]. Similarly, samples were diluted 
with water before LLE [87,88] or SPE [81,89-91]. For example, Elian et al. (2011) [89] assumed that 
a 50-µl sample and synthetic urine, consisting of inorganic salts and proteins in an aqueous 
medium, would act in a similar way as 50-µl deionized water, if these were all diluted in 4 ml of 
Chapter I.B Screening and confirmation methods  
 
 
29 
 
water prior to SPE. As a consequence, calibrators and controls could be prepared in water instead 
of blank matrix, which is especially of interest for GHB, endogenously present in human samples.  
 
I.B.5.1.2 Deproteinization of the biological fluid 
For compounds with low protein binding such as GHB, protein precipitation is an adequate and 
easy technique to remove a variety of interferences present in blood and plasma, such as blood 
cells, proteins and lipids prior to analysis [10,81]. To illustrate, Shima et al. (2005) [10] compared 
protein precipitation with various SPE and LLE techniques to clean up urine samples, and found 
that protein precipitation led to the highest GHB recovery and cleanest chromatograms. Generally, 
there are 4 protein precipitation techniques: organic solvents, acids, salts and metal ions [92]. To 
our knowledge, for GHB analysis, only the first 3 have been applied.  
 
As organic solvent, acetonitrile [e.g. 13,15,22,93,94-96], methanol (MeOH) [10,97] or a 
combination of both (ice-cold acetonitrile:MeOH 85:15 v:v [81,91]) and acetone [9,98] have been 
used. Also water:MeOH (3:97, v:v) has been used [99]. Placing samples in a freezer for at least 10 
min before centrifugation may help to obtain complete precipitation [81].  
 
Organic solvents and acids have also been used simultaneously to improve protein precipitation 
and GHB recovery. For example, the addition of sulphuric acid during protein precipitation using 
acetonitrile was found to increase the recovery of GHB from 50 to 90 % [11,46,48]. Similarly, 
acidified methanol has been used for whole blood protein precipitation [84].  
 
Cold perchloric acid [5,7,34] has been added alone to plasma samples, thereby combining 
deproteinization and lactone-formation (see below). Finally, anhydrous sodium sulphate (Na2SO4) 
has been added to biological fluids prior to HS-trap analysis for protein precipitation and for 
salting-out purposes [20].  
 
Similar to the above mentioned dilute-and-shoot approach, it is important to evaluate matrix 
effects, particularly when protein precipitation is (almost) the only sample preparation technique 
prior to LC -MS/MS analysis. For example, when blood or serum samples were subjected to protein 
precipitation, with subsequent centrifugation and 1:1 dilution of the supernatant with acidified 
water prior to LC-MS/MS analysis, about 40 % suppression of the GHB signal was observed. Again, 
the use of a deuterated internal standard such as GHB-d6 is emphasized, since it is able to 
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compensate for the matrix effect [84]. To our knowledge, only three sample preparation 
procedures merely consist of protein precipitation prior to LC-MS/MS injection, with only two 
evaluating matrix effects [95,96,99]. For example, one procedure that did evaluate matrix effects 
saw a 16 to 27 % enhancement of GHB ionization which was compensated for by the use of GHB-
d6 [99].  
 
I.B.5.1.3 Chemical modification of GHB 
Because GHB is a polar (sometimes anionic) molecule, with lactone-formation seen at high 
injector-port temperatures or induced chemically (at low pH), chemical modification prior to GC is 
necessary for reliable quantification [57,100]. For GC analysis, two major strategies have been 
applied: either lactone-formation through the addition of acid, or derivatization using various 
derivatization reagents. Formation of a derivative prior to LC analysis and detection has proven to 
be useful as well; however, it has been applied to a lesser extent when compared to its use in GC-
based applications. Both strategies – lactone formation and derivatization – may improve 
extraction properties of GHB and/or chromatographic analysis, as discussed more into detail below. 
Fig. I.B.1 gives a schematic overview of possible derivatization procedures, with resulting 
derivatives of GHB, using common derivatization reagents. 
 
I.B.5.1.3.1 Chemical modification to improve extraction 
GHB undergoes intra-molecular esterification within minutes in acidic environment [18] and the 
GBL formed is more easily extracted from biological matrices than GHB. Lactone-formation has 
been accomplished by the addition of 6 N hydrochloric acid (urine samples [5,7]; [101]), 
concentrated sulphuric acid [19,102], 20 % trifluoroacetic acid [103] or 1.6 or 0.8 N perchloric acid 
(plasma [5,7,34]) to plasma, urine or oral fluid samples. By adding perchloric acid to plasma 
samples, lactone-formation and deproteinization were performed in a single step. Subsequently, 
the acidified sample or the supernatant following centrifugation [5,7,34] were placed at room 
temperature [101,102] for 5 min [19], at 80 °C for 20 min [5,7] or at 75 °C for 1 h [103] to allow for 
complete conversion. As a consequence, differentiation between the initial GBL present in the 
sample and the GBL formed as a result of the acid-induced cyclization of GHB is no longer possible 
[87], unless two aliquots of the same sample are analyzed, one with and one without acid 
treatment [7,19].  
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In addition, derivatization reagents suitable for “in-situ” or “in-vial” derivatization can be added 
directly to the sample matrix, thereby allowing the samples to be analyzed by solid-phase micro 
extraction (SPME) or HS-based extraction (and injection) techniques by forming a more volatile 
derivative of GHB. Hexylchloroformate, in the presence of the catalyst pyridine, has been used to 
derivatize the carboxylic group of GHB [16,86], while dimethylsulphate (DMS) in alkaline medium 
has been utilized to modify both functional groups [20].  
 
Br-MMC: 4-bromomethyl-7-methoxy coumarin; BSTFA: N,O-bis(trimethylsilyl)trifluoroacetamide; HFB-OH: 
heptafluorobutanol; MSTFA: N-methyl-N-(trimethylsilyl)-trifluoroacetamide; MTBSTFA: N-(tert-butyldimethylsilyl)-N-
methyl-trifluoroacetamide; TFAA: trifluoroacetic acid anhydride  
 
Fig. I.B.1 Overview of the applied derivatization procedures for GHB determination 
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To overcome the difficulties seen when extracting the hydrophilic and small analyte GHB in those 
methods requiring derivatization, extractionless derivatization procedures have been reported. In 
addition, sample preparation time, as well as organic solvent waste is reduced. Van hee et al. 
(2004) [14] were the first to report on an extractionless sample preparation, based on the direct 
derivatization of GHB in biofluids with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA). The 
addition of excess derivatization reagent to a 20 µl sample of biofluid (serum, plasma, urine) 
resulted in a simple and fast method with sufficient sensitivity for routine toxicological analysis. 
Similarly, starting from 1 µl oral fluid, an extractionless procedure with direct derivatization has 
been reported, allowing determination of exogenous GHB concentrations [51]. Furthermore, GHB 
has been derivatized directly (“on spot”) in DBS with a mixture of trifluoroacetic acid (TFAA) and 
heptafluorobutanol (HFB-OH), thereby omitting the extraction step [24,49]. 
 
I.B.5.1.3.2 Chemical modification to improve chromatographic analysis and 
detection 
Apart from improving or facilitating extraction, chemical modification may also improve 
chromatographic analysis and detection. GC properties of GHB are improved by conversion to its 
more volatile and stable lactone-form GBL, achieved by applying the same procedures as to 
improve extraction via GBL formation (see above). Secondly, various derivatization reagents have 
been used to increase its molecular weight, at the same time decreasing its polarity, thereby 
enhancing volatility, separation efficiency and/or selectivity, and consequently, method sensitivity.  
As shown in Table I.B.1, silylation is widely used to derivatize GHB off-line in GC-based applications. 
Mainly BSTFA [e.g. 9,10,11,13,14,22,23,29,30,40,42,43,46,48,51,73,93,94,104-107,109] has been 
applied, next to N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) [87,97,107] and N-(tert-
butyldimethylsilyl)-N-methyl-trifluoroacetamide (MTBSTFA) [15,88]. Using these reagents, the 
hydroxyl and carboxyl functional groups of GHB are derivatized simultaneously, thereby avoiding 
lactone-formation since no acidic conditions are used [10]. Moreover, to avoid GBL formation and 
GHB losses during evaporation, Kimura et al. (2003) [73] alkalinized urine samples prior to 
derivatization, producing the non-volatile salt form of GHB. Furthermore, the resulting di-
trimethylsilylderivative of GHB (Fig. I.B.1) can be injected directly into the GC-MS, without removal 
of excess reagent. Of course, the latter requires increased maintenance of the injection port and 
MS source to prevent contamination between runs. Another issue is the possibility of co-eluting di-
TMS urea, requiring baseline separation of GHB and the urea di-TMS derivative under the GC 
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conditions used. As silylating reactions mostly require heating for 5 to 30 min, injection-port [88] 
and micro-wave assisted silylation [13] may offer valuable alternatives to reduce technical time. 
Also the aforementioned derivatization reactions improve chromatographic analysis and detection.  
 
Although derivatization is primarily known for its use in GC applications, it may also be applied in 
LC-based separations. For example, to allow fluorescence detection, the carboxylic group has been 
derivatized by adding 4-bromomethyl-7-methoxy coumarin (Br-MMC) to an aqueous-free sample 
residue in the presence of dibenzo-18-crown-6-ether acting as a catalyst to improve the reaction 
yield [71]. Furthermore, butylation of the carboxylic function of GHB using HCl n-butanol improved 
detection with ion-trap mass spectrometry [110].  
 
I.B.5.1.4 Liquid-liquid extraction (LLE) of GHB or GBL 
 
 I.B.5.1.4.1 Liquid-liquid extraction of GHB 
Solvents commonly used to extract GHB from biological fluids include ethylacetate 
[29,30,40,42,43,88,104-110], t-butylmethylether [87,110] and hexane [23]. Because the physical 
properties of GHB make it a poor candidate for LLE, various approaches to enhance the transfer of 
GHB to the organic solvent have been reported. GHB has to be in its uncharged or neutral form to 
obtain an optimum extraction yield and selectivity, influenced by the choice of solvent, pH and 
additives [83]. Therefore, the charge of the carboxylic group (pKa 4.6-4.8) has been influenced by 
the addition of 0.1 M HCl or cold 0.1 N H2SO4 to urine, serum and blood samples, enhancing its 
transfer to ethylacetate [42,104,110]. Also, for whole blood samples, Pan et al. (2001) [15] 
reported the use of water scavenging material such as dimethoxypropane and N,N-
dimethylformamide (80:20) to facilitate GHB extraction. Furthermore, salting-out approaches have 
been reported, whereby the ionic strength of the aqueous phase increases, improving the 
partitioning of relatively water-soluble analytes between two immiscible phases [87]. For this 
purpose, saturated salt solutions such as saturated ammoniumchloride buffer [31,107,109] have 
been added to the test tubes or NaCl (solid salt) has been pre-loaded [87] prior to extraction.  
 
 I.B.5.1.4.2 Liquid-liquid extraction of GBL 
Following lactone-formation (see above), GBL has been extracted from biologic fluids with 
methylenechloride [19], chloroform [101,103] or benzene [5], solvents that are preferentially 
avoided in the modern laboratory. Since GBL may be protonated under the acidic conditions 
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required for complete conversion, recoveries can be improved by adding sodium chloride to the 
solution for salting-out purposes, but also by neutralizing (pH 6-7) the initial acidic pH (pH 1) using 
e.g. phosphate buffer and sodium hydroxide [5,34,103]. Following LLE, the mixture is generally 
centrifuged and the supernatant subsequently concentrated, but not completely evaporated since 
GBL may be lost during evaporation to dryness, being more volatile than the free acid [74]. As an 
example, it was found essential to evaporate with low nitrogen flow and at low temperatures (max 
35 °C) to avoid unacceptable losses of GBL [5].  
 
I.B.5.1.5 Solid phase extraction (SPE) of GHB 
A first type of SPE sorbent used to extract GHB from biofluids is (strong) anion exchange. When 
using this type of cartridges, the classical SPE procedure of conditioning, loading, washing, drying 
and eluting has been followed. The interaction is based on ion exchange chemistry, whereby the 
organic moiety or quaternary ammonium material bonded to the solid matrix maintains its 
positive charge over the whole pH range, allowing pH-dependent interaction with GHB. At neutral 
pH, the carboxylic group will be negatively charged (pKa 4.6-4.8), and will interact with the 
positively charged sorbent. To elute GHB, it is necessary to neutralize its negative charge using an 
acidic elution solvent [89,90,111]. 
 
In addition, SPE cartridges can also be used to retain interfering substances, allowing the analyte of 
interest to pass through the sorbent and collecting the resulting eluate for further analysis. For this 
purpose, Clean Screen® SPE cartridges have been applied to clean-up vitreous humour, blood and 
urine. The collected eluate contained GHB without substances that could interfere during 
subsequent analysis [9,23,108]. In addition, a (strong) cation exchange sorbent can be used for 
sample clean-up of whole blood samples following protein precipitation. Introducing this 
additional clean-up resulted in improved peak shape of GHB and in reduced baseline noise [81,91]. 
 
An advantage of SPE is that it can be automated more easily than current precipitation or 
derivatization techniques which typically require off-line manual operations [89]. To illustrate this, 
an automated SPE (Oasis® HLB 30) using a 96-well plate has recently been applied for the 
extraction of GHB from whole blood samples, following protein precipitation [81]. Combining this 
automated SPE with LC-MS/MS resulted in a high-throughput method suitable for screening more 
than 6000 samples a year [81].  
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Also SPME, as a modification of the more classical SPE, has been introduced. In contrast to 
conventional extraction methods, which use multi-step techniques and excess organic solvents, 
SPME only consists of one solvent-free step to concentrate the analytes of interest. This technique 
has been applied to determine GHB (derivatized with hexylchloroformate) in urine samples, using 
a fused silica fibre coated with a stationary phase absorbing the analytes of interest. The SPME 
fiber can be brought directly in the sample, or alternatively, in the headspace (see further, 
headspace extraction of GHB) [37,86].  
 
I.B.5.1.6 Headspace extraction of GBL or derivatized GHB 
Only a minority of the presented GC methods uses HS as extraction and injection technique. The 
reason for this may lie not only in the more complex optimization of these procedures but also in 
the fact that typically a larger sample volume is required to obtain similar sensitivity as compared 
to more traditional sample preparation procedures such as LLE or SPE [7,86]. Also, the 
requirement for a more specific configuration, which also may imply the use of a more specific 
analytical column (see Table I.B.1) limits its general use. Nonetheless, these techniques have the 
advantage that GHB, in a derivatized form or as GBL, can be extracted directly from the aqueous 
sample, requiring less manual operations, being fully automatable, consuming less solvent (being 
solvent-free) and saving technical time [16,86]. Sample preparation is mostly limited to adding the 
following to a HS vial: an aliquot of the sample, anhydrous salt to enhance the transfer of the 
analyte of interest to the headspace, derivatization reagents or acid for lactone-formation. Next, 
after proper sealing of the vial, it can be placed in the HS oven for analysis.   
 
 I.B.5.1.6.1 Headspace extraction of derivatized GHB  
Combining “in-vial” derivatization with headspace injection techniques may extend the application 
range normally reserved for volatile compounds to semi- or non-volatile analytes such as GHB. 
Following derivatization with hexylchloroformate or dimethylsulphate, derivatized GHB has been 
extracted using SPME or HS-trap, respectively [16,20]. Both methods have minimal sample 
preparation time.  The method using SPME is one of the most sensitive methods reported, having 
an LLOQ of 0.1 µg/ml, starting from 0.5 ml urine. The HS-trap method is suited for the 
determination of GHB in various biological fluids, requiring only 100 µl of sample.  
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 I.B.5.1.6.2 Headspace extraction of GBL 
A static HS method has been described for the determination of GHB, based on LLE of 1 ml urine or 
whole blood samples, followed by conversion to GBL [19]. Headspace SPME and solid-phase 
dynamic extraction (SPDE) have also been applied to determine GHB as total GBL in plasma and 
urine samples, resulting in methods with sufficient sensitivity (LLOQ from 1 - 5 µg/ml) but requiring 
relatively large sample volumes (ranging from 0.5 to 1.0 ml) compared to other sample 
preparation techniques (0.02 – 0.5 ml) [7,102].  
 
I.B.5.2 CHROMATOGRAPHIC ANALYSIS AND DETECTION 
 
I.B.5.2.1 Gas chromatography 
Although the nature of GHB does not favour the use of GC (see above), it remains the most 
popular separation technique of the last two decades, enabled by the use of appropriate sample 
preparation techniques. Toxicological analyses are commonly performed using an analytical 
column with a stationary phase consisting of silica with 95 % methyl - 5 % phenyl groups, which is 
also well suited for the determination of derivatized GHB and/or GBL (and analogues), reflected in 
its wide use. The majority of GC-based methods focus on the detection of GHB, either in 
derivatized form or in the form of GBL, while a few methods also include simultaneous analysis of 
glycols, BHB, GHV, 1,4-BD and/or SSA [9,13,14,17,105,106]. 
 
 I.B.5.2.1.1. Gas chromatography – flame ionization detection 
Although various authors use this universal detector to initially screen for GHB, followed by 
confirmation using GC-MS [19,36], Jones et al. (2007) [98] used GC- flame ionization detection (FID) 
to quantify GHB as GBL in blood samples within a wide calibration range, starting at 8 µg/ml.  
 
 I.B.5.2.1.2 Gas chromatography – mass spectrometry 
To unequivocally demonstrate and determine GHB in biological fluids, GC is preferably used in 
conjunction with mass spectrometry. It has been used in electron impact ionization (EI) and 
positive or negative chemical ionization mode (PCI or NCI). For quantification, the MS operates in 
SIM (selected ion monitoring) mode, following those m/z ions typical for GBL or derivatized GHB. 
Derivatization using silylating or other derivatizing reagents is generally advantageous for MS 
detection, by increasing the molecular weight and the fragments’ masses. Hence, more selective 
ions are formed than those formed from GBL (m/z 42, 56 and 86 in EI mode). In addition, 
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fragmentation of the di-TMS-derivative via CI instead of EI results in mass spectra with more 
abundant and higher molecular weight ions [42]. PCI has been used by Kerrigan (2002) [42] and 
Chen et al. (2003) [93] to quantify GHB in various biofluids following silylation and by Lenz et al. 
(2009) [102] and Frison et al. (2000) [7] following GHB conversion to GBL. Although one method 
had a relatively lower LLOQ of 0.4 µg/ml, no relevant gain in sensitivity has been observed when 
compared to GC methods where the MS performs in EI mode. On the other hand, using the MS in 
NCI mode to quantify GHB as GBL in plasma samples has been shown suitable for the 
determination of endogenous concentrations, with a calibration range situated in the low µg/ml 
range [101].  
 
Although not routinely performed using GC-based methods, simultaneous analysis of GHB and 1,4-
BD or other compounds such as BHB and SSA is possible, as was done by Lora-Tamayo et al. and 
Sakurada et al., [105,106] respectively, who only slightly modified the method of Couper and 
Logan (2000) [104]. GHV and GHB can be analyzed simultaneously [9] and recently, Andresen-
Streichert et al. (2013) [17] reported a GC-MS method for the simultaneous analysis of GHB and 
GHV in urine samples, with an extraction and derivatization procedure based on the method 
published by Kerrigan (2002) [42]. 
 
 I.B.5.2.1.3 Gas chromatography - tandem mass spectrometry 
Coupling tandem MS to GC enables the monitoring of a selected transition from a parent ion to (a) 
specific daughter ion(s), which may reduce the requirement for time-consuming sample clean-up 
techniques. However, although very high sensitivity as a result of increased selectivity may be 
valuable for hair analysis, the advantage of being able to detect low GHB levels by MS/MS 
techniques is not crucial for blood and urine samples, since GHB is readily endogenously present at 
relatively high concentrations (sub- and low- microgram-per-milliliter range). Nonetheless, MS/MS 
still may offer improvements in peak shape required for reliable integration [11]. Although tandem 
MS may have the advantage over existing methodologies of providing spectra free from 
background contaminants and thus being more selective, it remains or becomes even more 
important to evaluate if the di-TMS derivative of GHB is free from interferences from compounds 
with the same precursor ion (m/z 233), such as its positional isomers, AHB and BHB [11]. 
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I.B.5.2.2 Liquid chromatography 
The minority of confirmatory methods uses LC to determine GHB in biofluids. This may be due to 
historical reasons, since GC has been longer and more widely available for routine analyses in 
toxicological laboratories, but also because of practical reasons, since poor retention of the native 
molecule on classical reversed phase (RP) columns is expected. Nonetheless, LC techniques may 
offer advantages over existing GC methods. For one, although similar sensitivity has been obtained, 
workload and use of toxic solvents may be reduced, since the introduction of tandem MS has 
resulted in simpler sample preparations, such as dilute-and-shoot, without the requirement for 
derivatization or conversion prior to analysis. The fact that no conversion is required makes that 
several LC methods can detect GHB and its precursor GBL simultaneously, while most of the 
reported GC methods require additional analyses [81]. Finally, introduction of ultra-high 
performance LC (UHPLC), having higher efficiency than traditional high performance LC (HPLC), 
and automated sample preparation techniques have further led to the development of highly 
useful high-throughput LC-MS/MS methods [12,50,81,84].  
 
I.B.5.2.2.1 Liquid chromatography – ultraviolet detection/ fluorescence 
detection 
Since GHB has no chromophoric group, UV-detection is only possible at a low wavelength (220 nm), 
as reported by De Vriendt et al. (2001) [90]. Starting from 60-µl plasma samples, quantification 
was possible in a range from 10 to 750 µg/ml, the LLOQ being 5 to 10-fold higher than the majority 
of confirmatory methods reported here. Introducing an UV-active or fluorescent group through 
derivatization should allow for enhanced sensitivity and improved certainty of identification, as 
illustrated by Zacharis et al. (2004) [71]. These authors derivatized GHB, producing a highly 
fluorescent derivative starting from 500-µl oral fluid samples, with the lowest calibrator 
corresponding to 0.25 µg/ml.  
 
 I.B.5.2.2.2 Liquid chromatography - tandem mass spectrometry 
UHPLC-MS/MS has the potential for shorter run times and improved sensitivity and precision 
compared to more traditional separation methods such as HPLC-UV or HPLC-Fluo, also facilitated 
by the possibility to use a stable isotopically labelled internal standard. To illustrate, Fung et al. 
(2004) [111] modified the LC-UV method described above [90] to a method suitable for LC-MS/MS, 
and although a slightly higher initial sample volume was required -100 instead of 60 µl - the run 
time was reduced to 5 min and sensitivity was increased 100-fold (LLOQ equal to 0.1 µg/ml).  
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Also, LC-MS/MS may allow for the simultaneous analysis of GHB and its precursors, GBL and 1,4-
BD [12], using isocratic elution (with 10 % MeOH or acetonitrile) or a slightly rising gradient. 
Adequate baseline separation of not only GBL and 1,4-BD but also of AHB, BHB and GVL from GHB 
has been shown [12,50,84]. This baseline separation of GHB and its positional isomers is 
particularly important for adequate identification of GHB using one parent and one product ion. 
Moreover, since under some conditions in ESI(+), the molecule might lose water within the 
instrument source with the formation of GBL, it is of interest that the method can distinguish 
between in-source generated GBL or GHB-H2O
+
 and actual GBL in a sample [12,84,91]. Interesting 
to note is that one method [84] used this in-source conversion of GHB to GBL to obtain sufficient 
sensitivity for GHB determination in whole blood samples, while others [12,91] only observed a 
relatively low conversion (factor 6 %) unsuitable for GHB quantification.  
 
Alternatively, to counter the detection of small m/z ions typical for GHB (m/z parent ion= 103), 
recently, an LC-MS/MS method for GHB in human serum has been reported, where quantification 
was based on the fragmentation of adducts formed with components of the mobile phase, more 
specifically on the fragmentation of the GHB sodium acetate adduct in ESI(-) (m/z 185) [99] .  
 
Tandem MS has been used in both atmospheric pressure chemical ionization (APCI) and ESI mode, 
with ESI(+) producing only one product ion with significant abundance and ESI(-) revealing three 
abundant transition products. The latter is more beneficial for method sensitivity and selectivity 
[89,91]. On the other hand, reversed phase C18 columns frequently used for GHB separation 
require acidified mobile phases to better control the retention of GHB (being a weak acid with a 
pKa 4.6 it is only uncharged in acidic mobile phases) [81]. This may lead to a restriction to work in 
the ESI (+) mode, since the acidic conditions used may reduce the response of GHB in ESI(-) mode 
[81,91]. However, Forni et al. (2013) reported lower background noise under their 
chromatographic conditions with the MS/MS operating in ESI(-) as compared to ESI(+) [50]. 
 
Sørensen et al. (2012) [87] and Lott et al. (2012) [96] suggested the use of a hydrophilic interaction 
liquid chromatography (HILIC) as an alternative to overcome this problem and to improve 
retention and chromatographic separation of small and polar molecules. HILIC allows for 
chromatography to be performed under neutral conditions, optimal for separation of GHB and 
analogues, which in addition also prevents inter-conversion between GHB and GBL [91]. To 
compare, using a typical C18 reversed phase column, GHB elutes first, followed by 1,4-BD and GBL, 
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while using HILIC the elution order is reversed, which simplifies optimization of the retention time 
of GHB by adjusting the composition of the mobile phase [91]. Despite these advantages, to 
reduce analysis costs of high-troughput methods, one may opt not to use HILIC methods with 
acetonitrile, given its higher toxicity and price than e.g. MeOH. Furthermore, also practical reasons, 
such as instrumental back-up, may influence the choice to use RP-columns and -chromatographic 
separation rather than HILIC-based chromatography [81].   
 
I.B.5.3 NON-CHROMATOGRAPHIC TECHNIQUES 
Gong et al. (2008) [85] reported a CZE-C
4
D method to determine GHB in urine and serum samples. 
Although not commonly used for toxicological purposes, this technique is well-suited for the 
determination of small and ionic molecules such as GHB (anionic form) [100]. Separation and 
detection of AHB, BHB and GHB was achieved without preceding extraction or derivatization but 
only by a simple 1:4 dilution with an optimized separation buffer with a pH > 4.7 to deprotonate 
the analytes and to obtain them in anionic form. In addition, the more alkaline pH also inhibits 
conversion of GHB to GBL. The method showed sufficient sensitivity to discriminate between 
endo- and exogenous GHB levels in urine samples (cut-off 10 µg/ml). Also, instrumentation is less 
expensive than other instruments used in clinical and forensic laboratories and a portable 
instrument may allow for on-site analysis of urine samples from suspected GHB-intoxications [85].  
 
I.B.6 CONCLUSION 
To conclude, various screening and confirmation methods are available to determine GHB (and 
analogues if required) in biological fluids. GHB screening/analysis in a toxicological laboratory is 
mostly performed based on a suspected ingestion of this club drug, supported by information of 
the police or physician, rather than on a routine basis, as is the case for more widely abused drugs 
such as cannabinoids, amphetamines and opioids [34,98]. However, since a few years, routine 
screening has become possible, not only by the commercialization of an enzymatic kit for GHB 
adaptable on common chemical analyzers,  but also by the availability of more simplified GC-MS 
methods and more sophisticated techniques such as UHPLC-MS/MS, which - when combined with 
automated sample preparation procedures - allow high-throughput. To confirm the presence of 
GHB in biological fluids, GC has remained the most widely used separation technique during the 
last twenty years, despite the small and polar nature of GHB, requiring conversion to GBL or 
derivatization to a more volatile and stable form. However, LC-based applications coupled to 
tandem MS are increasingly gaining interest as they may offer the advantage of more simple 
Chapter I.B Screening and confirmation methods  
 
 
41 
 
sample preparation techniques (e.g. no derivatization) or dilute-and-shoot. Of course, when 
sample preparation is minimal, matrix effects require special consideration. Furthermore, despite 
the advantages of reduced workload and shortened analysis time that tandem MS-techniques may 
offer, baseline separation of GHB from GBL and from its isomers AHB and BHB, achieved by 
adequate chromatography, remains important to avoid interference (respectively by in-source 
formation of GBL during MS/MS analysis and by similar transitions) [11]. As to method sensitivity, 
both GC- and LC-based applications offer similar LOQ’s, but as Kankaanpää et al. (2007) has nicely 
pointed out “the challenge is not to reach as low GHB concentration levels as possible, but to 
interpret the results correctly being able to make a distinction between use of GHB and 
endogenous levels” [87]. Indeed, once a result has been obtained using the above mentioned 
screening and confirmation methods, the interpretation is a second challenge for the toxicologist, 
whereby the analysis of different matrices may be useful for correct interpretation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I.B.1 Overview of confirmation methods to determine GHB in biological fluids, sorted by analytical technique 
 
GC  Unless specified: GC-MS: 1 µl injected in splitless injection, MS EI ionization mode and helium as carrier gas; *If method includes conversion of GHB to GBL: without acidification of the sample: 
determination of original GBL concentration possible 
Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Abanades et al., 
2006 [46]; 
Abanades et al., 
2007 [48] 
 
GHB Urine 
Plasma 
Oral fluid 
(100 µl) 
(Sweat) 
PP: 150 µl acetonitrile +50 µl 
0.1 M sulphuric acid  
Derivatization: 50 µl (BSTFA + 
1% TMCS) 70 °C 30 min 
5 % phenyl – 95 % 
methylpolysiloxane 
12 m x 0.2 mm, 0.33 µm 
(14 min) 
GHB-d6 
 
0.2-300 µg/ml  
Andresen et al., 
2010 
[30] 
GHB Urine 
Serum 
(100 µl) 
LLE: 200 µl 0.1 M HCl + 1 ml 
ethylacetate  
Derivatization: 100 µl 
ethylacetate + 50 µl  (BSTFA + 
1% TMCS)  
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(22.7 min) 
 
GHB-d6 2-12 µg/ml  
Andresen-
Streichert et al., 
2013 [17] 
GHB 
GHV 
Urine  
(100 µl) 
LLE: 200 µl 0.1 M HCl + 1 ml 
ethylacetate 
Derivatization: 50 µl 
acetonitrile + 25 µl (BSTFA + 
1% TMCS) 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(16.22 min) 
GHB-d6 (NR for GHB)  
Blair et al., 2000 
[86] 
 
 
 
 
GHB Urine 
(0.5 ml) 
Derivatization: 
40 µl pyridine + 24 µl 
hexylchloroformate 40 °C 5 
min 
Solution SPME: + 2ml 
deionized water + 1 ml pH 7 
buffer; PDMS SPME fiber 12 
min 40 °C 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(23.33 min) 
GHB-d6 5-500 µg/ml  SPME GC-Q-trap 
Bosman and 
Lusthof, 2004 
[34] 
 
GHB* Urine  
Blood  
(1 ml) 
PP + Conversion of GHB to 
GBL: 
1 ml 1 M perchloric acid 
1 ml supernatant: 80 °C 20 
min 
LLE of GBL: 300 mg NaCl, pH 
6.5 (1 ml 1.5 N phosphate 
buffer + 350 µl 2.5 M NaOH), 
5 ml chloroform 
100 % polydimethylsiloxane 
12 m  x 0.2 mm, 0.33 µm  
(15 min) 
GHB-d6 5-40 µg/ml Case reports 
Split injection (10:1) 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Brenneisen et 
al., 2004 
[103] 
GHB* Urine (2 ml) 
Plasma (0,5 ml) 
Oral fluid (1 ml) 
 
Conversion of GHB to GBL: 
0.5 ml 20 % trifluoroactetic 
acid, 75 °C 1 h 
LLE of GBL: 0.55 mL 2 M 
NaOH (pH adjusting to 6.5) + 3 
ml chloroform 
5 % phenyl – 95 % 
methylpolysiloxane 
25 m x 0.2 mm, 0.33 µm 
(10.1 min) 
 
GVL 10-50 µg/ml 4 µl injected 
Brown  et al., 
2007 
[16] 
GHB 
MAMP  
MDMA 
KET 
Urine 
(1 ml) 
Derivatization: 10 µl 
hexylchloroformate + 40 µl 
pyridine 
Headspace SPME of 
derivatized GHB: 0.5 ml 
derivatized sample 
+ 1 ml water; 100 µm PDMS 
fiber 90 °C 20 min;  1 min 
desorption at 225 °C 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.10 µm  
(12 min) 
GHB-d6 0.1-20 µg/ml SPME  
Chen et al., 
2003 
[93] 
GHB Plasma 
(100 µl) 
PP: 2ml acetonitrile  
50 µl supernatant evaporated 
Derivatization:  
100 µl BSTFA 75 °C 15 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 1 µm 
(9 min) 
GHB-d6 2.5-250 µg/ml 
 
GC-PCI-MS 
(ammonia as 
reagent gas) 
Couper and 
Logan, 2000 
[104] 
GHB Urine 
Plasma 
(1 ml) 
LLE: 250 µl cold 0.1N sulphuric 
acid + 6 ml ethylacetate (2 x) 
Derivatization: 30 µl (BSTFA + 
1% TMCS) + 60 µl acetonitrile 
70°C 15 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.33 µm  
(14 min) 
 
diethyleneglycol 1-200 µg/ml urine 
1-100 µg/ml plasma 
 
2 µl injected 
 
Crookes et al., 
2004 
[43] 
GHB Urine 
(2 ml) 
LLE: + 0.36 M sulphuric acid to 
obtain pH 2.75; + 3 ml 
ethylacetate 
Derivatization: 100 µl (BSTFA 
+ 1% TMCS) 60°C 30 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(26.2 min) 
GHB-d6 0.2-5 µg/ml 2 µl injected 
De Paoli and 
Bell, 2008 
[51] 
GHB Oral fluid 
(1 µl) 
Derivatization: 97 µl (BSTFA  + 
1 % TMCS) 50 °C 30 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.5 µm 
(16 min) 
GHB-d6 0.5-50 µg/ml Split injection (10:1) 
Duer et al., 2001 
[97] 
 
 
GHB Urine 
Blood 
Vitreous humour 
(25 µl) 
PP: 1.225 ml GHV methanolic 
solution 
Derivatization: 100 µl MSTFA 
+ 100 µl ethylactetate 60 °C 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(24.7 min) 
GHV 
GHB-d6 
Standard addition 
(10-500 µg/ml) 
GBL determination: 
conversion to GHB in 
alkaline conditions 
(using 1 ml 10mM 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Duer et al., 2001 
[97] 
continued 
30 min NaOH in methanol, 1 
h 60 °C) following 
GHB analysis;  
1,4-BD 
determination: 
di(dinitrobenzoyl) 
derivative using 
HPLC-UV 
Elian, 2000 
[107] 
GHB Urine 
(50 µl) 
 
LLE: 50 µl IS + 0.5 ml saturated 
ammonium chloride buffer + 3 
ml ethylacetate  
Derivatization: 50 µl (BSTFA + 
1% TMCS) + 50 µl ethylacetate  
30 min RT  
100 % polydimethylsiloxane 
12 m x 0.2 mm, 0.33 µm  
(9.7 min) 
  
GHB-d6 2-50 µg/ml 
 
2 µl injected 
Elian, 2001 
[109] 
GHB Blood   
(50 µl) 
LLE: 0.5 ml saturated 
ammonium chloride buffer + 3 
ml ethylacetate  
Derivatization: 20 µl (BSTFA + 
1% TMCS) + 80 µl ethylacetate  
70 °C 20 min 
100 % polydimethylsiloxane 
12m x 0.2mm,  0.33µm 
(11.0 min) 
GHB-d6 1-200 µg/ml 2 µl injected 
Elie et al., 2012 
[88] 
 
 
 
GHB Urine 
(300 µl) 
LLE : 300 µl urine + 900 µl 
ethylacetate  
Derivatization : 50 µl 
acetonitrile + 50 µl 
(MTBSTFA+1%TBCS) 
100 % polydimethylsiloxane 
30 m x 0.25 mm, 0.25 µm 
(15 min) 
Trans-4-
hydroxycrotonic acid 
0.17-1.67 µg/ml Injection port 
silylation: 
split/splitless 
injector with 
programmable 
pneumatic control  
Elliott, 2004  
[36] 
GHB  Urine 
Plasma 
(1 ml) 
LLE: 250 µl 0.05 M sulphuric 
acid + 6.0 ml ethylacetate  
Derivatization: 75 µl (BSTFA + 
1% TMCS) 90 °C 5 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(9 min) 
 
GHB-d6 5-200 µg/ml 1) GC-FID screening 
method for  GHB 
identification via 
GBL conversion 
2) GC-MS 
determination via 
derivatization 
(presented in detail) 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Elliott, 2004  
[25]; 
Elliott et al., 
2004 [40] 
GHB Urine 
Blood 
Vitreous humour 
(100 µl) 
LLE: 50 µl cold 0.05 M 
sulphuric acid + 0.5 ml 
ethylacetate  
Derivatization: 75 µl (BSTFA + 
1% TMCS) 90 °C 5 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(9 min) 
diethyleneglycol 
GHB-d6 
6.25-100 µg/ml 
(urine) 
1-100 µg/ml 
(plasma) 
 
Comparison with 
GC-FID method [25] 
Ferrara et al., 
1993 
[5] 
 
 
 
 
 
GHB* Urine 
Plasma  
(2 ml) 
Conversion GHB to GBL: 2 ml 
cold 0.8 N perchloric acid, 
supernatant (plasma PP) 0.2 
ml 6 N HCl (urine) 80 ° C 20 
min 
LLE of GBL: 300 mg NaCl, 1 ml 
pH 6.5 (1 ml 1.5 N phosphate 
buffer + 5 N NaOH), 8 ml 
(plasma) or 6 ml (urine) 
benzene 
100 % polydimethylsiloxane 
12 m  x 0.2 mm, 0.33 µm  
(15.6 min) 
 
δ-valerolactone 2-150 µg/ml urine 
2-200 µg/ml plasma 
 
 
Frison et al., 
2000 
[7] 
GHB* Urine 
Plasma 
(0.5 ml) 
Conversion GHB to GBL: 100 
µl cold 1.6 N perchloric acid, 
supernatant (plasma PP) 
25 µl 6 N HCl (urine) 80 ° C 20 
min 
Headspace SPME of GBL: 500 
mg solid phosphate buffer  
50-µm CW/TPR SPME fiber 
10 min 70 °C 
acid-modified polyethylene 
glycol phase 
25 m x 0.2 mm, 0.3 µm 
(9.8 min)  
GBL-d6 5-150 µg/ml urine 
1-100 µg/ml plasma 
 
 
SPME GC-PCI-MS  
(methane as reagent 
gas) 
Fukui et al., 
2003 
[101] 
GHB* Plasma  
(200 µl) 
Conversion GHB to GBL: 0.5 
ml 6 M HCl 
LLE of GBL: 2 ml 
dichloromethane (2 x) 
evaporation to 100 µl  
polyethyleneglycol 
30 m x 0.32 mm, 0.25 µm 
(11.5 min) 
GBL-d6 0.01-1 µg/ml  GC-NCI-MS 
Ingels et al., 
2010 
[24]; Ingels et 
al., 2011 [49] 
 
GHB DBS  
(50 µl [24] /6-mm 
punch [49]) 
 
Derivatization: 
100 [24]  or 50 µl [48] 
TFAA/HFB-OH (2:1) 
 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(12.3 min) 
GHB-d6 2-100 µg/ml  
Ingels et al., 
2013 
[20] 
GHB Urine 
Plasma/serum 
Blood/lyzed blood 
PP/salting-out: 100 mg 
Na2SO4 
Derivatization: 30 µl DMS + 
94 % dimethyl –  6 % 
cyanopropylphenyl 
polysiloxane  
GHB-d6 5-150 urine 
2-150 
plasma/serum 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Ingels et al., 
2013 
[20] continued 
(100 µl) 30 µl NaOH (0.5 M) 
Headspace-trap extraction of 
derivatized GHB: 30 min 90 °C 
30 m x 0.25 mm, 1.4 µm 
(15 min) 
3.5-200 blood/lyzed 
blood 
Jones et al., 
2007 
[98] 
GHB* Blood 
(0.5 g) 
 
PP: acetone 
Conversion GHB to GBL: 
sulphuric acid  
LLE of GBL: dichloromethane 
evaporation to 50-100 µl 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(NR) 
GVL 8-1000 µg/ml 2 µl injected 
GC-FID 
Kankaanpää et 
al., 2007 
[87] 
GHB 
GBL 
1,4-BD 
Urine 
Blood 
(200 µl) 
LLE: 400 µl water + 5 ml t-
butylmethylether + 0.5g NaCl 
Derivatization: 
100 µl acetonitrile + 30 µl 
MSTFA  
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.32 mm, 1.0 µm 
(12 min) 
benzylalcohol 3-75 µg/ml  
 
GBL determination: 
similar sample prep: 
without salting –out 
and derivatization + 
different GC-MS 
method 
3 µl injected 
Kerrigan,  
(2002) [42]; 
Mazzar-Proo 
and Kerrigan, 
(2005) 
[108] 
GHB Urine 
Blood 
Vitreous humour 
(0.5 ml) 
LLE:250 µl 0.1 M HCl + 2 ml 
ethylacetate (2 x) 
Derivatization: 100 µl (BSTFA 
+ 1% TMCS) [42]; 50 µl MSTFA 
[104] 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(13 min) 
GHB-d6 0.4-250 µg/ml GC-PCI-MS 
(methane as reagent 
gas) 
Kimura et al., 
2003 
[73] 
GHB Urine 
(0.01mg creatinine) 
Urease 37 °C 30 min 
Alkalinization: 10 µl 0.1 N 
NaOH 
Derivatization: 60 µl (BSTFA + 
1 % TMCS) 80 °C 30 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(20.9 min) 
dimethylsuccinic acid 
 
0.006-0.0127 µg/ml  
Lebeau et al., 
2000 
[19] 
 
 
GHB* Urine 
Blood  
(1ml) 
Conversion GHB to GBL: 0.15 
ml concentrated sulphuric 
acid 
LLE of GBL: 5 ml 
dichloromethane  
Static headspace injection: 
20 min 90 °C 
94 % dimethyl – 6 % 
cyanopropylphenyl 
polysiloxane  
30 m x 0.25 mm, 1.4 µm 
(15 min) 
α-methylene- γ- 
butyrolactone 
(screening) 
GHB-d6  
(single-point 
quantification) 
5-1000 µg/ml 1) headspace GC-FID 
screening 
2) headspace GC-MS 
confirmation 
 
nitrogen as carrier 
gas 
Lenz et al., 2009 
[102] 
 
 
GHB* Urine 
Serum 
(0.5 ml) 
Conversion GHB to GBL: 100 
µl sulphuric acid 
SPDE of GBL: + 1 g sodium 
sulphate; SPDE PDMS/AC 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 1.0 µm  
(10.5 min)  
GHB-d6 2-200 µg/ml SPDE GC-PCI-MS 
(methane as reagent 
gas) 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Lenz et al., 2009 
[102] continued 
coating; 150 extraction 
strokes at 50 °C; sample 
agitation 500 rpm 
Lora-Tamayo et 
al., 2003 
[105] 
GHB 
1,4-BD 
Urine 
Blood 
(1 ml) 
LLE: 250 µl cold 0.1N sulphuric 
acid + 6 ml ethylacetate  
Derivatization: 30 µl (BSTFA + 
1% TMCS) + 60 µl acetonitrile  
70°C 15 min; + 200 µl 
ethylacetate 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.33 µm  
(14 min) 
 
GHB-d6 2.5-85 µg/ml urine   
Louagie et al., 
1997 
[94] 
GHB Serum 
(20 µl) 
PP: 40 µl acetonitrile 
Derivatization: 20 µl MSTFA 
90°C 10 min 
100 % polydimethylsiloxane 
12 m  x 0.2 mm, 0.33 µm  
(9.6) 
valproic acid 2-200 µg/ml  
Marinetti et al., 
2005 
[9] 
GHB 
GHV 
Urine 
Blood 
Vitreous humour 
(200 µl) 
PP: 1 ml acetone 
SPE (CLEAN SREEN GHB): 
conditioning: 3 ml methanol, 
3 ml deionized water, 3 ml 
100 mM sodium phosphate 
buffer (pH 6); sample loading 
(reconstituted in 250 µl 100 
mM sodium phosphate buffer 
(pH 6)); elution: 1 ml 99:1 
methanol/ammonium 
hydroxide 
Derivatization: 100 µl (BSTFA 
+ 1 % TMCS) 55 °C 30 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(13.0 min) 
GHB-d6 5-150 µg/ml Post-mortem cases 
 
McCusker et al., 
1999 
[23] 
GHB Urine  
(200 µl) 
SPE (CLEAN SREEN GHB): 
conditioning: 3 ml methanol, 
3 ml deionized water, 0.5 ml 
sodium phosphate buffer (pH 
6); sample loading ; elution: 1 
ml 99:1 methanol/ammonium 
hydroxide 
LLE: DMF + hexane 
Derivatization: 100 µl 
ethylacetate + 100 µl (BSTFA+ 
1% TMCS) 60 °C 5 min 
 
100 % polydimethylsiloxane 
30 m x 0.25 mm, 0.25 µm  
(10.97 min) 
 
GHB-d6 5-500 µg/ml  
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Meyer et al., 
2010 
[13] 
GHB, DL-lactic 
acid, glycolic 
acid, ethylene 
glycol, and 
other glycols 
Urine 
Plasma 
(50 µl) 
PP: 50 µl acetonitrile 
Derivatization: 300 µl BSTFA + 
20 µl DMF 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(12 min) 
GHB-d6 10-200 µg/ml Micro-wave assisted 
silylation 
Pan et al., 2001 
[15] 
 
 
 
 
GHB 
Ethyleneglycol 
Urine  
Blood 
(100 µl) 
PP: 80 µl water + 200 µl 
acetonitrile 
LLE: supernatant 150 µl + 500 
µl DMP/DMF (80:20)  
Derivatization: 50 µl 
MTBSTFA + 50 µl ethylacetate 
70°C 60 min 
5 % phenyl – 95 % 
methylpolysiloxane 
25 m x 0.25 mm, 0.25 µm  
(16.3 min) 
 
 
2-hydroxy-3-
methylbutyric acid 
0-500 µg/ml 6 case histories 
Paul et al., 2006 
[11] 
GHB Urine 
Blood 
(50 µl) 
PP: 150 µl acetonitrile +50 µl 
0.1 M sulphuric acid  
Derivatization: 100 µl BSTFA 
60 °C 20 min 
5 % phenyl – 95 % 
methylpolysiloxane 
15 m x 0.25 mm, 0.25 µm  
(9.40 min) 
GHB-d6 2.5-100 µg/ml  
 
GC-EI-MS/MS  
 
Sakurada et al., 
2002 
[106] 
GHB 
1,4-BD 
SSA 
BHB 
Urine 
Blood 
(1 ml) 
LLE: 400 µl cold 0.1N sulphuric 
acid + 8 ml ethylacetate  
Derivatization: 50 µl (BSTFA + 
1% TMCS) + 60 µl acetonitrile  
70°C 15 min;+ 40 µl 
ethylacetate 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(14 min) 
 
diethyleneglycol 0-200 µg/ml 2 µl injected 
Shima et al., 
2005 
[10] 
GHB 
BHB 
AHB 
Urine 
(100 µl) 
 
PP: 500 µl methanol 
Derivatization: 50 µl (BSTFA + 
1% TMCS) + 50 µl acetonitrile 
60 °C 20 min 
50 % phenyl - 
methylpolysiloxane 
30 m x 0.32 mm, 0.25 µm 
(17 min) 
2-hydroxycaproic acid 0.01-30 µg/ml  
Van hee et al., 
2004 
[14] 
GHB, DL-lactic 
acid, glycolic 
acid, ethylene 
glycol, and 
other glycols 
Urine 
Plasma 
Serum 
(20 µl) 
Derivatization: 750 µl BSTFA + 
20 µl DMF 70°C 15 min  
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm  
(9.25 min) 
GHB-d6 3.2-200 µg/ml 
 
Split injection (60:1) 
 
Villain et al., 
2003 
[22] 
GHB Urine 
Blood 
(20 µl) 
 
PP: 45 µl acetonitrile 
Derivatization: 35 µl BSTFA + 
1% TMCS 70 °C 25 min 
5 % phenyl – 95 % 
methylpolysiloxane 
30 m x 0.25 mm, 0.25 µm 
(11.5 min) 
GHB-d6 1-200 µg/ml 
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LC 
Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Dahl et al., 2012 
[81] 
GHB 
GBL 
1,4-BD 
Pregabaline 
BHB 
Urine 
Blood 
(100 µl) 
Urine:  
Dilution/Filtration: 
1) 1:1 dilution: + 100 µl water 
2) 1.75 ml 0.2 % formic acid 
3) 500 µl: mini-UniPrep filter 
0.2 µm filter membrane 
Blood: 
Dilution: + 100 µl water 
PP: 400 µl ice-cold 
acetonitrile: methanol (85:15, 
v/v), 10 min freezer 
SPE: 96-well plate (30 mg 
OASIS HLB): conditioning: 
methanol and water; sample 
loading: supernatant + 250 µl 
0.4 % formic acid solution  
HSS T3 column  
(100 mm x 2.1 mm, 1.7 µm)  
gradient elution 
MP A: 0.2 % formic acid  
MP B: methanol  
(4.5 min) 
 
 
GHB-d6 2.6-312.3 µg/ml 
blood 
 
UHPLC-MS/MS 
ESI(+) 
Injection volume: 
3 µl blood/2 µl 
urine 
de Vriendt et 
al., 2001 
[90] 
GHB Rat plasma  
(60 µl) 
SPE (SAX Bond elut 
cartridges): 
conditioning: 1 ml methanol, 
6 ml 0.5 M formic acid, 1 ml 
water; sample loading: 60 µl; 
washing: 0.5 ml water, 0.5 ml 
water-methanol (1:1), 0.3 ml 
methanol; elution: 600 µl 
acetonitrile with 6 % acetic 
acid 
 C18 Aqua column  
(150 mm x 4.6mm, 5µm) 
isocratic elution  
MP: 100% potassium 
dihydrogenphosphate 
solution 20mM 
(10 min) 
(tested different IS) 10-750 µg/ml  
 
HPLC-UV (220 nm) 
injection volume: 
100 µl 
 
Dresen et al., 
2007 
[95] 
 
 
 
 
 
 
GHB Serum 
(100 µl) 
PP: 200 µl cold acetonitrile 
 
 
Polar-encapped 
phenylpropyl RP (Synergy 
Polar-RP) 
(50 mm x 2 mm, 4 µm) 
gradient elution  
MP A: 0.1 % formic acid with 
1 mmol/L ammonium 
formate 
MP B: acetonitrile with 0.1 % 
GHB-d6 1-200 µg/ml HPLC-MS/MS 
ESI(-) 
injection volume: 
20 µl 
No evaluation of 
matrix effect 
Chapter I.B Screening and confirmation methods  
 
 
50 
 
Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Dresen et al., 
2007 
[95] continued 
formic acid 95:5 (v/v) with 1 
mmol/L  ammonium formate 
 (15 min) 
Dziadosz et al., 
2013 
[99] 
GHB Serum 
(100 µl) 
PP: 1 ml water/methanol 
(3/97 v/v)  
15 min shaking 
Luna 5 µm C18 (2) 100 A  
(150 mm x 2 mm) 
gradient elution  
MP A: water/methanol 
(95/5) 
+ 10 mM ammonium acetate 
+ 0.1 % acetic acid (pH 3.2) 
MP B: water/methanol 
(3/97) 
+ 10 mM ammonium acetate 
+ 0.1 % acetic acid (pH 3.2) 
(3 min) 
GHB-d6 5-100 µg/ml UHPLC-MS/MS  
ESI(-) 
injection volume: 
10 µl 
Adduct supported 
detection 
Elian et al., 
2011 
[89] 
GHB Urine  
(50 µl) 
Dilution: 1ml water, mix, + 3 
ml water 
SPE (SAX, CUQAX 6 ml 500 
mg): 
conditioning: 3 ml methanol, 
3 ml water; sample loading; 
washing: 3 ml deionized 
water, 3 ml methanol; elution: 
3 ml 6 % acetic acid in 
methanol 
Allure biphenyl  
(150 mm x 4.6 mm, 5 µm) 
gradient elution 
MP A: 0.1 formic acid in 
water 
MP B: 0.1 % formic acid 
acetonitrile 
(4.1 min) 
 
GHB-d6 0.5-10 µg/ml 
 
HPLC-MS/MS 
APCI(-) 
injection volume: 
10 µl 
 
Forni et al., 
2013 
[50] 
GHB DBS 
(3 x 4.6 mm) 
Extraction: 200 µl methanol 
30 min 
HSS T3 column  
(100 mm x 2.1 mm, 1.8 µm)  
gradient elution 
MP A: 0.1 % formic acid  in 
water 
MP B: 0.1 % formic acid  in 
acetonitrile 
(4 min) 
GHB-d6 1-128 µg/ml UHPLC-MS/MS 
ESI(-) 
injection volume: 
15 µl 
Fung et al., 
2004 
[111] 
 
GHB Rat plasma 
(100 µl) 
SPE (SAX Bond elut cartridges, 
100 mg 1 ml): conditioning: 1 
ml methanol, 6 ml 10 % acetic 
acid, 1 ml water; sample 
C18 Aqua column  
(150 mm x 4.6mm, 5µm) 
gradient elution 
MP A: 90 % 5mM formic acid  
GHB-d6 0.1-10 µg/ml HPLC-MS/MS  
APCI(-) 
injection volume: 
10 µl 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Fung et al., 
2004 
[111]  
continued 
loading: 100 µl; washing: 0.5 
ml water, 0.5 ml water-
methanol (1:1), 0.3 ml 
methanol; elution: 3 ml 
acetonitrile with 10 % acetic 
acid 
MP B: 10 % acetonitrile 
(5 min) 
Johansen and 
Windberg, 2011 
[84] 
GHB 
GBL 
1,4-BD 
GVL 
Urine 
(20 µl) 
Blood 
(0.2 g) 
Blood: 
PP: 260 µl acidic methanol  
Dilution: 50 µl supernatant 
diluted 1:1 acidic water  
Urine: 
Dilution: 10-fold dilution with 
acidic 10 % methanol 
Zorbax  SB C18  
(150 mm x 2.1 mm, 3.5 µm)  
gradient elution 
MP A:acidic water  
MP B: acidic methanol 
(19 min) 
GHB-d6 1-100 mg/kg blood 
 
 
HPLC-MS/MS 
ESI(+) 
injection volume : 5 
µl 
Kaufmann and 
Alt, 2007 
[110] 
GHB Urine 
Serum 
(250 µl) 
LLE: 
1) 125 µl 0.1 M HCl + 1 ml 
ethylacetate  
2) 750 µl t-butylmethylether 
Derivatization:  
50 µl 3 M HCl n-butanol 50 °C 
5 min 
C18 zorbax SB-18 Agilent  
(30 mm x 2.1 mm, 3.5 µm) 
gradient elution 
MP A: 5 mM ammonium 
formate in water 
MP B: 5 mM ammonium 
formate in acetonitrile 
(NR) 
GHB-d6 2-100 µg/ml 
 
HPLC-MS/MS 
Ion trap  
injection volume: 
10 µl 
Lott et al., 2012  
[96] 
GHB Serum 
(100 µl) 
PP: 200 µl acetonitrile 
 
Nucleodur HILIC column  
(NS, 3 µm) 
isocratic elution 
80 % acetonitrile  
20 % water with 5 mM 
ammonium acetate 
(15 min) 
GHB-d6 2-50 µg/ml HILIC, HPLC-MS/MS  
APCI(-) 
injection volume: 
10 µl 
 
 
 
Sørensen and 
Hasselstrøm, 
2012 
[91] 
 
GHB 
GBL 
1,4-BD 
Blood  
(200 µl) 
PP: + 100 µl methanol + 600 
µl acetonitrile  
SPE (3- ml strata-X-C 60 mg 
SCX): conditioning: 1 ml 
methanol, 1 ml water, 1 ml 1 
M sodium dihydrogen 
phosphate solution, 1 ml 
water; sample loading: 600 µl 
supernatant + 250 µl water  
SeQuant ZIC HILIC  
(100 mm x 2.1 mm, 5 µm)  
gradient elution 
MP A: 1mM ammonium 
acetate 
MP B: acetonitrile 
(10 min) 
 
GHB-d6 5-200 µg/ml 
 
 
HILIC, UHPLC-
MS/MS  
ESI(+) and ESI(-) 
injection volume: 
10 µl 
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Ref. Analyte Matrix  
(sample volume) 
Sample preparation Stationary phase 
(total run time)  
IS GHB Calibration  
Range GHB 
Remarks  
 
Wood et al., 
2004 
[12] 
GHB 
GBL 
1,4-BD 
Urine 
(250 µl) 
Dilution: 1:20 with deionized 
water  
Atlantis C18 column  
(100 mm x 3 mm, 5 µm) 
isocratic elution 
MP:  0.1 % aqueous formic 
acid: methanol (90:10) 
(11 min) 
GHB-d6 1-80 µg/ml 
 
HPLC-MS/MS 
ESI(+) 
injection volume: 
20 µl 
 
Zacharis et al., 
2008 
[71] 
GHB Oral fluid 
(500 µl) 
Oral fluid sample evaporated; 
residu reconstituted 200 µl 
DMF (water removal using 
preheated molecular sieves) 
Derivatization:  
1) 100 µl Br-MMC  70 °C 70 
min 
2) 100 µl anthracene + 1ml 
acetonitrile 
C18 Kromasil 
(250 mm x 4.6 mm, 4µm) 
gradient elution 
methanol/phosphate buffer 
(40 mM, pH 3) 
(25 min) 
anthracene 0.25-7.5 µg/ml  HPLC-Fluorescence 
detection (330 (λex) 
-390 (λem) nm) 
injection volume: 
25 µl 
 
Other confirmation method 
Ref. Analyte Matrix  
(sample volume) 
Extraction Separation buffer  Calibration  
Range GHB 
Remarks  
 
Gong et al., 
2008 
[85] 
GHB 
BHB 
AHB 
Urine 
Serum  
Dilution: 1:4 with 
separation buffer 
 
20 mM arginine;  10 mM maleic 
acid; 30 µM 
cetyltrimethylammoniumbromide 
5 mM vancomycin 
2-400 µg/ml urine 
5-150 µg/ml serum 
 
Capillary electrophoresis with contactless 
conductivity detection 
1,4-BD: 1,4-butanediol; AHB: alpha-hydroxybutyric acid; APCI: atmospheric pressure chemical ionization; BHB: bèta-hydroxybutyric acid; Br-MMC: 4-bromomethyl-7-methoxy coumarin; BSTFA: N,O-
bis(trimethylsilyl)trifluoroacetamide; CW/TPR: carbowax/templated resin; DMF: dimethylformamide; DMS: dimethylsulphate; EI: electron impact; ESI: electrospray ionization; FID: flame ionization detection; GBL: gamma-
butyrolactone; GC: gas chromatography; GHB: gamma-hydroxybutyric acid; GHV: gamma-hydroxyvaleric acid; GVL: gamma-valerolactone; HCl: hydrogen chloride; HFB-OH: heptafluorobutanol; HILIC: hydrophilic interaction liquid 
chromatography; HPLC: high performance liquid chromatography; IS: internal standard; KET: ketamine; LLE: liquid-liquid extraction; MAMP: methamphetamine; MDMA: 3,4-methylenedioxymethamphetamine; MP: mobile phase; 
MS: mass spectrometry; MS/MS: tandem mass spectrometry; MSTFA: N-methyl-N-(trimethylsilyl)-trifluoroacetamide; MTBSTFA: N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide; NaCl: sodium chloride; NaOH: sodium 
hydroxide; Na2SO4: anhydrous sodium sulphate; NCI: negative chemical ionization; NR: not reported; PCI: positive chemical ionization; PDMS: polydimethylsiloxane; PDMS/AC: PDMS/cyanopropyl; PP: protein precipitation; RP: 
reversed phase; SPDE: solid-phase dynamic extraction; SPE: solid-phase extraction; SPME: solid-phase micro-extraction; SSA: succinic semi-aldehyde; TBCS: butyldimethylchlorosilane; TFAA: trifluoroacetic acid anhydride; TMCS: 
trimethylchlorosilane; UHPLC: ultra high performance liquid chromatography; UV: ultraviolet 
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PART II 
DETERMINATION OF GHB IN DRIED BLOOD 
SPOTS USING “ON SPOT” DERIVATIZATION 
AND GC-MS 
In this part, we aimed to determine GHB in dried blood spots 
(DBS)  using a simple GC-MS method. First, a brief description of 
DBS and their use in toxicology is given, with the focus on the 
determination of drugs of abuse (Chapter II.A). To adequately 
quantify the club drug in DBS, chemical modification of this 
small and polar molecule was required. Since we preferred to 
derivatize GHB, derivatization techniques used in combination 
with DBS analysis are discussed more into detail in Chapter II.B.   
We chose a direct derivatization approach - addition of the 
reagent(s) directly on the DBS, thereby omitting the extraction 
step - which resulted in the set-up of a quick and efficient 
protocol. We coined this approach “on spot” derivatization. 
Thus, following the development and optimization of the GC-MS 
method used to determine derivatized GHB (Chapter II.C.1), the 
development and validation of the GC-MS method to quantify 
GHB in complete DBS with a fixed volume of 50 µl is presented in 
Chapter II.C.2.   
To address the need for a more practical approach, which is the 
collection of drops of blood directly on the filter paper, the first 
method was adjusted, as discussed in Chapter II.C.3.  Validation 
was performed, with the evaluation of additional parameters 
  
 
typical for analysis of DBS punches, where no longer a fixed 
volume is used but a fixed diameter. These parameters include 
the influence of punch localization, hematocrit and blood spot 
volume. Finally, applicability of this method was demonstrated 
by analyzing venous blood and capillary DBS, collected 
simultaneously from GHB-intoxicated patients.  
Chapter II.C.4 concludes with a study, conducted to evaluate the 
feasibility of the DBS sampling technique at home. Therefore, 
DBS were collected by patients who use the sodium salt of GHB 
(sodium oxybate, Xyrem®). Samples were sent by mail to our 
laboratory and analyzed using the method described in II.C.3.  
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II.A.1INTRODUCTION  
A dried blood spot (DBS) is capillary whole blood obtained by a finger or heel prick and collected 
on a filter paper. This sampling technique ensures an easy and rapid collection of a representative 
sample without specific handling and storage requirements. These advantages as to a 
venepuncture make it a cost-effective choice for the collection, transport and storage of blood 
samples (Fig. II.A.1) [1,2]. Already about a century ago, the potential of using DBS for 
biomonitoring was recognized by Ivar Bang, who demonstrated its usefulness for glucose 
monitoring [3]. However, it took another 50 years before the use of DBS became more 
widespread, ignited by the seminal paper by Guthrie and Susi, who demonstrated the applicability 
of screening newborn DBS for phenylketonuria [4]. Since then, an ever increasing amount of 
biomarkers has been included in DBS newborn screening programs worldwide [5-9]. Apart from its 
use for newborn screening, DBS sampling has also been applied in animals, children, adults and 
even post mortem, its applications rising rapidly the last few years, covering the analysis of DNA 
(e.g. HIV, serotyping of bacteria, genotyping), proteins (e.g. enzyme activity or antibody-based 
analysis), small molecules (endogenous or exogenous, e.g. amino acids or therapeutic drugs), as 
well as trace elements (e.g. lead). 
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The different subdisciplines of toxicology for which DBS sampling has been reported include the 
application of DBS for the analysis of therapeutic drugs (toxicokinetics), drugs of abuse, 
environmental contaminants, toxins and (trace) elements. The main focus of this overview is the 
application of DBS for the analysis of drugs of abuse. Topics not covered are the use of DBS for 
therapeutic drug monitoring (TDM) and for metabolic screening, two fields which, although having 
some overlap with toxicology because toxic effects may be encountered, are considered as distinct 
disciplines.  
 
The interest in using DBS for the purpose of TDM (including clinical toxicology), with sampling 
either in the clinic or at the patient’s home, has recently shown a strong increase. Also here, apart 
from follow-up and reassuring that therapeutic concentrations are reached in patients, toxicology 
may come into play when considering the purpose to monitor (and avoid) supratherapeutic 
(potentially toxic) concentrations. However, it is beyond the scope of this review to provide a full 
overview of all therapeutic drugs for which DBS sampling has been applied. The reader is referred 
to other, comprehensive reviews on this topic (e.g. [2,10,11]).  
 
Metabolic screening programs based on DBS sampling aim at identifying disturbed balances in 
endogenous biomolecules, which may lead to toxic effects. A forensic application worth 
mentioning in this context is the “metabolic autopsy”, which can be performed on DBS to screen 
for inherited metabolic disorders in cases of sudden infant death syndrome or sudden unexplained 
death syndrome [12]. These DBS can either be obtained post mortem or can be those that were 
obtained at birth in cases where only later a metabolic disorder is suspected in deaths of 
previously unknown cause. 
 
II.A.2 DRIED BLOOD SPOTS – SOURCES 
In developed countries, typically five DBS, each corresponding to about 80 µl of blood, are 
obtained by heel stick from the vast majority (>95%) of newborns within the first 1-3 days of life. 
With the exception of the ‘positive’ cases, only a limited amount of this material is used for 
newborn screening programs, which primarily focus on inborn errors of metabolism. Thus, a 
substantial amount of valuable material is left behind. These remainders have proven to be a 
useful matrix for assessing certain exposures at birth. The prime aim of these assessments is to 
monitor prenatal exposure to toxic compounds capable of crossing the foetoplacental barrier. 
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However, as in most cases no information is available with respect to breastfeeding, it needs to be 
remarked that postpartum exposure of the newborn via mother milk cannot be excluded. 
Moreover, when interpreting the results in the context of epidemiological studies, several 
potential sources of bias need to be kept in mind [13]. First, although newborn screening is almost 
universal in developed countries, non-participation is unlikely to be random (e.g. infants may have 
died before DBS sampling or parents may have refused DBS sampling). Second, less (or no) 
material may be left from those newborns that tested positive in newborn screening programs.  
 
As analyses are typically performed on material that has been archived up to several years, 
contamination has to be excluded and analyses are limited to analytes with long-term stability in 
DBS. In addition, parameters potentially influencing the analytical result, such as hematocrit, blood 
volume spotted and site of punching (peripheral versus central) [14,15] have not been examined in 
many cases. Nevertheless, keeping these limitations in mind, newborn DBS can be valuable 
material for screening and may provide important retrospective information on the extent of 
exposure to a wide array of chemicals or elements. Given the fact that these early life exposures 
may be relevant to disease later in life, this information may not only result in a close follow-up of 
‘positively scored’ newborns, but may also form the basis for intervention studies, targeting 
women at specific locations and/or belonging to specific (social) groups. 
 
Apart from DBS sampling for newborn screening, more recently, this sampling technique has 
increasingly gained interest for its use in both animal and human studies. In humans (both adults 
and children), DBS are mostly obtained by finger prick. The resulting DBS, which may be directly 
applied from the finger onto the filter paper or via a precision capillary (Fig. II.A.1), are in general 
smaller than those obtained by heel stick. Advantages associated with the sampling itself primarily 
include its ease and its minimal invasiveness, facilitating sampling in remote areas and in 
paediatric studies by non-specialized individuals. Sampling from animals at specified time intervals 
after administration of a given drug is generally performed using microsampling devices (e.g. 
precision capillaries). The blood collected with these devices can be used to generate DBS, or it can 
be frozen, diluted in another solution or centrifuged to prepare plasma [16,17]. Applications 
include pharmaco- and toxicokinetics, TDM and clinical, forensic and environmental toxicology. 
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II.A.3 ANALYSIS OF THERAPEUTIC DRUGS - TOXICOKINETICS 
Currently, many pharmaceutical companies undertake major efforts to implement DBS rather than 
classical plasma samples as starting material for bioanalytical measurements. These efforts are 
situated in the preclinical phase of the drug discovery process (e.g. toxicokinetics) as well as in 
later phases (pharmacokinetics and TDM). Here, we will primarily focus on the use of DBS for 
toxicokinetics, determining the relationship between systemic exposure of an animal to a 
compound and the harmful effects (toxicity) of this compound. A preliminary safety assessment 
can be derived from parameters such as bioavailability and dose proportionality, serving as a basis 
to decide which doses can be used in future studies. 
 
From the point of view of animal welfare, DBS sampling conforms very well to the ‘3R principle 
(Replacement, Reduction, Refinement)’ in toxico- and pharmacokinetic studies. The fact that finer 
needles can be used to obtain DBS and that there is no need to warm the animals prior to 
sampling, causes less distress to the animals. Besides this refinement, resulting in less animal 
burden, the implementation of DBS sampling also leads to a strong reduction in the number of 
animals needed in early drug discovery and preclinical studies. More specifically, DBS sampling 
requires less blood to be taken at each time point than is the case when analyses are performed 
using the ‘classical’ matrices plasma or serum. For the latter, the number of samples that can be 
collected per animal is limited by both ethical and physiological constraints. These constraints are 
greatly relieved by ‘microsampling’, resulting in the generation of DBS and allowing serial sampling 
from a strongly reduced amount of laboratory animals, including small rodents such as mice. This 
allows the replacement of composite pharmaco- or toxicokinetic profiles (obtained from different 
animals) by serial profiles (obtained within individual animals), which leads to higher data quality 
[18-20]. Apart from a large improvement in animal welfare, DBS sampling is also beneficial for the 
(pharmaceutical) companies involved. From a financial point of view, there is a serious reduction in 
costs associated with animal studies (including amount of test compound that should be available) 
and with sample handling. The latter includes both transportation costs to a bioanalytical facility 
and storage costs. Both transportation and storage are often facilitated, as experience has learned 
that stability, though requiring analyte-specific evaluation, is generally good. Thus, in many cases 
prolonged storage, even at ambient temperatures, is possible. Despite these many advantages, 
however, pharmaceutical companies initially somewhat restrained from utilizing DBS as an 
alternative to plasma or serum. Importantly, the use of DBS instead of plasma or serum 
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necessitated a rethinking of bioanalytical procedures, particularly in the pre-analytical phase. This 
not only includes the selection of the filter paper card, but ideally also encompasses evaluation of 
the influence of spotting temperature, anticoagulant, the spotting device used, the volume 
spotted, the site of punching and the hematocrit, in addition to evaluation of the “on spot 
stability” and the effect of drying and storage conditions. Additionally, one should also dispose of 
means for detecting contamination, such as evaluation of blanks and/or incurred sample reanalysis 
[21-26]. However, setting up new bioanalytical procedures is (was) not the main problem for the 
‘switch’ from plasma to DBS. More important are regulatory constraints and the fact that plasma 
and serum have been used for decades as the gold standard, with all currently available toxico- 
and pharmacokinetic data having been obtained in these matrices. The latter implies that care 
should be taken, not only in evaluating how plasma concentrations correlate with blood or DBS 
concentrations, but also if and how capillary concentrations correlate with venous concentrations 
[27]. This may be particularly relevant when evaluating early time points in kinetic experiments 
[28]. Another factor to consider is the anticipated concentration: when in the low- or sub-ng/ml 
range, the limited amount of available material may impose analytical challenges that have to be 
dealt with. Recent improvements in analytical equipment, with primarily LC-MS/MS becoming 
more widespread available, have catalyzed progress in this field. Currently, major efforts are also 
being undertaken to render DBS analysis high-throughput-capable. Examples include the 
automated analysis of DBS, the on-line extraction and analysis of DBS (‘direct elution’) and direct 
desorption of DBS (e.g. [20,29]). These new developments have recently been reviewed elsewhere 
[30,31]. 
 
II.A.4 ANALYSIS OF DRUGS OF ABUSE 
Several publications and meeting abstracts demonstrate (or suggest) the potential of DBS for 
detecting exposure to drugs of abuse (Table II.A.1 and Appendix 1). Analytes measured include 
both legal drugs (scheduled drugs available on prescription) and illegal drugs. It needs to be 
mentioned, though, that some of these reports focus on the potential of determining these drugs 
for TDM (e.g. narcotic painkillers) or for newborn screening (e.g. monitoring exposure to cocaine), 
rather than for forensic purposes. In addition, several reports have demonstrated the possibility to 
identify drugs of abuse, as well as ethyl glucuronide, a marker for alcohol abuse, in blood spotted 
on different surfaces, rather than on filter paper. As in these cases the resulting blood spots are 
bloodstains rather than DBS, we do not consider these as true ‘DBS applications’ [32-34]. Overall, 
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two sources of DBS can be distinguished for monitoring drugs of abuse: firstly DBS obtained from 
adults, where the application can be classified under ‘forensic toxicology’, and secondly DBS from 
newborns, where the aim is to assess exposure prior to birth. Owing to the low concentrations to 
be detected in minute amounts of material, LC-MS/MS has been the method of choice in the vast 
majority of applications, although also GC-MS has been applied in some cases (Table II.A.1). 
 
II.A.4.1 FORENSIC TOXICOLOGY 
There is a substantial number of reports describing DBS applications for drugs of abuse (for an 
overview, see Table II.A.1). Analytes of particular forensic interest that have been measured in DBS 
include benzodiazepines (alprazolam, clonazepam, diazepam, flunitrazepam, flurazepam, 
lorazepam, midazolam, nitrazepam, nordiazepam, oxazepam, phenazepam, temazepam), 
zolpidem, zopiclone, zaleplon, MDMA, 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxyethylamphetamine (MDEA), amphetamine, methamphetamine, cocaine, 
tetrahydrocannabinol (THC), opiates (6-monoacetylmorphine, morphine, codeine, 
hydromorphone, hydrocodone, oxycodone, noroxycodone), tramadol, methadone, 
buprenorphine, fentanyl, ketamine and their respective metabolites, gamma-hydroxybutyric acid 
(GHB) and novel psychoactive substances [35-68]. Also interesting from a forensic point of view is 
the potential to monitor alcohol abuse via the determination of ethylglucuronide and ethylsulfate 
or phosphatidylethanol in DBS [69-71]. 
 
Table II.A.1 Overview of the analytes discussed in this review, with referral to the utilized analytical 
techniques. (Update of (the markers of) drugs of abuse until July 2013).p72-75. 
Analyte Technique Selected References 
(MARKERS OF) DRUGS OF ABUSE 
Amphetamine LC-MS/MS 
 
GC-MS 
Jantos and Skopp, 2011 [51]; Lauer et al., 2011 [55]; Saussereau 
et al., 2012 [56]; Ambach et al., 2013 [57] 
Langel et al., 2011 [54] 
MDMA, MDA LC-MS/MS 
 
 
 
GC-MS 
Skopp, 2007 [58]; Jantos and Skopp, 2011 [51]; Jantos et al., 
2011b [53]; Lauer et al., 2011 [55]; Thomas et al., 2012 [59]; 
Saussereau et al., 2012 [56], Déglon et al., 2012a [30], Ambach 
et al., 2013 [57] 
Langel et al., 2011 [54] 
MDEA LC-MS/MS Lauer et al., 2011 [55]; Saussereau et al., 2012 [56]; Déglon et 
al., 2012a [30]; Ambach et al., 2013 [57] 
Methamphetamine LC-MS/MS 
 
GC-MS 
Lauer et al., 2011 [55]; Saussereau et al., 2012 [56]; Déglon et 
al., 2012a [30]; Ambach et al., 2013 [57] 
Langel et al., 2011 [54] 
Novel psychoactive substances  LC-MS/MS Ambach et al., 2013 [57] 
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Cocaine, benzoylecgonine and 
other metabolites 
RIA, GC-MS 
RIA, LC-MS 
LC-FLUO 
LC-MS/MS 
 
 
GC-MS 
Henderson et al., 1993 [35] 
Henderson et al., 1997 [37] 
Mercolini et al., 2010 [45] 
Sosnoff et al., 1996 [36]; Alfazil and Anderson, 2008 [38]; Lauer 
et al., 2011 [55]; Thomas et al., 2012 [59]; Saussereau et al., 
2012 [56]; Déglon et al., 2012a [30] 
Langel et al., 2011 [54] 
Benzodiazepines LC-MS/MS 
 
 
GC-MS 
Alfazil and Anderson, 2008 [38]; Havard et al., 2010 [42]; 
Thomas et al, 2010 [46]; Jantos and Skopp, 2011 [51]; Lauer et 
al., 2011 [55]; Déglon et al., 2012a,b [30,60] 
Langel et al., 2011 [54] 
Zolpidem LC-MS/MS Hudson et al., 2011 [49]; Lauer et al., 2011 [55]; Déglon et al., 
2012a,b [30,60] 
Zopiclone LC-MS/MS 
 
GC-MS 
Jantos and Skopp, 2011 [51]; Lauer et al., 2011 [55]; Jantos et 
al., 2012 [61]; Déglon et al., 2012a,b [30,60] 
Langel et al., 2011 [54] 
Zaleplon LC-MS/MS Déglon et al., 2012b [60] 
Ketamine and norketamine LC-MS/MS Moll et al., 2009 [40]; Ambach et al., 2013[57] 
Gamma-hydroxybutyric acid LC-MS/MS 
GC-MS 
Forni et al., 2013 [68] 
Ingels et al., 2010 [43]; Ingels et al.,2011 [50] 
Opiates and metabolites LC-MS/MS 
 
 
 
 
GC-MS 
Skopp et al., 2007 [58]; Garcia Boy et al., 2008 [39]; Thomas et 
al., 2010 [46]; Marin et al., 2010 [44]; Clavijo et al., 2011a [47]; 
Jantos et al., 2011a [52]; Lauer et al., 2011 [55]; Saussereau et 
al., 2012 [56]; Déglon et al., 2012a [30]; Mommers et al., 2013 
[63] 
Langel et al., 2011 [54] 
Buprenorphine and metabolites LC-MS/MS 
 
GC-MS 
Thomas et al., 2010 [46]; Marin et al., 2010 [44], Lauer et al., 
2011 [55] 
Langel et al., 2011 [54] 
Methadone and metabolites LC-MS/MS 
 
LC-coulometry 
GC-MS 
Clavijo et al., 2010 [41], Lauer et al., 2011 [55]; Déglon et al., 
2012a  [30] 
Addolorate Saracino et al., 2012 [62] 
Langel et al., 2011 [54] 
Fentanyl and metabolites LC-MS/MS Clavijo et al., 2011b [48]; Jantos et al., 2011a [52], Lauer et al., 
2011 [55]; Déglon et al., 2012a [30] 
Tramadol LC-MS/MS 
GC-MS 
Déglon et al., 2012a [30] 
Langel et al., 2011 [54] 
Tetrahydrocannabinol and 
metabolites 
LC-MS/MS 
 
GC-MS 
Thomas et al., 2010 [46], Thomas et al., 2012 [59]; Déglon et al., 
2012a [30]; Mercolini et al., 2013 [64] 
Langel et al., 2011[54] 
Cotinine LC-MS/MS 
GC-MS 
Murphy et al., 2013 [65] 
Spector et al., 2007 [84] 
Ethylglucuronide – ethylsulfate LC-MS/MS Hernández Redondo et al., 2011 [58], Hernández Redondo et 
al., 2013 [66] 
Phosphatidylethanol LC-MS/MS Faller et al., 2011 [56]; Jones et al., 2011 [57]; Faller et al., 2013 
[67] 
ENVIRONMENTAL CONTAMINANTS 
Benzene oxide GC-MS Funk et al., 2008 [86] 
Organochlorine pesticides GC-ECD 
GC-HRMS 
Dua et al., 1996 [87]; Burse et al., 1997 [88] 
Shlosberg et al., 2012 [89] 
Perfluoroalkyl compounds LC-MS/MS Spliethoff et al., 2008 [80]; Kato et al., 2009 [91], Shlosberg et 
al., 2012 [89] 
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Polychlorinated biphenyls GC-HRMS Shlosberg et al., 2012 [89]; Lu et al., 2012 [93] 
Polybrominated diphenyl esters GC-HRMS Shlosberg et al., 2012 [89]; Lu et al., 2012 [93] 
Perchlorate IC-MS/MS Otero-Santos et al., 2009 [95] 
Bisphenol A LC-MS/MS Leonard et al., 2011 [96] 
Cholinesterase Inhibitors Cholinesterase 
activity 
measurement 
Heilbronn, 1953 [98]; Augustinsson and Heimburger, 1953 [97]; 
Augustinsson and Holmstedt, 1965 [99]; Holmstedt and Oudart, 
1966 [100]; Collombel and Perrot, 1970 [101]; Oudart and 
Holmstedt, 1970 [102]; Augustinsson et al., 1978 [103]; Eriksson 
and Faijersson, 1980 [104]; Rhyanen et al., 1984 [105]; Hilborn 
and Padilla, 2004 [106]; Trudeau et al., 2007 [72]; Quandt et al., 
2010 [107] 
BIOTOXINS   
Domoic acid C-ELISA Maucher and Ramsdell, 2005 [116] 
Brevetoxins R-binding assay 
RIA 
C-ELISA 
Fairey et al., 2001 [112]; Woofter et al., 2003 [113] 
Woofter et al., 2003 [113]; Woofter et al., 2005 [114] 
Maucher et al., 2007 [117] 
Ciguatoxin Cytotox. assay Bottein Dechraoui et al., 2005 [119] 
(TRACE) ELEMENTS 
As ICP-MS Shlosberg et al., 2012 [89] 
Ba LA-ICP-MS Hsieh et al., 2011 [124] 
Be LA-ICP-MS Hsieh et al., 2011 [124] 
Bi LA-ICP-MS Hsieh et al., 2011 [124] 
Ca LA-ICP-TOF-MS 
SF-ICP-MS 
Cizdziel, 2007 [122] 
Langer et al., 2010 [109] 
Cd ICP-MS 
SF-ICP-MS 
LA-ICP-MS 
Chaudhuri et al., 2009 [123]; Shlosberg et al., 2012 [89] 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
Co LA-ICP-MS Hsieh et al., 2011 [124] 
Cr SF-ICP-MS Langer et al., 2010 [109] 
Cs SF-ICP-MS Langer et al., 2010 [109] 
Cu LA-ICP-TOF-MS 
SF-ICP-MS 
LA-ICP-MS 
Cizdziel, 2007 [122] 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
Fe LA-ICP-TOF-MS 
SF-ICP-MS 
Cizdziel, 2007 [122] 
Langer et al., 2010 [109] 
Hg ICP-MS Chaudhuri et al., 2009 [123]; Shlosberg et al., 2012 [89] 
K SF-ICP-MS Langer et al., 2010 [109] 
Li SF-ICP-MS Langer et al., 2010 [109] 
Mg SF-ICP-MS 
LA-ICP-MS 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
Mn LA-ICP-MS Hsieh et al., 2011 [124] 
Mo SF-ICP-MS Langer et al., 2010 [109] 
Na SF-ICP-MS Langer et al., 2010 [109] 
Ni SF-ICP-MS 
LA-ICP-MS 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
P SF-ICP-MS Langer et al., 2010 [109] 
Pb AAS 
GFAAS 
SS-GFAAS 
ICP-MS 
 
LA-ICP-TOF-MS 
Cernik et al., 1971 [129]; Verebey et al., 1991 [132] 
Shen et al., 2003 [125] 
Resano et al., 2007 [121] 
El-Hajjar et al., 2007 [135]; Chaudhuri et al., 2009 [123]; 
Shlosberg et al2012 [89] 
Cizdziel, 2007 [122] 
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SF-ICP-MS 
LA-ICP-MS 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
Rb SF-ICP-MS Langer et al., 2010 [109] 
S SF-ICP-MS Langer et al., 2010 [109] 
Sb LA-ICP-MS Hsieh et al., 2011 [124] 
Se AAS 
ICP-MS 
Lombeck et al., 1989 [140] 
Shlosberg et al., 2012 [89] 
Tl LA-ICP-MS Hsieh et al., 2011 [124] 
V LA-ICP-TOF-MS Cizdziel, 2007 [122] 
Zn LA-ICP-TOF-MS 
SF-ICP-MS 
LA-ICP-MS 
Cizdziel, 2007 [122] 
Langer et al., 2010 [109] 
Hsieh et al., 2011 [124] 
AAS: atomic absorption spectrometry; C-ELISA: competitive enzyme-linked immunosorbent assay; GC-ECD: gas 
chromatography with electron capture detection;  GC-HRMS: gas chromatography with high resolution mass spectrometric 
detection; GC-MS: gas chromatography with mass spectrometric detection; IC-MS/MS: ion chromatography with tandem 
mass spectrometric detection; ICP-MS: inductively coupled plasma mass spectrometry; LA-ICP-MS: laser ablation 
inductively coupled plasma mass spectrometry; LA-ICP-TOF-MS: laser-ablation inductively coupled plasma time-of flight 
mass spectrometry; LC-MS: liquid chromatography with mass spectrometric detection; LC-MS/MS: liquid chromatography 
with tandem mass spectrometric detection; R-binding assay: receptor-binding assay; RIA: radio-immuno assay;  SF-ICP-MS: 
sector-field inductively coupled plasma mass spectrometry; SS-GFAAS: solid sampling graphite furnace atomic absorption 
spectrometry 
 
 
Although most reports have included patient samples, two important remarks need to be made. 
First, various reports utilize DBS prepared by pipetting venous blood onto a paper card (e.g.  
[39,41,43,53,69,70]), with only a limited amount of reports describing the analysis of true capillary 
DBS (e.g. [36,45,50]). Although the latter can be obtained by using a precision capillary [45], our 
experience learned that this significantly complicates the procedure and ideally requires some 
training. Instead, direct application of the blood drop from the pricked fingertip onto the paper is 
generally found to be easy, also for a non-trained individual. However, as DBS obtained in this way 
do not represent a fixed volume, quantitative evaluation requires the analysis of DBS punches 
rather than of complete DBS. This brings us to the second remark. Analysis of (very) large spots, 
obtained from spotting up to 100 µl, has been performed in a substantial number of publications 
(e.g. [38,39,51,69]). These volumes are not easily obtained by finger prick; in our experience a spot 
applied directly from a pricked fingertip onto paper corresponds typically to less than 40 µl of 
blood. Moreover, the non-volumetric application also has the consequence that disks (typically 3, 
6 or 6.35 mm diameter) need to be punched from the paper, further reducing the amount of 
material available for analysis. Important to mention in this context is that the validation of 
methods starting from disk punches rather than from complete blood spots requires the 
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evaluation of additional parameters such as punch location, hematocrit and volume spotted 
[10,50]. Thus, although promising results have been obtained, suggesting more widespread 
applicability in forensic toxicology, true ‘on-field’ studies are needed for a substantial amount of 
compounds, in which DBS are obtained by a finger prick.  
 
Below we discuss more into detail two specific advantages associated with DBS sampling and the 
opportunities these offer for implementation in forensic toxicology: the ease of sampling 
(facilitating rapid sampling) and the stabilizing effect of DBS. 
 
II.A.4.1.1 Ease of Sampling 
Although legislation in most countries does not (yet) allow non-medical staff to obtain DBS from 
someone else, the ease with which DBS can be taken renders it in principle possible to acquire a 
blood sample with a minimal loss of time. As this would imply that, at least in some instances, the 
sampling is done outside a medical facility or a laboratory, e.g. at the road-side, also care has to be 
taken to let the filter paper dry properly, as an analyte’s stability may be impacted by the drying 
time and drying conditions. In such situations, the paper can be dried by e.g. putting it in a box or 
bag with desiccant, taking care that the blood spots do not come into contact with other surfaces. 
This approach of pro-active drying has already been applied in field studies where blood was 
sampled from wild birds [72]. Furthermore, sufficient experience and frequent sampling most 
likely contribute to collection of high quality DBS.  
 
Rapid sampling is particularly relevant in cases in which the half-life of a drug is short. Examples 
include cocaine, heroin (and its metabolite 6-monoacetylmorphine, 6-MAM) and GHB [35-
39,43,45,50,68]. Whereas cocaine intake can be demonstrated by virtue of its metabolite 
benzoylecgonine, heroin abuse cannot be simply deduced from the presence of its hydrolysis end-
product, morphine (see also below). An even more difficult case is presented by GHB, which is also 
endogenously present and is rapidly cleared from the circulation. GHB or one of its precursors is 
sometimes used in cases of drug-facilitated sexual assault (DFSA). In these cases, there is most 
often readily a delay before the victim presents at the police station, thus sampling should be done 
as fast as possible (without needing to wait for a doctor to arrive). DBS sampling may be a good 
option in these cases. 
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The ease and speed of sampling also allows to investigate the epidemiology of drug abuse in a 
nightclub environment, where DBS could be obtained in “first aid” rooms (e.g. [73]). As in these 
cases informed consent needs to be obtained from individuals who are under the influence of 
drugs, this may pose bio-ethical issues, which can be dealt with via informed consent from a 
relative or via delayed informed consent.      
 
DBS sampling in the context of DUID (driving under the influence of drugs) has only been evaluated 
to a limited extent [74]. Although for DUID testing, oral fluid has become the matrix of choice for 
both screening and confirmation in countries such as Belgium, Australia and Spain, some 
controversy exists whether the obtained concentrations always closely mirror blood 
concentrations (supposedly best correlating with intoxication) and whether falsification by e.g. 
mouth washing may be possible [75,76]. DBS sampling does not suffer from these drawbacks and 
combines the advantages (relevance and reliability) of obtaining the ultimate specimen for 
determination of drug concentrations - i.e. blood - with an easy and rapid collection procedure by 
non-specialized staff. A key issue related to DBS sampling in this context is the exclusion of 
contamination. 
 
For the follow-up of drug and alcohol addicts, DBS sampling may be useful to control abstinence 
from drugs and/or intake of substitution medication. Here, the use of DBS, though offering a more 
restricted window of detection, may offer an alternative for urine testing, which is now routinely 
used. Importantly, DBS sampling is gender neutral and is not hampered by privacy issues, which 
often lead to unsupervised sampling (and possibly adulteration) of urine. As there is also no need 
for medical staff, one may envisage a system in which unwittingly (former) addicts get a phone call 
at irregular time intervals and have to present themselves at a given centre to provide DBS under 
supervision. Moreover, given the higher prevalence of viral infections (e.g. hepatitis and HIV) in 
people with a history of intravenous drug abuse, the low biohazard risk posed by the resulting DBS 
is an additional important advantage. Once a DBS has been collected (using safety measurements 
similar to venous sampling), no further manipulation of the blood is required (in contrast to e.g. 
the preparation of plasma, requiring centrifugation) and DBS can be transported via regular mail 
with no risk of breaking or leaking, thus minimizing the risk of transmitting blood-borne viruses 
and overcoming the need for taking special safety precautions [77]. In fact, viruses such as HIV-1 
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lose their infectivity as their envelope is disrupted upon drying, which has led to the use of DBS for 
routine HIV monitoring in screening and follow-up programs in developing countries [78].  
 
II.A.4.1.2 Stabilizing Effect 
Multiple publications have pointed out that DBS may have a stabilizing effect (e.g. [79,80]). In a 
forensic context, this can be exemplified by several examples. First, the stabilizing effect on drugs 
having e.g. an ester function was demonstrated by the increased stability (reduced hydrolysis) of 
cocaine and 6-MAM (a metabolite of heroin) in DBS, as compared to whole blood [35,38,39]. This 
is of particular importance as identification of 6-MAM unequivocally demonstrates heroin use 
(whereas the presence of morphine alone does not). Secondly, DBS may also overcome the 
problem of ex vivo formation of a given compound. Whereas ex vivo formation of the club drug 
GHB in whole blood has been reported [81,82], prolonged storage of DBS at room temperature (up 
to 6 months) demonstrated no significant changes [50]. Similarly, whereas the presence of ethanol 
in blood may result in the ex vivo generation of phosphatidylethanol (1-palmitoyl-2-oleyl-sn-
glycero-4-phosphoethanol) upon storage [83,70], this ex vivo formation does not take place in DBS 
[70]. Thus, DBS sampling is able to counter a serious drawback associated with classical venous 
sampling, thereby increasing the trustworthiness of the result. 
 
In the forensic toxicology laboratory, the use of DBS may also offer the possibility to preserve small 
amounts of sample in an economical way in ‘closed cases’, where all other evidence is to be 
discarded. When, for one reason or another, a case is to be reopened, there is at least some 
material left, potentially allowing targeted analysis. A similar approach has also been suggested for 
other biological matrices, such as urine [84]. Obviously, a limitation is that only analytes can be 
detected that remain stable for an extended period of time [84]. 
 
II.A.4.2 NEWBORN SCREENING 
Benzoylecgonine and cotinine, which are metabolites of cocaine and nicotine, respectively, have 
been determined in newborn DBS to assess the prevalence of the use of cocaine and tobacco 
products among childbearing women [35-37,85]. An inherent limitation here is that positive results 
will only indicate the mother’s use of cocaine or tobacco near the time of delivery, thus only 
offering a limited view on the use during pregnancy. On the other hand, a factor likely extending 
the interval for detecting positive cases, is the immature liver function in newborns.  
Chapter II.A DBS in toxicology: Focus on drugs of abuse 
 
 
79 
 
Although immunological assays have been found to be a useful tool for initial screening of 
benzoylecgonine in DBS, confirmation is required using other techniques, such as mass 
spectrometry (GC-MS or LC-MS/MS) [35-37]. With respect to decision-making, any positive signal 
(above the limit of detection, LOD, or lower limit of quantification, LLOQ) may raise an alert. This 
implies that the lower the LOD or LLOQ of a given method, the higher the expected detection rate. 
Implementing a cut-off value in DBS testing of newborns for drugs of abuse may facilitate the 
inter-laboratory comparison of prevalences. While defining this decision limit, the potential error 
caused by the possible effect of e.g. varying hematocrit and volume spotted should be taken into 
account. However, as the cut-off would necessarily be above the LOD or LLOQ, the % of false 
negatives will undoubtedly increase. 
 
II.A.5 ANALYSIS OF ENVIRONMENTAL CONTAMINANTS 
Screening for environmental contaminants has been performed using DBS from both humans 
(primarily newborns) and animals. Examples of analytes that have been monitored include 
environmental pollutants such as benzene oxide (a metabolite of benzene, monitored via its 
adducts with hemoglobin) [86], organochlorine pesticides [87-89], perfluoroalkyl compounds 
(PFCs) [89-92], polychlorinated biphenyls (PCBs) [89,93], polybrominated diphenyl esters (PBDEs) 
used as flame-retarding chemicals [89,93,94], perchlorate [95], heavy metals, as well as certain 
toxins. Although no published reports are available, yet, DBS have also been suggested to be useful 
for monitoring bisphenol A [92,96]. 
 
An alternative, indirect way for assessing the exposure to a contaminant, is the monitoring of a 
biological activity directly influenced by this contaminant (via a so-called ‘biomarker of effect’). 
Insecticides like organophosphates and carbamates are good candidates for this approach, as 
exposure can be assessed by virtue of their inhibition of cholinesterase activity. The first reports on 
the determination of cholinesterase activity in blood samples absorbed on filter paper readily date 
back to 1953 [97,98], a decade before Guthrie and Susi published on the detection of 
phenylalanine in newborn DBS [4]. It needs to be remarked, though, that sensitivity is rather 
limited and ideally one should know an individual’s enzyme activity prior to exposure, with only 
considerable intoxications resulting in a significant decrease in enzyme activity. Yet, multiple other 
publications have shown the potential to use (dried) blood and plasma spots for monitoring 
cholinesterase activity, primarily for occupational surveillance of exposed workers [99-107]. 
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Several of the DBS applications for monitoring environmental contaminants are discussed more 
into depth below.  
 
II.A.5.1 NEWBORN SCREENING 
The organochlorine dichlorodiphenyldichloroethylene (a metabolite of 
dichlorodiphenyltrichloroethane, DDT) and the PFCs perfluorooctane sulphonate and 
perfluorooctanate, as well as benzene oxide and perchlorate, have been detected in all evaluated 
newborns’ DBS [86,88,90,91,95], mirroring their general spread in ecosystems and their presence 
in virtually 100% of the adult population, including pregnant women [108]. Interestingly, a sharp 
decline in perfluoroalkyl content in DBS from newborns after the year 2000, coinciding with the 
phasing-out of perfluorooctane sulphonate in the US, nicely demonstrates the utility of this 
approach for assessing temporal trends in exposure to environmental chemicals [90]. Newborn 
DBS have also been demonstrated to have the potential for monitoring exposure to 
supraphysiological levels of trace elements (e.g. lead), allowing the extraction of (semi)quantitative 
information [109]. However, most of these studies have not been performed within the context of 
newborn screening and are therefore discussed in a separate paragraph.  
 
II.A.5.2 BIOMONITORING OF ANIMALS 
Intoxication of animals with cholinesterase inhibitors (e.g. organophosphate and carbamate 
insecticides) may occur via ingestion (e.g. of exposed prey) or via dermal contact. Assessment of 
cholinesterase activity in DBS of avian species has been found sensitive enough to serve as a 
diagnostic tool for identifying exposure to cholinesterase-inhibiting pesticides. DBS sampling of 
animals allows the collection of samples at remote areas and in non-specialized centres, where no 
special equipment like a centrifuge is available and where proper storage of a blood sample is 
difficult [72]. 
 
A recent initiative in the context of monitoring exposure of animals to toxic substances, somewhat 
paralleling the efforts done for evaluating a newborn’s exposure to environmental contaminants 
via DBS, is DABSE (“Database for avian blood spot examination”) [110]. This biomonitoring project 
aims at setting up reference values for exposure of wild birds to five groups of environmental 
contaminants: trace elements, organochlorine pesticides, PCBs, PFCs and PBDEs. Referral to the 
values within this database should help to pinpoint a possible cause in cases in which an individual 
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bird or a bird population presents with a problem. A first application of this biomonitoring project 
was performed on griffon vultures, demonstrating detectable levels of several contaminants in 
DBS obtained from these birds [89].  
 
Environmental health can also be assessed by monitoring the exposure of top predators, acting as 
sentinels. In coastal waters in the Gulf of Mexico, this approach has been used for monitoring the 
exposure of bottlenose dolphins to the marine algal biotoxins domoic acid and brevetoxins, 
respectively produced by members of the diatom genus Pseudo-nitzschia and by the dinoflagellate 
Karenia brevis [111]. Both biotoxins have been measured in DBS, obtained by spotting filter paper 
cards with 100 µl of blood, obtained from either exposed laboratory test animals (mice, rats or the 
fish species striped mullet) or from free-living dolphins [111-115]. Toxin detection in DBS extracts 
has been performed using receptor-binding assays [112] and radio immuno-assay (RIA, for 
brevetoxins) [113] and, more recently, by competitive enzyme-linked immunosorbent assay 
(ELISA), either detecting brevetoxins and their metabolites, or domoic acid [116,117]. Ciguatoxins 
are another class of highly potent neurotoxins, sharing with brevetoxins the binding site 5 on the 
α-subunit of voltage-gated sodium channels as effector site [118]. Using a neuroblastoma 
cytotoxicity assay, ciguatoxins have been determined in DBS extracts from exposed mice [119]. 
 
II.A.6 ELEMENTAL ANALYSIS 
Biomonitoring of toxic trace elements (metals and metalloids) in human blood has been applied 
for decades. Examples include lead, which exerts neurological toxicity, and arsenic, cadmium, 
mercury, chromium, copper, nickel and vanadium, all of which have distinct toxicity profiles. When 
aiming at (primarily) single-element analysis, analysis is usually performed by atomic absorption 
spectrometry, or more recently by (solid sampling) graphite furnace atomic absorption 
spectrometry [120,121]. Inductively coupled plasma mass spectrometry (ICP-MS) has been used 
for both single-element and for multi-element analysis, with more recent developments being 
laser ablation-ICP-(TOF-)MS and sector-field-ICP-MS [109,122-124]. 
 
Considering the analysis of trace elements in DBS, most attention has been given to the 
determination of Pb in DBS obtained from children. Although the determination of venous Pb 
concentrations is considered the gold standard, venepuncture of infants and toddlers is 
impractical, may be traumatic for the children and in many countries is not widely accepted by the 
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parents as a screening test for asymptomatic children [125]. As children are particularly sensitive 
to Pb and in most countries Pb concentrations peak at approximately 2 years of age [126,127], a 
minimally invasive technique such as DBS sampling offers many advantages for obtaining a 
representative blood sample. Micro-sampling of blood for Pb determination in DBS was first 
reported in the early seventies [128,129]. Although since then, many reports have been published 
on the determination of Pb in DBS, this approach has also been the subject of controversy, given 
the risk of contamination that may take place, as opposed to blood collection by venepuncture 
[120,130-134]. Indeed, given the ubiquitous presence of Pb in the environment, special care has to 
be taken to avoid contamination at every step, from paper handling, sampling, and drying, over 
transport to analysis. More specifically, falsely elevated Pb concentrations may result from 
contamination by Pb present on the skin (thus necessitating suitable cleansing before sampling) 
and/or by improper paper handling [131,133,135].  
 
In contrast to a controlled clinical environment, in which the issue of contamination can be dealt 
with from sampling to analysis, one has to be aware that DBS sampling ‘on-field’, with less control 
on pre-analytical variables, potentially suffers from an increased risk of contamination. Yet, 
especially in developing countries, where studies have shown that the threshold limit of Pb 
poisoning is exceeded in a large percentage of children [136-138], the lack of resources renders 
DBS sampling one of the most feasible ways for screening large populations [125]. Sampling can be 
done on-site by a relatively untrained collector and samples can be sent by mail to an analytical 
laboratory. To correct for possibly inhomogeneous Pb distribution on the filter paper, analysis of 5 
replicates (3.2-mm punches obtained from a single 50-µl blood spot) has been recommended by 
Resano and colleagues [121]. However, in practice, blood spots often correspond to smaller blood 
volumes, which may limit the number of punches and/or may pose a problem when larger 
punches (e.g. 6 or 6.35 mm diameter) are to be analyzed [139]. The Pb concentrations determined 
in DBS have been shown to be independent from the volume spotted and from the site of 
punching (excluding the area near the perimeter, where concentrations are higher owing to a 
higher amount of red blood cells). Moreover, a good correlation was found between Pb 
concentrations in DBS and those in venous blood [121,135]. DBS obtained from subjects with 
strongly deviating hematocrit values, however, may give rise to discordant results [135]. 
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Apart from Pb, also other toxic metals, as well as elements of clinical or forensic interest, have 
been determined (or have been shown to be detectable) in DBS, including As, Ba, Be, Bi, Ca, Cd, 
Co, Cr, Cs, Cu, Fe, Hg, K, Li, Mg, Mn, Mo, Na, Ni, P, Rb, S, Sb, Se, Tl, V and Zn [89,109,123,124,140]. 
Quantification of several of these elements may lead to the generation of an individual’s “metallic 
profile”, from which exposure to a certain contamination source may be deduced [141].  
 
An important obstacle for fully quantitative analysis of a substantial amount of elements, however, 
is the variable contribution by the filter paper (both within and between lots) and possible 
contamination, requiring adequate control of blank filter paper. This implies the control of 
different lots of unexposed blank paper, directly from the manufacturer, as well as the control of 
paper (“internal blanks”) at some distance from the DBS. Yet, still, one cannot fully exclude the 
scenario in which contamination within, but not near the DBS took place [109,123]. The 
background values obtained from the controls can either be used for subtracting (possibly causing 
a negative bias) or can merely be used for evaluating the overall extent of contamination. Either 
way, replicate analysis of the same DBS (punch) and/or analysis of another DBS (punch) from 
positive cases is recommended to reduce the reporting of false positives [122,123]. In this respect, 
the technique of laser ablation ICP-TOF-MS, providing a “line scan” with several data points per 
blank and per DBS, allows easy discrimination of potential random contamination [122]. Moreover, 
as reported by Cizdziel, the use of isotope ratio’s determined by this technique may also allow to 
discriminate contamination extraneous to the blood sample [122].  
 
To overcome the major problem of contamination encountered in elemental analysis of DBS and, 
at the same time, to account for possible variations in hematocrit and/or volume spotted, 
normalization may be another possible future improvement. This can be done using one or 
multiple elements, having a narrow physiological distribution and/or being (almost) absent in 
blank filter paper. As suggested by Langer et al., one such candidate could be potassium [109]. 
Finally, it is important to mention that decision-making in the case of environmental pollution 
(including the analysis of trace elements) is somewhat distinct from that in the case of drugs of 
abuse. Whereas for the latter any positive signal (above the LOD, LLOQ or a certain cut-off) can 
raise an alert, positivity for the former can in many cases be considered as ‘normal’, with only 
levels exceeding a certain threshold warranting further follow-up. 
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II.A.7 CONCLUSION AND FUTURE PERSPECTIVES 
DBS sampling is being applied in a wide range of applications in toxicology, covering fields as 
toxicokinetics, epidemiology and environmental and forensic toxicology. The analytes measured in 
DBS include therapeutic drugs, drugs of abuse, environmental contaminants and (trace) elements. 
Among the advantages associated with DBS sampling, the ease of collecting a representative 
sample with minimal discomfort is of particular importance for its application in toxicology. This 
holds true for sampling of animals, newborns, children, but also for adults, considering the 
potential of DBS sampling at home or in the context of DFSA, DUID or the follow-up of drug 
addicts. The stabilizing effect of DBS, largely preventing both ex vivo degradation and de novo 
formation of analytes, is another significant advantage associated with this sampling technique, 
facilitating sample handling and transport and often allowing long-term storage of samples. 
Despite these -as well as other- important advantages, also some remarks should be made with 
respect to the use of DBS for toxicological purposes. A first remark is the issue of contamination, 
which primarily (but not only) is a problem in the field of elemental analysis. Although this issue 
can be largely dealt with in a tightly controlled environment, contamination can never be 
excluded, especially in the case of ‘on-field’ sampling. Given the bioanalyst’s awareness of this 
problem, various avenues are being explored to increase the confidence one may have in a 
positive result. As mentioned above, these include e.g. the analysis of blank controls, the 
acquisition of multiple data points from a single spot or from replicate spots and/or attempts to 
normalize for e.g. hematocrit using one or multiple elements. A second remark is that for many 
analytes the influence of parameters such as hematocrit, volume spotted and site of punching has 
not been examined. Lack of knowledge about the influence of these (as well as other) parameters 
adds an additional, often neglected, factor of uncertainty to the reported analytical result. Thirdly, 
although promising results have been obtained in e.g. forensic toxicology, the approaches 
followed are often not fully compatible with the collection of true ‘on-field’ capillary blood 
samples, requiring more extensive validation. Apart from these points of attention, requiring more 
work to be done, it is our feeling that the largest contribution of DBS sampling in toxicology may lie 
in the field of drug development. There, its implementation of ‘refinement’ and ‘reduction’, 
allowing “small sampling of small animals” closely follows the 3R principle and is even 
accompanied by improved data quality. Also in (pre)clinical studies, the implementation of DBS 
sampling may be an incentive, e.g. by facilitating patient recruitment. As this evolution will 
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evidently lead to a large amount of samples to be analyzed, current efforts are now being focused 
on automation and rapid, direct analyses of DBS. 
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II.B.1 INTRODUCTION 
The dried blood spot (DBS) sampling technique has several advantages over a venepuncture, 
making it a cost-effective choice for the collection, transport and storage of blood samples. 
Inherent to DBS sampling is the small sample volume available, ranging from 5 to 100 µl, compared 
to 1 ml or more obtained by venepuncture. Although this may represent an advantage in case of 
sampling patients with restricted or limited venous access, such as neonates and children, these 
small amounts may impose an analytical challenge and require efficient sample treatment, as well 
as sensitive detection [1-4]. To achieve adequate method sensitivity for the analysis of different 
pharmaceutical compounds or biomarkers in DBS, even at lower concentration levels, the majority 
of DBS applications use tandem mass spectrometry (MS/MS) coupled to liquid chromatography 
(LC). Other analytical techniques such as direct MS/MS, LC coupled to fluorescence (LC-FLUO) or 
ultraviolet detection (LC-UV), or gas chromatography coupled to MS (GC-MS) or tandem MS (GC-
MS/MS) have been demonstrated to be suitable alternatives [5-7]. Additionally, to achieve the 
required method sensitivity, DBS analysis may involve derivatization. This may lead to an 
improvement of the chromatographic properties of the analytes of interest, which consequently 
may also influence method sensitivity by enhancing volatility, separation efficiency and/or 
selectivity [8]. Derivatization is primarily known as a technique extending the molecular application 
range of GC [9]. During sample work-up of DBS GC-MS (/MS) applications, derivatization reactions 
as silylation, alkylation and/or acetylation have been performed [5,10,11]. Also LC-UV or LC-FLUO 
applications may integrate a derivatization step during DBS analysis to improve detection 
sensitivity and selectivity by enhancing the UV properties or the fluorescence yield of the target 
analytes, respectively [6,12,13].  
 
In contrast, derivatization is less commonly used for LC-MS/MS analysis, especially because 
omission of derivatization in an analysis is recognized as a major advantage, but also because 
variation and artifacts can be introduced [14,15]. However, the integration of derivatization 
techniques could enhance the capabilities of certain MS/MS-based applications and may give rise 
to several advantages such as improved chromatography and improved mass spectrometric 
properties (e.g., ionization efficiency, m/z) of the target compounds [15]. For example, the 
electrospray ionization (ESI) yield of neutral ketosteroids may be low as they lack a functional 
group that is easily ionized under normal conditions. This limitation can be overcome by 
introducing a chargeable moiety. In this way, derivatization of 17-hydroxyprogesterone to its 
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positively charged hydrazone before LC-ESI-MS/MS analysis, resulted in a 10-fold gain in sensitivity 
[16,17].  
 
Although, in theory, higher ionization yield and better selectivity are expected for small molecules 
or neutral compounds when using derivatization, it may be important to evaluate the differences 
between derivatization and non-derivatization procedures on an analyte-per-analyte basis prior to 
selecting the most suitable sample work-up protocol. This point was demonstrated by De Jesus 
and co-workers, comparing the ionization efficiency for acylcarnitines and amino acids (AA) in 
derivatized (butyl ester) and non-derivatized forms (free acid) [18]. The authors found that for the 
majority of the selected compounds, minor differences in quantitative results were observed 
between both methods, while mass spectrometric responses varied from more intense without 
derivatization, over being similar, to less than 66% of the mass spectrometric ion counts obtained 
by derivatization. Moreover, without derivatization the method may be less selective, not capable 
to differentiate isobaric acylcarnitines.  
 
Different traditional derivatizing reagents are available for GC-MS, LC-FLUO and -UV based 
procedures, and some of these have been applied in (LC-) MS/MS applications. However, for the 
latter, limitations may be encountered such as suboptimal ionization efficiency and product ion 
yield. Furthermore, different LC behaviors are expected for the derivatized compounds. Therefore, 
efforts have recently been made to design derivatives specifically for (LC-) MS/MS based 
approaches [15,16,19]. Examples that illustrate the advantages gained as a result of derivatizing 
the target compounds in DBS are given below. However, as it is beyond the scope of this chapter 
to provide an exhaustive overview of current derivatization techniques and reagents utilized in GC, 
LC and (LC-) MS/MS methods, we would like to refer to comprehensive reviews on this subject 
[8,9,15,16,19,20-22].  
 
II.B.2 OVERVIEW OF DERIVATIZATION TECHNIQUES IN DBS ANALYSIS 
The aim of this chapter is to present an overview of DBS methods utilizing derivatization published 
since 1990 up till now. Generally, formation of derivatives can be carried out during sample work-
up (pre-column) or post-column before the column eluate enters the detection system [23]. A few 
DBS methods reported in the eighties opted for such a post-column derivatization technique in 
combination with LC–FLUO, mainly to avoid instability of the derivatives during sample work-up 
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and separation [24,25]. By mixing column eluates on-line with the derivatizing reagents, the 
derivatized target compounds are directly detected, but as these are also diluted this resulted in 
sensitivity loss that needs to be compensated for by the gain in sensitivity due to derivatization 
[26]. Although considerable improvements in method sensitivity and analysis time have been 
made in comparison to the original procedures, only a minority of recently reported DBS methods 
uses this derivatization technique [27]. Hence, contribution of the post-column derivatization 
technique in DBS analysis has been considered as too limited, and consequently, beyond the scope 
of this chapter.  
 
The focus of this overview lies on derivatization techniques utilized during sample preparation. 
Therefore, we made a classification based upon the DBS sample work-up procedure. The first 
group of methods has in common that the conducted DBS sample treatment is considered to be 
the ‘general’ procedure (Table II.B.1, Fig. II.B.1: general procedure). Tables II.B.2 to II.B.4 
summarize selected methods with modifications to this ‘general’ procedure (Fig. II.B.1: modified 
sample work-up procedure 1-3). The latter include direct derivatization, a procedure in which 
(extracting and) derivatizing solutions are applied in one single step to the DBS.   
 
Fig. II.B.1 Schematic overview of the general and modified sample work-up procedures in DBS analysis 
including derivatization 
 
 
Important factors that contribute to the choice for a certain derivatization DBS sample work-up 
procedure are the choice of derivatizing reagent and the circumstances required to form a stable 
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derivative in a quantitative way. The choice of derivatization reagent depends on the physical and 
chemical properties of the target analytes and on the instrument characteristics. The reaction yield 
can be influenced by the type and amount of derivatizing reagent, the pH, temperature and time 
needed to complete the reaction. In addition, some reagents require an aprotic environment for 
the reaction to occur while others react well in aqueous media. Furthermore, as not all reagents 
can be injected directly into an analytical system, excess derivatization reagent may need to be 
removed prior to analysis [8,15,28].  
 
II.B.2.1 GENERAL DBS SAMPLE WORK-UP PROCEDURE INCLUDING DERIVATIZATION  
An overview of selected procedures that apply the ‘general’ procedure is shown in Table II.B.1. 
These procedures have been widely applied in metabolic screening of newborn DBS and in follow-
up monitoring of symptomatic patients [29]. Thereby, as shown in Table II.B.1, various assay 
methods such as (LC-) MS/MS and GC-MS and derivatization procedures have been utilized to 
achieve required method sensitivity and/or selectivity. All selected methods follow a similar 
sample work-up (Fig. II.B.1: general procedure) and start with elution of the analytes of interest 
from the DBS, sometimes followed by an extra purification step such as solid-phase extraction 
(SPE) in order to increase analytical column lifetime and reduce MS cleaning [30,31]. Subsequently, 
(an aliquot of) the extract is transferred and evaporated under a stream of nitrogen before adding 
the derivatization reagent(s). Then, after completion of the derivatization, the excess reagent is 
removed by evaporation under a stream of nitrogen, followed by reconstitution of the derivatized 
extract prior to injection.  
 
In an LC-MS/MS method developed to determine 17-hydroxyprogesterone and 17-
hydroxypregnolone in DBS, the target compounds were derivatized according to this general 
procedure to enhance ionization during ESI-MS/MS [30]. In addition, direct MS/MS, without 
chromatographic separation, has become a well-established technique for the quantitative 
determination of several biomarkers in DBS after derivatization. Corresponding butylesters are 
prepared prior to analysis, in order to enhance sensitivity and to reduce potential background 
interferences by increasing m/z values as a result of mass gain. This procedure, first reported in the 
nineties by Chace et al. [32-34], has replaced historically used newborn screening tests and has 
evolved to a single-run analysis using fully automated ESI MS/MS, detecting over 65 metabolites 
and/or specific markers for disorders in amino acid, fatty acid or organic acid metabolism [35,36].  
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Table II.B.1 Selected examples of DBS methods using the ‘general’ sample work-up procedure  
Assay method  Type of 
derivatization  
Analyte(s) of interest Application Selected references 
LC-MS/MS Hydrazone complex 
formation 
17-OH-progesterone 
17-OH-pregnolone 
NBS Higashi et al.; 2008 [30] 
Lai et al.; 2001 [17] 
 
Alkylation: 
butylesterification 
Guanidinoacetate 
creatine 
NBS Bodamer et al.; 2001 
[44] 
Diels Alder  25-OH-vitamin D3 
25-OH-vitamin D2 
NBS Eyles et al.; 2009 [37] 
 
Diels Alder - 
Acetylation  
(2-step) 
25-OH-vitamin D3 
3-epi-25-OH-vitamin D3 
NBS Higashi et al.; 2011 [31] 
MS/MS Alkylation: 
butylesterification 
AA 
(Acyl)carnitine(s) 
Guanidinoacetate 
creatine 
NBS Jebrail et al., 2012 [45]; 
Chace et al., 1993 [32]; 
Chace et al., 1995 [33]; 
Chace et al., 1996 [34]; 
Naylor and Chace, 1999 
[35]; Chace et al., 2009 
[46]; Turgeon et al., 
2008 [47]; 
Carducci et al., 2006 
[29]; Fingerhut et al., 
2001 [48] 
GC-MS Alkylation: 
butylesterification- 
Acetylation  
(2-step) 
AA NBS Deng et al., 2002b [39]; 
 Deng and Deng, 2003 
[40] 
 
 
Silylation  AA NBS Shen et al., 2006 [10]; 
Deng et al., 2002a [38]; 
Deng et al., 2005b [41]; 
Deng et al., 2005c [42] 
AA: amino acids; GC: gas chromatography; LC: liquid chromatography; MS/MS: tandem mass spectrometry; MS: mass 
spectrometry; NBS: newborn screening 
 
 
Under some conditions, a 2-step derivatization reaction that involves the sequential application of 
non-compatible derivatization reagents may be required to obtain suitable derivatives. The 
usefulness of including a 2-step reaction is illustrated by the following example. Eyles et al. [37] 
and Higashi et al. [31] both developed an LC-MS/MS method for the determination of 25-OH-
vitamin D3 in DBS to diagnose vitamin D deficiency. In the first method, 25-OH-vitamin D2 and D3 
were derivatized using a single derivatization reaction to increase their ESI-MS/MS response. In 
addition, to separate the target analyte from a potentially interfering epimer (3-epi-25-OH-vitamin 
D3) during LC, Higashi et al. [31] performed an additional derivatization reaction, thereby 
enhancing method selectivity and avoiding overestimation of the vitamin D3 level.  
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Although (LC-) MS/MS has been generally recognized as a powerful tool for newborn screening 
(NBS), it can be too expensive in some circumstances. Then, a possible and suitable alternative is 
GC-MS, known to be a relatively inexpensive, simple, but sensitive technique. For the 
determination of different AA in newborn DBS using GC-MS, previously reported 2-step 
derivatization sample work-up procedures using alkylation and acetylation have been improved by 
the use of single-step silylation, hence contributing to simplified sample work-up procedures [38-
40,10]. Moreover, instead of classical silylation, microwave-assisted-silylation has been 
successfully applied to determine AA in DBS. Heating the sample mixture in a sealed vessel by 
microwave energy resulted in a strong reduction of the time required for energy transfer, and, 
consequently, in faster completion of derivatization processes [41-43].  
 
II.B.2.2 MODIFICATIONS  
Several modifications have been made to the above mentioned ‘general’ procedure, mainly to 
minimize and simplify the DBS sample preparation. Reported modified sample work-up procedures 
can be classified into three groups. Procedures in the first group only differ from the ‘general’ 
procedure in that the derivatized extract is not dried and reconstituted, but is directly injected into 
the analytical system (Table II.B.2, Fig. II.B.1: modified sample work-up procedure 1). In the second 
modified sample work-up, the evaporation step between the extraction and derivatization is 
omitted (Fig. II.B.1: modified sample work-up procedure 2). Furthermore, once derivatized, an 
aliquot of the sample mixture can be injected into the analytical system either after removal of the 
excess reagent (Table II.B.3a) or directly (Table II.B.3b). The third group achieves a simplified 
sample work-up by using a direct derivatization technique, meaning that DBS extraction and 
derivatization of the extracted compounds is performed in one single step (Fig. II.B.1: modified 
sample work-up procedure 3). To this end, DBS can be exposed to extraction and derivatization 
reagents simultaneously, or only to the latter, leading to “on spot” derivatization without the use 
of any extraction solvent. Similar to modified sample work-up procedure 2, the final sample 
mixture can be injected either after removal of the excess reagent (Table II.B.4a) or directly after 
derivatization (Table II.B.4b). In the following subsections, these modified sample work-up 
procedures are further explained and illustrated by several examples. 
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II.B.2.2.1 Modified sample work-up procedure 1: Extraction-evaporation-
derivatization 
A first modification of the ‘general’ sample treatment consists of extraction of a DBS, derivatization 
of the dried extraction residue and direct injection of an aliquot of the derivatized extract (Fig. 
II.B.1: modified sample work-up procedure 1). Removal of the excess derivatizing reagent is no 
longer required if it can be injected directly without causing contamination or chemical damage of 
the column or detection system. In Table II.B.2, selected examples of DBS methods using this 
sample work-up procedure are shown.  
 
Table II.B.2 Selected examples of DBS methods using the modified sample work-up procedure 1: Extraction-
evaporation-derivatization 
Assay method Type of 
derivatization  
Analyte(s) of interest Application Selected references 
GC-MS Silylation  Metabolites (for profiling) 
23 drugs of abuse 
Free fatty acid (cis-4-
decenoic acid) 
17-OH-progesterone 
MP  
TOX 
NBS 
Kong et al., 2011 [49]; 
Langel et al., 2011 [50]; 
Heales and Leonard, 
1992 [51]; Deng et al., 
2005a [52] 
 
Silylation – Acetylation 
(2-step): Formation of 
TMS-TFA- derivatives 
AA  
Organic acids 
Glycines 
NBS (DPS) Yoon, 2007 [57] 
LC-FLUO Intramolecular excimer 
fluorescence 
derivatization using 
pyrene reagent 
Methylmalonic acid NBS Al-dirbashi et al.; 2005 
[13] 
LC-UV Formation of AQC-
derivatives 
AA NBS Swenson and 
McWhinney, 2009 [58] 
LC-MS/MS Alkylation: 
butylesterification – 
hydrazone formation 
(2-step) 
Succinylacetone NBS Al-Dirbashi et al., 2006 
[55]; Al-Dirbashi et al., 
2008 [56] 
AA: amino acids; AQC: 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate; DPS: dried plasma spots; FLUO: fluorescence; 
GC: gas chromatography; LC: liquid chromatography; MP: metabolomic profiling; MS/MS: tandem mass spectrometry; MS: 
mass spectrometry; NBS: newborn screening; TFA-: trifluoroacyl-; TMS-: trimethylsilyl-; TOX: toxicology; UV: ultraviolet 
 
 
In this context, a suitable strategy for GC-MS applications is silylation. Using silylating reagents 
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), N-methyl-N-(trimethylsilyl)-trifluoroacetamide 
(MSTFA) and N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide (MTBSTFA), specific 
metabolites (for metabolomic profiling), 23 drugs of abuse, a free fatty acid (cis-4-decenoic acid) 
and 17-hydroxyprogesterone were successfully determined in DBS, the latter following microwave-
assisted-silylation [49-52].  
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Several reagents for pre-column derivatization of nonfluorescent compounds to their fluorescent 
derivatives prior to reversed-phase high-performance liquid chromatography (RP-HPLC) separation 
are also suitable for direct injection. In addition, these reagents can mostly be applied directly to 
the extraction mixture (see subsection II.B.2.2.2), but in some circumstances the extraction solvent 
needs to be evaporated as it may influence fluorescence yield and stability. For example, for the 
determination of methylmalonic acid in DBS, the DBS methanolic extract was dried and 
reconstituted in water, followed by addition of the pyrene reagent and catalysts in 
dimethylsulphoxide. This procedure resulted in intense fluorescence of the dipyrene derivative of 
methylmalonic acid, which, in addition, could clearly be discriminated from that of the monomeric 
fluorescing compounds, thereby eliminating these interferences [13,53,54].  
 
Dansylhydrazine, originally used as derivatization reagent in LC-FLUO applications, has been 
successfully applied in DBS LC-MS/MS methods determining succinylacetone (SA), which shows 
very poor ionization efficiency in ESI-MS [16]. Al-Dirbashi and co-workers developed a 2-step 
derivatization reaction, as they concluded that applying dansylhydrazine alone to the DBS residue 
resulted in a mono-dansylhydrazone derivative with unfavorable chromatographic properties. 
Thus, to improve the chromatographic properties such as acceptable retention and less peak 
tailing and to increase ionization efficiency, SA was butylated prior to dansylation. Between the 
derivatization processes, the butylated extract was dried and after allowing the second reaction to 
occur, an aliquot of the resulting mixture was subjected to high-performance LC (HPLC)- or ultra-
high-performance LC (UHPLC)-MS/MS analysis [55,56].    
 
II.B.2.2.2 Modified sample work-up procedure 2: Two-step extraction-
derivatization 
GC and LC applications have been reported where the reagents are applied to the (aqueous) 
extraction mixture without prior evaporation (Fig. II.B.1: modified sample work-up procedure 2). 
Derivatization reagents that react under the conditions of the extraction solvent are suitable 
candidates for this purpose. Moreover, some reagents have the additional advantage of reacting 
fast without heating. Table II.B.3 shows selected examples of DBS methods using this modified 
sample work-up procedure, divided into procedures where the excess reagent is removed prior to 
injection (Table II.B.3a) and procedures where the final mixture is injected directly into the 
analytical system (Table II.B.3b). 
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Table II.B.3 Selected examples of DBS methods using the modified sample work-up procedure 2:  
Two-step extraction and derivatization, followed by removal of the excess reagent (a) or by direct injection (b) 
(a) 
Assay method Type of derivatization  Analyte(s) of 
interest 
Application Selected references 
GC-MS Alkylation: alkyl 
chloroformation 
AA NBS Kawana et al., 2010 [59]; 
Deng et al., 2004 [60] 
LC-UV Formation of 
phenylthiocarbamyl-
derivatives  
AA NBS Dale et al., 2003 [12] 
 
AA: amino acids; GC: gas chromatography; LC: liquid chromatography; MS: mass spectrometry; NBS: newborn screening; 
UV: ultra-violet 
 (b) 
Assay method Type of 
derivatization  
Analyte(s) of 
interest 
Application Selected references 
LC-FLUO OPA
1  
Formation of isoindolic 
derivatives 
AA 
Aminoglycoside 
antibiotics 
NBS 
TDM 
Preclinical 
studies 
Kand’ar et al.. 2009 [61]; 
Moretti et al., 1990 [62]; 
Lundsjo et al., 1990 [64]; 
Vollmer et al., 1990 [66] 
Benzoin 
Formation of 2-
substituted amino-4,5-
diphenylimidazoles 
GAA NBS Carducci et al., 2001 [26] 
OPD2 
Formation of 2-
quinoxalinol derivatives 
α-keto acids NBS Kand’ar et al., 2009 [61] 
LC-MS/MS Formation of PFB
3-
derivatives 
Seven-carbon sugars NBS Wamelinck et al., 2011 
[65] 
1OPA: O-phtalaldehyde; 2OPD: O-phenylenediamine; 3PFB-derivatives: O-2,3,4,5,6-pentafluorobenzyl-derivatives 
AA: amino acids; FLUO: fluorescence; GAA: guanidinoacetic acid; LC: liquid chromatography; MS/MS: tandem mass 
spectrometry; NBS: newborn screening, TDM: therapeutic drug monitoring 
 
 
When using GC, the injection of excess reagent but also of residual water into the GC system is 
preferentially avoided (Table II.B.3a). This can be achieved by extracting the derivatized target 
analytes from the (aqueous) reaction mixture. A GC-MS method developed for the determination 
of several AA in DBS after “in situ” derivatization with propyl chloroformate illustrates this 
principle. As water does not interfere with alkyl chloroformation, the chloroformate can be added 
directly to the eluate of an SPE step, isolating AA from a DBS extract. After completion of the 
reaction within 1 minute at room temperature, the resulting derivatives are isolated by liquid-
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liquid extraction (LLE) using a water-immiscible organic solvent, of which an aliquot was injected 
[59]. In another method, isobutyl chloroformate derivatized AA were extracted from an aqueous 
reaction mixture by solid-phase micro extraction (SPME), followed by desorption of the fiber into 
the GC-MS injector [60].  
 
Likewise, excess derivatizing reagents enabling LC-UV detection may be removed by additional 
purification steps to avoid interference during analysis (Table II.B.3a). Dale et al. (2003) [12] used 
this approach for the determination of phenylalanine and tyrosine in DBS. Following extraction and 
the generation of phenylthiocarbamylderivatives, the extracts were dried and reconstituted in 0.1 
M sodium acetate buffer. The excess reagent still present in the final aqueous mixture was trapped 
in methylene dichloride along with other possibly interfering compounds prior to analysis of the 
clear aqueous phase by reversed-phase HPLC with UV detection.  
 
Similar procedures have been reported in combination with LC-FLUO or LC-MS/MS methods, 
having the advantage that an aliquot of the final reaction mixture can be injected directly (Table 
II.B.3b). For example, pre-column derivatization of several AA, guanidinoacetic acid (GAA) and α-
keto acids has been performed in order to achieve highly sensitive and selective LC-FLUO methods 
[61,26,62]. A way to achieve reproducible results and avoid errors from instability of the derivative 
when applying certain derivatizing reagents pre- rather than post-column, is controlling the time 
between derivatization and injection by an on-line derivatization technique [61,63,64]. On-line 
derivatization can be achieved by derivatizing in the autosampler, as has been demonstrated for 
several DBS-extracted AA, derivatized with o-phthaldialdehyde immediately prior to separation 
[61,64]. An LC-MS/MS example is the determination of the derivatized seven-carbon sugar 
sedoheptulose, which proved to be substantially more sensitive, with no interferences of other 
sugars possibly present in the DBS. Additionally, as retention was increased due to derivatization, 
simple reversed-phase chromatography using a common mobile phase composition could be 
performed [65]. 
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II.B.2.2.3 Modified sample work-up procedure 3: Direct derivatization 
techniques  
The most convenient approach for derivatizing analytes from DBS is direct derivatization. This 
approach has been reported for the analysis of conventional matrices such as blood, plasma and 
serum and of aqueous matrices such as drinks. In those cases, an aliquot of matrix (20-50 µl) is 
directly derivatized by adding an excess of derivatization reagent (up to 1 ml), thereby omitting the 
extraction step [67-69]. Implementing this principle in DBS analysis, extracting and derivatizing 
solutions could be applied simultaneously to the DBS or even only the derivatizing reagent(s) could 
be added without use of any extraction solvent (Fig. II.B.1: modified sample work-up procedure 3). 
We coined the latter approach “on spot” derivatization. Table II.B.4 shows selected examples of 
DBS methods using direct derivatization techniques, followed by removal of the excess reagent 
before injection (Table II.B.4a) or by direct injection (Table II.B.4b).  
 
Depending on the type of derivatization reagents used, a proper extraction solvent should be 
selected, which still allows the reaction to occur and results in acceptable extraction recovery of 
the (derivatized) target analyte. For example, for the determination of antidepressants in DBS, a 
method was developed combining a fast and sensitive GC-MS/MS technique with direct 
derivatization of the DBS. Fluorinated agents were chosen to derivatize the analytes, increasing 
electro-affinity which was important for MS/MS detection operating in negative chemical 
ionization (NCI) mode (this mode being highly selective and sensitive for compounds with high 
electron-affinity). Although the use of methanol and water as extraction solvent resulted in higher 
extraction recovery of fluoxetine, norfluoxetine, reboxetine and paroxetine, the authors selected 
an aprotic organic solvent (butyl chloride), as this could be applied simultaneously with the 
fluorinating agent, simplifying sample work-up and still resulting in the required method sensitivity 
[5].   
 
In some circumstances, adequate sensitivity and selectivity can be achieved by applying the 
derivatization reagent (mixture) directly “on spot”, without the use of additional (co-) extracting 
solvent. In this scenario, it is assumed that the reagent functions both as extracting and 
derivatizing agent, as no other solutions or solvents are added to the DBS. To our knowledge, up-
to-date this approach of “on spot” derivatization has only been applied for the GC-MS-based 
determination of gamma-hydroxybutyric acid (GHB), a notorious club and date-rape drug, in DBS 
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[11,70]. More specifically, GHB was derivatized by adding a mixture of trifluoroacetic acid 
anhydride (TFAA) and heptafluorobutanol (HFB-OH) directly “on spot”. Although only a small 
volume of whole blood was analyzed (a 6-mm diameter punch from a DBS, corresponding to 
approximately 10 µl), adequate sensitivity was achieved [70]. 
 
Table II.B.4 Selected examples of DBS methods using the modified sample work-up procedure 3: Direct 
derivatization, followed by removal of the excess reagent (a) or by direct injection (b)  
(a) 
Assay method Type of 
derivatization  
Analyte(s) of 
interest 
Application Selected 
references 
GC-MS/MS Acetylation  Antidepressants TDM Déglon et al., 2010 
[5] 
GC-MS On spot alkylation and 
acetylation  
GHB TOX Ingels et al., 2010 
[11] ; Ingels et al., 
2011 [70] 
Transmethylation  Free fatty acids NBS Kimura et al., 2002 
[71]; Morton and 
Kelley, 1990 [76] 
MS/MS Formation of 1-phenyl-
3-methyl pyrazolone 
derivatives 
Oligosaccharides MD Ramsay et al., 2003 
[73]; Rozaklis et al., 
2002 [72] 
GC: gas chromatography; GHB: gamma-hydroxybutyric acid; MD: metabolic disorder; MS/MS: tandem mass spectrometry 
direct injection; MS: mass spectrometry; NBS: newborn screening; TDM: therapeutic drug monitoring; TOX: toxicology  
 (b) 
Assay method Type of 
derivatization  
Analyte(s) of 
interest 
Application Selected 
references 
LC-MS/MS Formation of DAABD-
AE-derivatives 
3-OH-glutaric acid 
Glutaric acid  
NBS (DUS) Al-Dirbashi et al., 
2011 [74] 
MS/MS Hydrazone formation  Succinylacetone NBS Allard et al., 2004 
[75] 
DAABD-AE: 4-2-(N,N-dimethylamino)ethylaminosulfonyl-7-(2-aminoethylamino)-2,1,3-benzoxadiazole; DUS: dried urine 
spots; LC: liquid chromatography; MS/MS: tandem mass spectrometry direct injection; NBS: newborn screening  
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Although in the above-mentioned GC-methods, removal of the excess reagent was achieved by 
simple evaporation, in some circumstances, additional LLE and/or SPE is required in order to 
isolate the derivatized analyte and/or remove the excess reagent before injection (Table II.B.4a). 
For example, after a single step transmethylation of free fatty acids present in DBS, the reaction 
was halted by adding 6% potassium carbonate and the derivatives were extracted in hexane, of 
which an aliquot was injected into the GC-MS [71]. In another example, the excess reagent used to 
derivatize oligosaccharides in DBS with a single step extraction/derivatization procedure was 
trapped in chloroform. The remaining aqueous layer was subjected to SPE, including wash steps to 
further remove any unincorporated reagent, and finally, the eluate containing the derivatives was 
dried and reconstituted before injection into the ESI-MS/MS system [72,73].  
 
As complicated procedures to remove excess reagent extend the sample work-up associated with 
a simplified extraction/derivatization procedure, direct derivatization techniques in which an 
aliquot of the supernatant can be analyzed directly are even more practical (Table II.B.4b). Since in 
this scenario the complete DBS sample preparation has been reduced to a single step, sample 
throughput is consequently only limited by the time required for the derivatization reaction to 
occur. To illustrate this, sample work-up of an LC-MS/MS method determining 3-hydroxy-glutaric 
acid and glutaric acid in dried urine spots (DUS) was completed within 45 min since the direct 
derivatization step required 45 min at 60°C to obtain maximum derivatization yield. Here, internal 
standard solution and derivatizing reagents were added successively to the dried spot, hence 
eliminating a separate extraction step, and an aliquot of the final derivatized solution was analyzed 
directly after the reaction had been stopped. Derivatization was required to enhance ionization 
and fragmentation of the target compounds [74]. 
 
Special considerations will need to be taken into account when using direct derivatization 
techniques. This is because the derivatization yield reflects both elution of the target compounds 
from the DBS filter paper as well as the formation of the derivatives. An example is the 
simultaneous extraction of SA from DBS and production of SA derivatives by the use of a single 
step derivatization using a hydrazine-containing solution. The simultaneous extraction is assumed 
to occur via cleavage of covalently linked SA-protein adducts by hydrazine and results in extraction 
of SA as a hydrazone derivative. Moreover, although it might be possible to obtain a lower limit of 
quantification by including a purification step before MS/MS analysis and an additional 
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derivatization step (see subsection II.B.2.2.1), the main advantages of the method are simplicity, 
the requirement of only minimal technical time and the provision of enough sensitivity to detect 
positive cases [75].  
 
Another point to consider with direct derivatization techniques is that the filter paper is 
derivatized as well. Normally after extraction, an aliquot of the solvent is transferred in order to 
evaporate, filter or derivatize the extraction solvent containing the extracted compounds. Since 
the reagents are now applied directly to the filter paper present in the test tube, it might be 
relevant to check for interferences as a result of derivatizing the blank filter paper. In the case of 
derivatizing the blank filter paper used for applying whole blood from possible GHB-intoxicated 
patients, a small interference was seen at the retention time of GHB (< 20 % of the LLOQ) [11].  
 
II.B.3 CONCLUSION AND FUTURE PERSPECTIVES 
To conclude, DBS analysis has proven useful in a wide range of applications, because of the typical 
benefits associated with this sampling technique. Although LC-MS/MS is commonly used for DBS 
analysis, other techniques such as GC-MS (/MS) may also play a role in the determination of drugs 
or biomarkers in DBS. To determine trace levels of low molecular weight compounds in DBS, a 
derivatization step during DBS sample work-up may be necessary or may help to achieve adequate 
method sensitivity. Dependent on the target compounds and the derivatizing reagents, different 
procedures are possible as shown in Fig. II.B.1. Moreover, a single DBS can be subjected to a 
combination of sample work-up procedures including different derivatization techniques to extend 
the range of target compounds of a DBS method. For example, to include SA, most favorably 
extracted as hydrazone-derivative (see subsection II.B.2.2.3), in a method determining amino acids 
(AA) and acylcarnitines (AC) in newborn DBS, combinations of the ‘general’ procedure (for AA and 
AC) and the direct derivatization technique (for SA) have been described [46,47,77].  
 
Although incorporating a derivatization procedure in DBS sample work-up may significantly 
increase method sensitivity, this additional step may be experienced as laborious and tedious (e.g., 
requiring more technical time). Hence, replacement of manual preparation by automated 
techniques but also implementation of procedures using simpler sample work-up such as direct 
derivatization, may be less time-consuming and lead to increased sample throughput.  
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Thus, the introduction of automated techniques may result in high-throughput DBS methods 
including derivatization, as illustrated by a recently developed fully automated sample preparation 
technique using a digital microfluidic method including extraction and derivatization of several AA 
in DBS by in-line or off-line nano-ESI-MS/MS [45]. In addition, modified sample work-up 
procedures such as direct derivatization techniques, using a single step extraction and 
derivatization or “on spot” derivatization, may lead to a less time-consuming and less laborious 
sample work-up. These procedures may be considered in cases where a derivatization step is 
needed, to ensure a minimal, economic and fast sample treatment.  
 
Consequently, a similar workload may be achieved as with classical DBS analyses which only use 
extraction and purification procedures, but with additional gain in method sensitivity and 
selectivity due to derivatization. Hence, the application range of DBS analysis may be extended. 
Automated techniques are being developed such as paper-spray ionization MS/MS analysis with 
on-line derivatization, implemented by preloading reagents onto the paper or using solutions 
containing the derivatizing reagents. This approach was already successfully applied to detect 
cholesterol in dried serum spots via formation of a characteristic fragment ion, with enhanced 
MS/MS sensitivity and selectivity [78]. Furthermore, we envisage that direct derivatization 
approaches may gain importance in the future, not only in GC, but also in LC-MS/MS and other 
MS(/MS)-based approaches, where they could be combined with on-line elution, or could even 
precede direct desorption from the DBS (e.g., following application of a derivatizing reagent 
sprayed on the DBS).  
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II.C.1 OPTIMIZATION OF THE GC-MS METHOD TO DETERMINE DERIVATIZED GHB IN 
PLASMA AND DBS 
 
II.C.1.1 INTRODUCTION 
As the polarity and the low molecular weight of GHB requires derivatization or conversion to GBL 
prior to GC analysis, we chose to modify the derivatization procedure reported by Sabucedo et al. 
in 2004 [1]. These authors used a mixture of trifluoroacetic acid anhydride (TFAA) and 
heptafluorobutanol (HFB-OH) to derivatize GHB in aqueous samples (drinks). Fig. II.C.1 shows the 
reaction scheme of the derivatization reaction.  
 
 
Fig. II.C.1 Reaction scheme of the applied derivatization reaction to derivatize GHB in plasma and DBS  
 
 
In this section, optimization of the GC-MS method parameters to determine GHB, following 
derivatization with TFAA/HFB-OH, is described. To this end, 50 µl plasma was spiked with 100 µl of 
a 40 µg/ml-solution. As we wished to use the final GC-MS method to determine GHB in DBS, the 
optimal temperature program was selected based on selectivity and peak characteristics of GHB 
specifically in DBS extracts. We aimed for an optimal resolution within the shortest run time 
possible. Therefore, GC-MS parameters have been adjusted, in particular sample introduction (1), 
chromatographic separation (2) and MS detection (3) (Table II.C.1). 
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Table II.C.1 Overview of the different parameters, those in bold were optimized for the determination of GHB 
(derivatized with TFAA/HFB-OH) 
 
 
II.C.1.2 MATERIALS AND METHODS 
 
II.C.1.2.1 Standards, solvents and reagents 
GHB (sodium salt) as a 1-mg/ml solution in methanol, as well as a 1-mg/ml solution in methanol of 
the internal standard (IS) GHB-d6 (sodium salt) were obtained from Sigma-Aldrich (Steinheim, 
Germany). The derivatization reagents TFAA and HFB-OH were also purchased from Sigma Aldrich. 
Methanol, toluene, acetonitrile and ethylacetate, all of suprasolve quality suitable for GC analysis, 
were delivered by Merck (Darmstadt, Germany). Hexane was purchased from Fluka (Bornem, 
Belgium). 
 
II.C.1.2.2 Preparation of working solutions 
Working solutions of GHB were prepared by appropriate dilution of the 1 mg/ml stock solution to 
obtain 0.1 mg base/ml methanolic solutions. For the IS, a solution of 0.05 mg base/ml was 
prepared starting from a 1-mg Na-GHB-d6/ml stock solution in methanol. All solutions were stored 
at -20 °C.  
 
II.C.1.2.3 Sample preparation 
GC-MS method parameters to determine GHB following derivatization with TFAA/HFB-OH were 
optimized using a working solution with a GHB concentration of 40 µg/ml. One hundred µl of this 
solution was added to 50 µl plasma, and the samples were stored overnight at 4 °C. Prior to GC 
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analysis, to complete protein precipitation, acetonitrile was added to the plasma samples (2:1 
acetonitrile:sample, v:v), followed by a 10-min centrifugation (1600 x g; Mistral MSE 200 BRS, 
Drogenbos, Belgium). The resulting supernatant was transferred and subsequently evaporated 
under a gentle stream of nitrogen at 40 °C.  
 
As mentioned above, a procedure based on the one reported by Sabucedo et al. (2004) [1] to 
determine GHB in aqueous samples (drinks) has been adjusted to derivatize GHB: 75 µl of a freshly 
prepared mixture of TFAA and HFB-OH (2:1) was added to the dried residue. Following thorough 
vortexing, the sample extract was heated for 30 min at 85 °C in a heating block (Lab-Line, Tier, The 
Netherlands). Then, the derivatized extract was evaporated after cooling down for 10 min. Finally 
the residue was dissolved in 100 µl of injection solvent. 
 
II.C.1.2.4 GC-MS conditions 
Samples were analyzed on an Agilent HP 6890 GC system coupled to a HP 5973 mass-selective 
detector (Agilent technologies, Avondale, PA, USA). An Agilent Chem Station, version D.02.00 
(G1701DA) was used for data acquisition. The HP 7683 split/splitless injector contained a splitless 
deactivated inlet liner with glass wool. Splitless injections were performed automatically at an 
injection temperature of 250 °C and a purge time of 2 min. The injection volume was 1 µl. Helium 
was used as carrier gas at a constant flow rate of 1.0 ml/min.  A 30 m x 0.25 mm i.d. x 0.25 µm 
Agilent HP-5-MS capillary column was used. The temperature program when using hexane as 
injection solvent was started at 45 °C for 2 min, ramped at 5 °C/min to 110 °C, then raised by 30 
°C/min to 300 °C, which was held for 2 more min for optimal column performance and 
maintenance, resulting in a total run time of 23.3 min (non-optimized).  
 
The transfer line temperature and MS ion source temperature were set at 280 and 230 °C, 
respectively. MS quadrupole temperature was set at 150 °C and ionization energy of 70 eV was 
used. The MS, which operated in electron impact ionization (EI) mode, was first used in full-SCAN 
mode to obtain a total mass spectrum of derivatized GHB (TIC or total ion chromatogram). Next, 
for GHB and its internal standard GHB-d6, 1 quantifier and 2 qualifier ions were selected for 
quantification using the MS in selected ion monitoring mode (SIM). A quantifier ion was chosen as 
the m/z value with the highest abundance in the spectrum, while qualifier ions were selected 
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based on their selectivity for the analyte of interest [2]. Once the MS operated in SIM mode, 100 µl 
plasma was spiked with 100 µl of a 40 µg/ml GHB solution prior to analysis.   
 
II.C.1.3 METHOD DEVELOPMENT AND DISCUSSION  
 
II.C.1.3.1 Sample introduction 
We opted for a splitless injection, which was required to determine trace levels of GHB in 
biological matrices. A splitless injection consists of 3 subsequent steps (Fig. II.C.2) [3]. First, the 
liquid sample is injected into the heated liner, while the split outlet is closed. Secondly, the sample 
will evaporate in the heated injection port and will be transferred onto the column by mixing with 
the mobile phase. This is called the splitless period, since the split outlet is still closed. Finally, in a 
third step, the split outlet is opened to remove what is left from the sample.  
    
Fig. II.C.2 Principle of splitless injection with opening of the split outlet (Grob, 1993) [3] 
 
 
II.C.1.3.1.1 Injection solvent 
The choice of the injection solvent is based on the start temperature of the GC temperature 
program and on the best solvation properties for derivatized GHB. In optimum conditions, for low 
boiling compounds, the temperature should ideally be 20 °C lower than the boiling point of the 
organic solvent used as injection solvent [3]. This means that for hexane, it should be around 45 °C, 
for ethylacetate around 60 °C, and for toluene around 85 °C. Toluene was not an option as the 
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begin temperature of the GC program was too high for derivatized GHB, which eluted too early. 
We evaluated hexane and ethylacetate, and finally chose ethylacetate, as the highest signals for 
GHB were observed and the temperature program could start around 60 °C, positively influencing 
analysis time. 
 
II.C.1.3.1.2 Injection temperature 
The injection temperature should be high enough to completely and rapidly evaporate the 
analytes of interest without degradation [4]. Therefore, injection temperature was varied between 
200, 250 and 300 °C (n=3). As shown in Fig. II.C.3, resulting peak areas of GHB were similar with 
these injection temperatures; therefore, 250 °C was chosen. 
 
     
 Fig. II.C.3 Influence of injection temperature on GHB signal (mean ± SD, n=3). The dried derivatized extracts 
were redissolved in 100 µl ethylacetate and the MS operated in SCAN mode.  
 
 
II.C.1.3.1.3 Purge activation time 
The purge activation time is the time point when the split outlet is opened during a splitless 
injection. If this outlet is opened too early, sample losses will occur; opening of the outlet too late 
has as a consequence that the solvent peak will be wider and components have more time to 
degrade in and adsorb onto the liner. The optimal purge activation time depends on the flow rate 
of the carrier gas. Ideally, the split outlet is opened when approximately 1 to 1.5 liner volumes of 
carrier gas have passed through the injector [5].  
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The following equation can be used to calculate the sweep rate or the time when 1 volume of 
carrier gas has left the injector: 
Sweep rate = volume of the liner / F        [5] 
With  volume of the liner (cm
3
) = π r
2
 L 
 F (ml/ min): flow rate  
In subsection II.C.1.3.2.2, 1.3 ml/min was chosen as optimal flow rate of helium, while the liner has 
a length of 8 cm and internal diameter of 0.4 cm. Consequently, the sweep rate was 46 sec. 
Multiplying it with 1 and 1.5 results in purge activation times of 46 and 70 sec. Therefore, samples 
were injected using the following purge activation times: 45, 60, 75, 90 and 120 sec (n=3). As 
shown in Fig. II.C.4, the peak areas are clearly similar for the times tested and 90 sec was chosen 
since peaks with little or no tailing were seen in the chromatogram with a sufficiently high signal.  
 
   
Fig. II.C.4 Influence of varying purge activation times on the peak area of GHB (m/z 227; mean ± SD, n=3). The 
dried derivatized extracts were redissolved in 100 µl ethylacetate. 
 
 
II.C.1.3.1.4 Pulse time and pulsed splitless injection 
Inlet pressure needs to be high enough to ensure a complete transfer of the sample to the column 
and to avoid peak broadening. If the inlet pressure is too high, resolution will be decreased. It is 
possible to increase the inlet pressure during injection, so-called pulse injection, resulting in a 
narrower initial band on the column and therefore more efficient chromatography. On the other 
hand, a constant high gas flow during analysis lowers resolution. Therefore, when the injection is 
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done, the inlet pressure should decrease again to obtain the optimum flow rate to separate the 
analytes of interest. The time when this pressure is reduced again is called the pulse time and is 
ideally 0.1 to 0.5 min longer than the purge activation time to prevent the pressure from 
decreasing while the split line is opened [5]. 
 
Since purge activation times of 90 and 120 sec showed little difference in resulting GHB signal and 
chromatography (Fig. II.C.4), we chose to evaluate 2 pulse times for each purge activation time. 
Pulse times of 1.6 and 2.0 min were tested for a 90 sec (1.5 min) purge activation time, and 2.1 and 
2.5 min for 120 sec (2 min). Fig. II.C.5a shows that there is little difference in mean peak area of 
GHB for the various pulse times; therefore, we chose to work with 90 sec purge activation time 
and 2.0 min pulse time. 
 
Starting from these purge activation and pulse times, different inlet pressures were tested: 11.8 
psi or the pressure required for 1.3 ml/min flow rate was compared with pulsed splitless injections 
using 20, 25 or 30 psi during injection. As shown in Fig. II.C.5b, no pulsed splitless injection was 
required for injection of derivatized GHB. Although at an inlet pressure of 30 psi, GHB eluted 
earlier, the mean GHB signal was higher when no-pulsed splitless injection was used.  
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(a) 
    
(b) 
    
Fig. II.C.5  
(a) GHB peak area (m/z 227; mean ± SD, n=3) in function of the different pulse times tested. The dried 
derivatized extracts were redissolved in 100 µl ethylacetate. 
(b) Comparison of peak area of GHB (m/z 227; mean ± SD, n=3) in function of various inlet pressures: 
non-pulsed (11.8 psi) vs. pulsed splitless injection (20, 25, 30 psi).  
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II.C.1.3.2 Chromatographic separation 
 
II.C.1.3.2.1 Analytical column and temperature program 
We chose a capillary column with a stationary phase containing 95 % dimethyl- and 5 % 
diphenylpolysiloxane, often used in forensics. More specifically, a HP-5-MS column (Agilent, 
Avondale, USA) of 30 m, 0.25 mm ID, 0.25 µm film thickness was used, with acceptable retention 
(time) and peak shape for GHB and its internal standard GHB-d6. Furthermore, various 
temperature programs were tested and the final choice was based on peak shape, run time, 
injection solvent and selectivity. As mentioned above, DBS extracts were injected and the final, 
optimized temperature program started at 65 °C for 1.5 min, ramped at 10 °C/min to 110 °C, then 
at 50 °C/min to 300 °C, which was held for 2 more min. 
 
II.C.1.3.2.2 Mobile phase and flow rate  
The type of carrier gas passing through the analytical column with a given velocity influences 
resolution and retention times. Helium was used as carrier gas, an inert carrier gas typically used in 
GC. The optimum flow rate of the carrier gas depends on type of column used (length, diameter 
and film thickness) as well as on the volatility of the analytes of interest. Optimization of this 
parameter aims for an acceptable resolution in the shortest analysis time possible. The flow rate 
stands for the volume of gas that flows through the column per time unit and the optimum flow 
rate is predicted using the linear gas velocity (u). The latter is the velocity by which the carrier gas 
flows through the column [5]. 
 
When using a 30 m x 0.25 mm x 0.25 µm column, the optimum linear velocity is 30 to 40 cm/ sec. 
These linear velocities correspond to flow rates of 0.88 (0.7) to 1.18 (1.5) ml/ min. In addition, 
combining GC separation with MS detection limits the flow rate to 1 to 2 ml/ min. So, flow rates 
varying from 0.7 to 1.5 ml/ min were tested for derivatized GHB (n=3) and Fig. II.C.6 shows the 
mean peak area of GHB (mean ± SD, n=3) in function of the various flow rates.  Besides the peak 
area, resolution and peak shape were also evaluated. Little differences in peak area were seen, so 
we chose a 1.3 ml/min flow rate.  
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Fig. II.C.6 Peak area of GHB (m/z 227; mean ± SD, n=3) in function of various flow rates of the carrier gas 
helium 
 
 
II.C.1.3.3 MS detection 
 
II.C.1.3.3.1 Full-scan monitoring 
Analyzing a standard solution (with a concentration of 100 µg/ml) of GHB and its internal standard 
GHB-d6 in full scan (m/z varying from 35 to 400) resulted in a chromatogram and for each peak, a 
mass spectrum could be reconstructed. Fig. II.C.7 gives the resulting mass spectrum for GHB 
following derivatization with TFAA/HFB-OH (using the non-optimized GC temperature program). 
                 
   
 Fig. II.C.7 Full-scan mass spectrum of GHB derivatized with TFAA/HFB-OH 
Chapter II.C Determination of GHB in DBS using “on spot” derivatization and GC-MS 
 
 
133 
 
II.C.1.3.3.2 SIM-monitoring 
If an MS operates in SIM-mode, one or a selected group of m/z ions will reach the detector and be 
registered. Since the MS spends more time per m/z value, SIM-mode results in better detector 
sensitivity than when the MS operates in scan. Which m/z ions should be registered depends on 
their intensity in the full-scan mass spectrum and on their value. Intensity should be high enough 
to obtain sufficient sensitivity, while higher m/z ions are more selective for the compound of 
interest, since the chance of occurrence of these m/z values in co-eluting analytes decreases when 
their value increases [6]. 
 
From the mass spectra obtained in scan-mode (Fig. II.C.7), 1 quantifier and 3 qualifier ions were 
selected for GHB and GHB-d6. The quantifier ion will be used for quantification, while the qualifier 
ions should result with high certainty from fragmentation of the analyte of interest [2]. The 
following ions were monitored in the SIM-mode: m/z 155, 183, 227 and 242 for derivatized GHB 
and m/z 161, 189, 231 and 245 for derivatized GHB-d6 (underscored ions represent the quantifier 
ions, as they had high abundance, the other ions were selected as qualifier ions). Fig. II.C.8 gives 
the proposed fragments corresponding to m/z 155, 183 and 242. Formation of the fragment with 
m/z 242 can be explained by McLafferty rearrangement. The fragmentation leading to m/z 227 
(and the identity of the resulting fragment) could not be determined. Sabucedo et al. [1] proposed 
the following fragment [CF3-CF2-CF2-CH2-O-CO]
+
. Although this fragment has indeed a m/z of 227, it 
does not correspond to the m/z value of 231 of the corresponding fragment observed by us 
resulting from the fragmentation of GHB-d6. Fig. II.C.9 shows a representative chromatogram of a 
DBS extract analyzed with the optimized GC-MS method (using the final temperature program, see 
II.C.1.3.2.1).  
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Fig. II.C.8 Proposed fragments of GHB derivatized with TFAA/HFB-OH 
 
Fig. II.C.9 Representative chromatogram of a 50-µl DBS spiked with GHB at 2 µg/ml and GHB-d6 at 10 µg/ml, 
analyzed with GC-MS in EI-SIM mode using the optimized GC-MS parameters  
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II.C.2 DETERMINATION OF GHB IN 50-µL DBS  
 
(Based on Determination of gamma-hydroxybutyric acid in dried blood spots using “on spot” derivatization 
and a simple GC-MS method. Anal Bioanal Chem. 398:2173-2182 (2010). Ann-Sofie M.E. Ingels, Willy E. 
Lambert, and Christophe P. Stove.) 
 
II.C.2.1 INTRODUCTION 
Gamma-hydroxybutyric acid (GHB) as well as its precursors gamma-butyrolactone (GBL) and 1,4-
butanediol (1,4-BD) are popular as a party or club drug (“liquid ecstasy”) and appear occasionally 
in drug-facilitated sexual assaults (DFSA). This is due to their effects and chemical properties as 
they are colourless and odourless liquids which can be easily mixed with other liquids [7-10]. GHB 
is mostly misused in combination with other drugs, such as alcohol, ecstasy (MDMA), cocaine, 
amphetamines and cannabis [8,9,11]. Most commonly reported effects of GHB abuse are 
euphoria, increased sexuality, well-being and tranquillity, while an overdose results in seizures, 
respiratory depression, coma and sometimes even death [11-13]. The range between the desired 
effects and an overdose is narrow, frequently resulting in (non-) fatal intoxications in humans, as 
described in several case reports [14-20]. Consequently, the identification and correct 
quantification of GHB is important in forensic and clinical toxicology. Many previously reported 
analytical methods detect GHB in different biological matrices and involve the use of gas 
chromatography (GC) [1,2,21], but also liquid chromatography (LC) [22,23] and capillary zone 
electrophoresis (CZE) [24]. Also the determination of GHB through headspace solid phase micro 
extraction (SPME) and dynamic extraction (SPDE) has recently been published [25,26].  
 
However, the determination of GHB in biological matrices remains an analytical challenge for 
several reasons. First, GHB is a small polar molecule, making its extraction and the direct detection 
with GC difficult. Hence, two approaches are generally used: besides the conversion of GHB under 
acidic conditions to GBL, which is more easily extracted from the biological matrix, the carboxyl 
and hydroxyl group can be derivatized, resulting in a more volatile and less polar compound. As 
derivatization technique, silylation is mostly used, but also alkylation and acylation have previously 
been described [1,21]. Furthermore, GHB occurs naturally in blood and urine, so no blank matrix is 
available and positive samples must be carefully interpreted. To enable the differentiation 
between exogenously-administered and endogenous GHB, cut-off levels have been proposed by 
several authors. These are currently set at 4 or 5 µg/ml for blood samples and 6 or 10 µg/ml for 
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urine samples [27-30]. In addition, once orally ingested, GHB is rapidly metabolized, with a 
reported plasma half-life of less than one hour. As this limits the detection window, plasma 
samples must be taken within 6 hours and urine samples within 12 hours (or better both within 6 
hours) after ingestion [14]. 
 
In this study, we use dried blood spots (DBS) to improve the detection and quantification of GHB 
by facilitating sample collection. A DBS is capillary whole blood obtained by a finger or heel prick 
and collected on a filter paper. This sampling technique ensures an easy and rapid collection of a 
representative sample without specific handling and storage requirements. These advantages as to 
a venepuncture make it a cost-effective choice for the collection, transport and storage of blood 
samples [31,32]. The DBS sampling method, originally used in newborn screening for metabolic 
disorders, is currently applied for the determination of various compounds such as biomarkers and 
is promoted for therapeutic drug monitoring (TDM). Already several compounds can be detected 
in DBS, most common are anti-malaria drugs, immunosuppressive drugs, anti-epileptics, antibiotics 
and anti-diabetics [32]. Inherent to DBS sampling is the small sample volume available, ranging 
from 10 to 200 µl, comparing to 1 ml or more obtained by a venepuncture. Although this may be 
an advantage when the collection of larger amounts of whole blood is limited, such as in neonates 
and children, these small amounts may impose an analytical challenge, requiring an efficient 
sample pre-treatment and a sensitive detection [33,34].  
 
The determination of GHB in DBS may be interesting in situations where there is a suspicion of 
illicit use of GHB or one of its precursors, for example in case of driving under the influence of 
drugs (DUID) or a presumed DFSA. As mentioned above, the short half-life of GHB implies a limited 
detection window and, consequently, a rapid collection to obtain a representative sample. A delay 
caused by the need for a venepuncture by medical staff may bring the blood levels of GHB under 
the established cut-off levels. Moreover, no extraction step is necessary as DBS can be directly 
derivatized, minimizing the sample preparation and reducing the sample turn-around time. 
Besides the advantages of a rapid collection, also storage of whole blood samples as DBS may be of 
interest as this may avoid in vitro formation of GHB, which has previously been reported 
[29,35,36]. 
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Only recently, an LC-MS/MS-based method has been reported to screen for elevated GHB 
concentrations in DBS obtained from newborns. This method was developed to detect the 
presence of a rare inherited metabolic disorder, i.e. succinic semi-aldehyde dehydrogenase 
(SSADH) deficiency [37]. Even though most DBS analyses are commonly performed using LC-
MS/MS, we opted to use GC-MS for several reasons. First of all, GC is a common and available 
technique in forensic laboratories, proven to be suitable for the detection of derivatized GHB with 
good sensitivity [21]. Secondly, given the low molecular weight of GHB, adequate and sensitive 
detection following liquid chromatography requires extensive sample pre-treatment, involving an 
extraction step and/or derivatization to enhance selectivity. The aim of our study was to develop 
and validate a GC-MS method for the identification and quantification of GHB in DBS, based on a 
new procedure, involving direct derivatization of GHB “on spot”, ensuring a minimal, economic 
and less time-consuming sample pre-treatment.  
 
II.C.2.2 MATERIALS AND METHODS  
 
II.C.2.2.1 Reagents 
 
II.C.2.2.1.1  Chemicals  
GHB (sodium salt) as powder and as a 1-mg/ml solution in methanol, as well as a 1-mg/ml solution 
in methanol of the internal standard (IS) GHB-d6 (sodium salt) were obtained from LGC standards 
(Molsheim, France).  The derivatization reagents trifluoroacetic acid anhydride (TFAA) and 
heptafluorobutanol (HFB-OH) were purchased from Sigma Aldrich (Steinheim, Germany).  
Methanol and ethylacetate, both of suprasolve quality suitable for GC analysis, were delivered by 
Merck (Darmstadt, Germany).  
 
II.C.2.2.1.2  Stock and working solutions 
Stock and working solutions of GHB were prepared by dissolving 10 mg of the base in 1 ml of 
methanol, followed by appropriate dilution to obtain 1 and 0.1 mg base/ml methanolic solutions. 
Quality controls (QC’s) for all analyses were obtained from the commercially available stock 
solution of 1 mg Na-GHB/ml methanol. For the IS, a solution of 0.05 mg base/ml was prepared 
starting from a 1-mg Na-GHB-d6/ml stock solution in methanol. All solutions were stored at -20 °C. 
 
 
Chapter II.C Determination of GHB in DBS using “on spot” derivatization and GC-MS 
 
 
138 
 
II.C.2.2.2 Materials  
Protein saver cards number 903, used as sampling paper, were kindly provided by Whatman (ref n° 
WHA10334885, Dassel, Germany). The automatic lancets for capillary blood collection were 
purchased from Becton Dickinson (ref n° VAC366594, Franklin Lakes, USA), while the 50-µl 
precision capillaries were obtained from Servo-Prax (Wesel, Germany) (Fig. II.C.10a). The 
centrifuges used were a MSE Mistral 2000 (Beun de Ronde Serlabo, Anderlecht, Belgium) and a 
5804R Eppendorf (Hamburg, Germany). Evaporation under nitrogen was conducted in a TurboVap 
LV evaporator from Zymark (Hopkinton, MA, USA).  
 
II.C.2.2.3 DBS sample collection 
Two methods are commonly used to obtain capillary whole blood on a filter paper. The drop of 
blood can be collected directly on the filter paper or with the aid of a precision capillary (Fig. 
II.C.10a). In this study, we opted to apply a drop with a fixed volume onto the paper, similar to the 
application with a precision capillary. As the complete drop can be excised instead of punching out 
a disk from it, a fixed sample volume is analyzed and the effect of hematocrit and sampling 
technique is minimized [32]. 
 
 
Fig.II.C.10  
(a) A 50-µl precision capillary (left) used to collect capillary whole blood obtained by a fingerprick using 
an automatic lancet (right)  
(b) Examples of 50-µl DBS spotted on Whatman 903 filter paper. The inner circle must be enterily filled 
with blood, the outer circle line was used for excision of the DBS. 
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In the procedure to obtain a DBS, the hand is first cleaned and held down or warmed for a few 
minutes. With the help of an automatic lancet, the fingertip is pricked. While the first drop is 
wiped off with a sterile piece of cloth because of the presence of tissue fluid, the following drops 
are collected in a 50-µl precision capillary. Then, once completely filled, the entire capillary is 
placed in the centre of two concentric circles pre-printed on a Whatman 903 filter paper (Fig. 
II.C.10b). The inner circle (10 mm diameter) must be entirely filled with blood, but blood may not 
pass the outer circle line (15 mm diameter), which was used for excision of the DBS. Although the 
blood is spot on just one side, both sides of the filter paper must be coloured. After visual 
inspection of the DBS, the analyses can start [32].  
 
For method development and validation, we used 50-µl spots of venous whole blood from healthy 
non-user volunteers with endogenous GHB concentration below the established lower limit of 
quantification (LLOQ) and preserved for maximum one week at 4 °C. The DBS are dried for 
minimum 4 hours at ambient temperature and subsequently analyzed or preserved in a sealable 
plastic bag at room temperature or -20 °C until analysis.  
 
II.C.2.2.4 Optimization of the DBS sample preparation 
First, 10 µl of the IS solution was applied to a DBS and left to dry for 15 min. Subsequently, the 
spot was completely excised following the outer circle line, placed in a test tube and a freshly 
prepared mixture of TFAA and HFB-OH was added, followed by sonication for 5 min. Sabucedo and 
Furton [1] described the use of 1 ml of this mixture to derivatize GHB in aqueous samples (drinks) 
at 85 °C for 30 min, while we desired the derivatization of GHB in a biological matrix. For this 
purpose, the main critical parameters for derivatization, such as amount of reagent, temperature 
and time, were thoroughly evaluated. So, different amounts of derivatization mixture were tested, 
respectively 75, 100 and 125 µl of a TFAA/HFB-OH (2:1) mixture. Also derivatization temperatures 
varying from room temperature to 60, 70, 85 and 100 °C and derivatization times ranging from 5 
to 30 min were tested. For each condition, at least 3 DBS spiked with GHB at a 10 µg/ ml 
concentration level were analyzed and the resulting absolute peak areas of derivatized GHB were 
compared.  
 
After the derivatization step, the DBS was cooled down by centrifugation for 5 min at 4 °C and 
evaporated to dryness under a gentle stream of nitrogen at 25 °C to remove excess of 
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derivatization reagent. The dried sample was redissolved in 200 µl of ethylacetate, sonicated and 
centrifuged for 5 min at 1600 x g. Eighty-five µl was transferred, centrifuged again and finally 50 µl 
was transferred to a vial, of which 1 µl was injected into the GC-MS.  
 
II.C.2.2.5 The analytical procedure 
Samples were analyzed on an Agilent 6890 GC system coupled to a 5973 mass-selective detector. 
Splitless injections were performed automatically at an injection temperature of 250 °C, a purge 
time of 1.5 min and helium was used as carrier gas at a constant flow rate of 1.3 ml/min.  A 30 m x 
0.25 mm i.d. x 0.25 µm Varian VF-5-MS column (Varian; Middelburg, The Netherlands) was used. 
The temperature program was started at 60 °C for 1.5 min, ramped at 10 °C/min to 110 °C, then 
raised by 50 °C/min to 300 °C, which was held for 2 more min for optimal column performance and 
maintenance, resulting in a total run time of 12.3 min. The transfer line temperature and ion 
source temperature were set at 280 and 230 °C, respectively. MS quadrupole temperature was set 
at 150 °C and ionization energy of 70 eV was used. The mass spectrometer operated in the 
selected ion monitoring (SIM) mode using electron impact ionization (EI) for quantification of GHB 
and GHB-d6. By running standards in full scan, typical mass spectra were obtained and following 
ions were monitored in the SIM mode: m/z 155, 183, 227 and 242 for derivatized GHB and m/z 
161, 189, 231 and 245 for derivatized GHB-d6 (underscored ions represent the quantifier ions, as 
they had the highest abundance, the other ions were selected as qualifier ions). 
 
II.C.2.2.6 Validation 
The following criteria were evaluated to validate the method: linearity, precision, accuracy, 
sensitivity, selectivity and stability [38-40].  
 
II.C.2.2.6.1 Linearity, precision, accuracy and sensitivity 
As no blank matrix is available, fresh venous human whole blood withdrawn on EDTA as anti-
coagulant was used to prepare the calibration standard solutions. The concentration of 
endogenous GHB was tested to be below the LOQ of the method (less than 2 µg/ml) and the ratio 
GHB to GHB-d6 was always lowered with the mean ratio of the zero samples (blank whole blood + 
IS, in duplicate) measured on each calibration day.  
 
A 5-point calibration curve was constructed six times on six different days. Each day a blank, 2, 10, 
25, 50 and 100 µg/ml solution of GHB in whole blood was prepared, as well as the QC solutions at 
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low (2 µg/ml), medium (10 µg/ml) and high (100 µg/ml) concentration level, covering the whole 
calibration range. From each solution, 50-µl spots were made, left to dry at room temperature for 
minimum 4 h, followed by analysis. The resulting data were statistically evaluated and weighted if 
necessary, based on the sum % relative error (RE) and the % RE plot versus concentration, where % 
RE is the concentration found lowered with the nominal concentration, divided by the nominal 
concentration and multiplied by 100. Linearity was assessed by performing the Fisher-test [38,41]. 
 
Intra-batch-precision was assessed by replicate analysis of spiked samples (n=5 at low, medium 
and high concentration level) in a single day, inter-batch-precision was evaluated by determination 
of spiked samples per concentration on 6 days. Precision was measured by calculating the relative 
standard deviation (RSD, SD divided by the mean and multiplied by 100 %). Also accuracy was 
determined for each concentration level, calculated by the percent deviation from the nominal 
concentration (presented as % bias).  
 
For evaluation of sensitivity, the limit of detection (LOD) and the limits of quantification (LLOQ and 
ULOQ) were determined. The LOD was estimated as the minimum concentration of GHB with a 
signal-to-noise ratio equally or larger than 3, so with reliable differentiation of the background 
noise and in compliance with the identification criteria [41,42]. The lowest and highest 
concentration of GHB still measured with acceptable precision (RSD less than 20 % for LLOQ, 15 % 
for ULOQ) and accuracy (80-120 % for LLOQ, 85-115 % for ULOQ) were chosen as the LLOQ and 
ULOQ, respectively.  
 
Furthermore, possible dilution of the final extract of samples above the ULOQ was investigated. 
Therefore, human whole blood was spiked at 200 µg/ml (twice the ULOQ) and 50-µl spots were 
processed as described above (n=2 x 3). Ten µl of the final derivatized extract was diluted to 100 µl 
with ethylacetate, analyzed by GC-MS and corrected for the dilution factor. The RSD was 
calculated using one-way-ANOVA as described by Wille et al., and needed to be < 15 % [43]. 
Accuracy needed to be within 85 to 115 % of the nominal value. Carry-over was also tested by 
injecting the highest concentration level of the calibration curve, followed by 3 blank 
(ethylacetate) injections.  
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II.C.2.2.6.2 Selectivity 
The possible contribution of the isotopically labelled IS was assessed by analyzing both blank and 
zero (blank spiked with IS) samples. Furthermore, we investigated the possible interference of 
structural analogues such as beta-hydroxybutyric acid (BHB), alpha-hydroxybutyric acid (AHB) and 
GABA and the precursors GBL and 1,4-BD (spiked at 100 µg/ml); as well as the mainly co-ingested 
club and date-rape drugs (alcohol, cocaine, benzoylecgonine, Δ9-tetra-hydrocannabinol (THC), 11-
nor-9-carboxy-THC, ketamine, flunitrazepam, MDMA and amphetamine, spiked at or well above 
concentrations typically found in abusers). At least six different sources of whole blood were 
spiked and analyzed, in order to compare the ratio of GHB to GHB-d6 of blank samples, spiked at a 
known GHB concentration, with that of the samples containing the interferences. 
 
II.C.2.2.6.3 Stability  
As the filter paper matrix is expected to stabilize most analytes in DBS, we evaluated the stability 
of GHB in DBS stored at different conditions [31]. Therefore, three separate solutions in whole 
blood at both low (5 µg/ml) and high (100 µg/ml) concentration levels were prepared and the 
resulting spots were preserved in a sealable plastic bag at room temperature for one week, at 4 °C 
for 24 h and at -20 °C for 14 days. For the first 48 h at room temperature, DBS were analyzed after 
2, 4, 8, 12, 24 and 48 h to assess the influence of drying time. The mean percentage found needs 
to be within 85 to 115 % of the results obtained when analyzed after 4 h of drying, as this is the 
minimum drying time recommended by the manufacturer and therefore chosen as the reference 
time point.  
 
To assess the stability of the processed samples, extracts (low and high concentration level, in 
triplicate) were re-injected after 24 h at room temperature and after storage for minimum one 
week at -20 °C (per concentration level, in duplicate).  The ratio of GHB to GHB-d6 was compared 
to this of the directly analyzed extract. Stability of stock solutions at two concentration levels (n=3) 
was assessed over 14 days at -20 °C and after three freeze-thaw cycles.  
 
II.C.2.2.7 Application  
The described procedure was applied to blood samples of two young men suspected of GHB/GBL-
intake, along with other drugs, to evaluate the routine applicability and the easiness of the method 
in a laboratory setting. The two young men were found on the street under influence, one was in 
critical condition, and were brought to a nearby hospital. Blood and urine samples were taken and 
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sent to our laboratory for analysis of drugs and alcohol. As soon as the blood samples arrived at 
the laboratory, DBS were prepared and stored until analysis. Along with the DBS analysis, the 
blood samples were also subjected to routine toxicological analysis, involving screening by 
immuno- and enzymatic assays and confirmation of positive results by high performance liquid 
chromatography-diode array detection (HPLC-DAD) and GC-MS.   
 
II.C.2.3 RESULTS AND DISCUSSION 
 
II.C.2.3.1 Optimization of the DBS sample preparation 
Inherent to DBS sampling is the small sample volume available, necessitating an efficient sample 
preparation [33]. Therefore, different procedures were tested and compared to obtain the optimal 
conditions of extraction and derivatization of GHB, in order to work as sensitive as possible in an 
easy and time-saving way. First, the derivatization reaction was optimized. The influence of the 
amount of the TFAA/HFB-OH (2:1) mixture was evaluated. As shown in Fig. II.C.11a, the optimal 
amount added was 100 µl of the freshly prepared mixture. Then, different derivatization 
temperatures were evaluated. Fig. II.C.11b shows the resulting GHB peak area (mean ± SD) in 
function of the derivatization temperature, and 60 °C was chosen as optimum temperature to 
derivatize GHB to its corresponding derivative. Next, the time needed to perform the reaction was 
evaluated. Fig. II.C.11c gives the peak area of GHB in function of the derivatization times, and 10 
min was chosen.  
 
Optimization of the sample preparation resulted in the set-up of a quick and efficient protocol. 
Direct derivatization took place by adding 100 µl of a freshly prepared mixture of TFAA and HFB-
OH (2:1) to a test tube containing the excised DBS. Then, the test tube was sonicated for 5 min, 
ensuring the distribution of the derivatization reagent [44] and placed in a heating block at 60 °C 
for 10 min. After cooling down, the sample was dried under a gentle stream of nitrogen at 25 °C. 
Next, the DBS was re-dissolved in 200 µl of ethylacetate, sonicated and centrifuged two 
subsequent times, followed by transfer of an aliquot of the supernatant to a vial, of which 1 µl was 
injected into the GC-MS. The overall procedure from receipt of a DBS to a quantitative result can 
be completed in less than 2 h.  
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Fig. II.C.11 Optimization of the derivatization reaction using a freshly prepared mixture of TFAA/HFB-OH (2:1)  
(a) Influence of amount of the reagents on the area of derivatized GHB. DBS from venous whole blood were spiked 
with GHB (10 µl 0.5 mg/ml) and derivatized with TFAA/HFB-OH (2:1) at 85°C for 15 min; n=5 (mean ± SD). 
(b) Influence of temperature on the area of derivatized GHB. DBS from venous whole blood were spiked with GHB 
(10 µl 0.05 mg/ml) and derivatized with 100 µl TFAA/HFB-OH (2:1) for 15 min; n=5 (mean ± SD). 
(c) Influence of derivatization time on the area of derivatized GHB. DBS from venous whole blood were spiked with 
GHB (10 µl 0.05 mg/ml) and derivatized with 100 µl TFAA/HFB-OH (2:1) at 60 °C; n=3 (mean ± SD). 
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As the polarity and the low molecular weight of GHB requires derivatization or conversion to GBL 
prior to GC analysis, we chose direct derivatization instead of conversion, thus avoiding extraction 
and resulting in an easier, less time-consuming sample preparation. Apart from a method 
previously published by our group, only one other published method utilizes direct derivatization 
of GHB [1,2]. However, both methods have as a major drawback that they require a considerably 
larger amount of derivatization reagent, around 1 ml for each sample, while here only 100 µl is 
needed, contributing to a more economic and environmentally-friendly procedure. Déglon et al. 
recently published a method for the determination of antidepressants in DBS, with simultaneous 
extraction using 500 µl 0.02 % triethylamine in butyl chloride in combination with direct 
derivatization using 100 µl derivatization reagents [45]. However, to the best of our knowledge, 
our procedure is the first where derivatization reagents are applied directly “on spot” without the 
use of any extraction solvent.  
 
II.C.2.3.2 Analytical procedure and validation 
The optimized conditions for sample pre-treatment (heating the excised DBS for 10 min at 60 °C 
with 100 µl of a freshly prepared mixture of TFAA and HFB-OH (2:1), followed by drying and 
redissolving in 200 µl ethylacetate, see section II.C.2.3.1), and analysis by GC-MS (as described in 
section II.C.2.2.5) were carried out for validation of the method.  
 
II.C.2.3.2.1 Linearity, precision, accuracy and sensitivity 
To assess linearity, a blank, two zero (blank whole blood + IS) and 5 calibration samples were 
analyzed on six different days. Representative chromatograms of the injection of a derivatized 
extract of a blank DBS and a DBS containing GHB in a concentration at the lower end of the 
calibration curve (LLOQ) are shown in Fig. II.C.12a and II.C.12b, respectively.  
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Fig. II.C.12 Representative chromatograms analyzed with GC-MS in EI-SIM mode of (a) a blank DBS spiked 
with IS at 10 µg/ml (b) a DBS spiked at LLOQ, 2 µg/ml GHB, and IS at 10 µg/ml 
 
 
Table II.C.2a summarizes the calibration and sensitivity data. Ratios of GHB to GHB-d6 were 
calculated by dividing the peak area of GHB by the peak area of GHB-d6 and were lowered with 
the mean ratio of the zero samples. Results were statistically evaluated and a weighting factor 1/x
2 
was applied to the linear calibration curves. Also, the zero value was included in the 95 % 
confidence interval of the y-intercept, indicating absence of a constant error. As indicated in Table 
II.C.2b, overall intra- and inter-batch precision and accuracy were below 15 % and below 20 % at 
LLOQ level.  
 
To evaluate the ability to dilute samples with a GHB concentration above the ULOQ, replicate DBS 
of a 200 µg/ml solution were analyzed as described in the materials and methods section (II.C.2.2). 
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Following a 10-fold dilution of the derivatized extract, the concentration was back-calculated using 
daily calibration curves, and precision and accuracy were found to be within the acceptance limits 
of 15 % (Table II.C.2b). No carry-over was seen following injection of a sample with GHB spiked at 
ULOQ level (less than 0.085 %). 
 
Table II.C.2 Validation data for the determination of GHB in DBS using GC-MS 
(a) Calibration and sensitivity data 
 Slope 
Mean ±SD  
(95 % CI) 
(n=6) 
Intercept 
Mean ±SD  
(95 % CI) 
(n=6) 
Working 
range 
(µg/ml) 
LLOQ 
(µg/ml) 
R
2 
(n=6) 
Weighting 
factor 
50-µl DBS 0.087 ± 0.004 
(0.083; 0.090) 
-0.012 ± 0.03 
(-0.036; 0.011) 
2-100 2.0 1.000 1/x
2
 
 
(b) Intra- and interbatch precision (calculated as RSD %) and accuracy (calculated as % deviation from the 
nominal concentration) for QC low (2 µg/ml), mid (10 µg/ml) and high (100 µg/ml) 
 Nominal GHB 
concentration  
(µg/ml) 
Measured GHB 
concentration 
(µg/ml) 
Intra-batch 
precision 
(% RSD, n=5) 
Inter-batch 
precision 
(%RSD, n=6) 
Accuracy 
(Bias %) 
50-µl DBS 
QC low 2 2.14 5.1 16.1* 7.1 
QC mid 10 9.49 6.0 9.1 -5.1 
QC high 100 108.87 8.1 5.5 8.9 
2 x ULOQ 200 198.00 8.2 9.6 -1.0 
                * n=5, elimination of 1 outlier based on Grubs test for outliers 
 
 
II.C.2.3.2.2 Selectivity 
The fact that preliminary studies indicated a small interference at the retention time of GHB by 
injection of a derivatized extract of a blank filter paper, combined with the endogenous presence 
of GHB in whole blood, rendered it impossible to prove lack of response of the blank matrix. 
However, as the paper signal and the signal of the used whole blood had a peak area below 10 and 
20 % of that of the LLOQ, respectively, no unacceptable interferences were seen [40]. No 
unacceptable interferences were seen at the retention time of the IS either. When analyzing both 
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blank and zero samples (the latter corresponding to blank + IS), no significant difference was seen 
in the mean response of GHB. To further evaluate selectivity, six different sources of whole blood 
were spiked with a combination of structure-analogues of GHB, and certain club and date-rape 
drugs, with no interferences being observed.  
 
Not unexpectedly, the presence of a high concentration of GBL in the sample resulted in an 
increase of the GHB signal, likely due to conversion during sample preparation. The inter-
conversion between GBL and GHB is well-known and has extensively been investigated. It can be 
influenced by pH, temperature and time [22,46-48]. Upon spiking increasing concentrations of GBL 
to whole blood, followed by analyzing the resulting DBS, we saw an approximate 10 % conversion 
of GBL to GHB, independent from the GBL concentration. This result is consistent with that 
reported by Sabucedo and Furton [1], who found a 6.5 % conversion.  
 
Because upon ingestion, GBL is metabolized to GHB by serum lactonases within minutes in 
humans, normally no or only minimal amounts of GBL will be present in a blood sample. However, 
possible saturation of serum lactonases following ingestion of larger amounts of GBL has been 
reported, although this still remains unclear [20]. Anyway, cases in which GBL ingestion has 
occurred will likely readily have high GHB blood levels and although the ± 10 % conversion of GBL 
to GHB may somewhat falsely elevate the quantitative result of GHB, this will likely have no 
relevance, neither in the forensic context, nor in the clinical setting [20,49]. 
 
II.C.2.3.2.3 Stability  
The stability of GHB in DBS was thoroughly investigated as previous studies reported an increase in 
GHB concentration during preservation of blood samples withdrawn on certain anti-coagulants 
[29,36]. So, to investigate the short-term stability of GHB in DBS samples on Whatman 903 filter 
paper, we evaluated low and high concentration levels (n=3) at different preservation 
temperatures (room temperature, 4 and -20 °C). Table II.C.3 shows that GHB in DBS at both low 
and high concentration levels is stable when stored for at least one week at room temperature, 24 
h at 4 °C and 14 days at -20 °C, as the mean percentages were within the pre-defined 15 % limits.  
 
Based on these results, the collection of blood containing GHB on filter paper may result in a 
better storage manner of blood samples. Further examination is recommended to evaluate 
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whether DBS are indeed an alternative and reliable way for routinely storing suspicious blood 
samples over a longer period of time. Furthermore, although in this study the DBS were dried for 
minimum 4 hours at room temperature before analysis, in compliance with the manufacturer’s 
recommendations, a shorter drying time of 2 hours is also possible if needed. 
 
Table II.C.3 Stability data of GHB in DBS, stored at room temperature up to 7 days, at 4 °C up to 24 h and at -
20 °C up to 14 days, presented as the percentage of the results obtained when analyzed immediately after 4 h 
of drying, which is the recommended drying time according to the manufacturer 
 
 
 
Re-injection of processed samples after a waiting period of 24 h to verify autosampler stability of 
the derivatized extracts proved to be no problem as nearly no differences in peak area ratio were 
seen (RSD < 2.1 %). Also the stability of processed samples stored for one week at -20 °C was 
acceptable (RSD < 2.2 %). Stock solutions were stable for minimum 14 days preserved at -20 °C and 
after 3 freeze-thaw cycles. 
 
II.C.2.3.3 Application 
Besides the screening and subsequent confirmation of positive findings with GC-MS and HPLC-DAD 
of blood and urine samples, also DBS prepared from the blood samples of two young men 
suspected of drug intake were analyzed with the described method. Results for the routine 
investigation of a blood sample of one young man led to the confirmation of the presence of 
alcohol (1.42 pro mille), cocaine (benzoylecgonine), cannabinoids, MDMA and ketamine. By 
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analyzing the DBS, a GHB concentration of less than 1 µg/ml was found (Fig. II.C.13a). In the blood 
of the other young man, alcohol (0.73 pro mille), cannabinoids and MDMA were present. The 
latter young man was also positive for GHB abuse as a 44.4 µg/ml GHB concentration was found by 
analyzing the DBS (Fig. II.C.13b).  
 
 
Fig. II.C.13 Chromatograms obtained when analyzing DBS from two possible GHB/GBL-users with GC-EI-MS in 
the SIM mode with (a) a GHB concentration less than 1 µg/ml in the first sample and (b) a GHB concentration 
of 44.4 µg/ml in the second sample 
 
 
This positive and negative result were confirmed by analyzing the whole blood samples for GHB 
with our previously published method [2], suggesting that our newly developed method may be 
applicable in routine samples in a toxicological laboratory for screening purposes, as well as for the 
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confirmation of the presence of GHB in whole blood samples. Interesting to note in this respect is 
that analysis of these DBS 5 months later (storage at -20 °C) yielded similar results.  
 
II.C.2.4 CONCLUSION 
A sensitive and accurate GC-MS method was developed for the determination of GHB in whole 
blood samples spot on Whatman 903 filter paper. The DBS sample procedure has advantages as to 
the conventional blood collection, such as easy to handle and no specific storage requirements. 
Especially in the case of GHB, where an increase in GHB concentrations during preservation of 
whole blood cannot be excluded, flexibility in storage conditions is of interest. Furthermore, as the 
detection window is limited, it is important that samples are obtained as early as possible after 
ingestion. By facilitating this, DBS may consequently represent an alternative in forensic and 
clinical cases where there is a suspicion of illicit use of GHB, in case of DUID or when a DFSA is 
presumed. Our LLOQ of 2 µg/ml is well below the proposed cut-off levels of 4 and 5 µg/ml for 
blood samples, so this method provides enough sensitivity to distinguish between endogenous and 
exogenously-administered GHB, which is of major concern for the toxicological interpretation of 
clinical and forensic samples. Finally, our approach of direct derivatization “on spot” may also be 
suitable for the determination of other compounds which impose extraction problems.  
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II.C.3 DETERMINATION OF GHB IN 6-MM DBS PUNCHES  
 
(Based on Dried blood spot punches for confirmation of suspected gamma-hydroxybutyric acid intoxications: 
validation of an optimized GC-MS procedure. Bioanalysis. 3(20):2271-2281 (2011). Ann-Sofie M.E. Ingels, Peter 
De Paepe, Kurt Anseeuw, Diederik K. Van Sassenbroeck, Hugo Neels, Willy E. Lambert, and Christophe P. 
Stove.) 
 
II.C.3.1 INTRODUCTION 
The short chain fatty acid gamma-hydroxybutyric acid (GHB) was synthesized in the early sixties as 
a structural analogue of gamma-aminobutyric acid and occurs also naturally in blood, urine and 
peripheral and brain tissue [19,30]. Although the function of endogenous GHB has not completely 
been revealed yet, evidence suggests it may act as a neuromodulator or neurotransmitter [30]. As 
a legal substance (sodium oxybate), GHB has a role as an anaesthetic agent, in the treatment of 
narcolepsy with cataplexy and of alcohol and opiate withdrawal. In addition, it has also been sold 
as a substance of nutritional supplements to induce sleep and increase muscle mass. Currently, 
illegal GHB (liquid ecstasy) as well as its precursors gamma-butyrolactone (GBL) and 1,4-butanediol 
are popular as club drugs and appear occasionally in drug-facilitated sexual assaults (DFSA) [7]. In 
those toxicological cases, the interpretation of a positive analytical result is a real challenge, 
because of its endogenous presence and the reported in vitro production [29,36]. Therefore, cut-
off levels have been proposed by several authors and these are currently set at 4 or 5 µg/ml for 
blood (serum) samples [30]. In addition, the detection window is very limited as GHB is rapidly 
metabolized and eliminated after oral ingestion (plasma half-life < 1 h), so blood samples must be 
taken within 6 h after ingestion [14]. Consequently, a sampling delay may result in blood levels 
below the established cut-off level, no longer resulting in a positive case [35].  
 
Blood sample collection may be facilitated by using dried blood spot (DBS) sampling. A DBS is 
capillary whole blood obtained by a finger or heel prick and collected on a filter paper card. 
Advantages as to a venepuncture are the easy and rapid way to collect a representative sample 
and the less specific sample transport and storage requirements [32]. Whereas DBS sampling has 
generally been used for newborn screening, more recently, this alternative sampling strategy is 
increasingly gaining interest in the context of therapeutic drug monitoring and (pre-) clinical 
studies, as well as in toxicology [50,51]. We recently reported on the development and validation 
of a new procedure for GHB determination in DBS, using “on spot” derivatization and gas 
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chromatography coupled to mass spectrometry (GC-MS) [52]. Also other drugs of forensic interest 
have been determined in DBS, such as MDMA, morphine, 6-acetylmorphine and cocaine 
[44,53,54].  
 
To obtain a DBS on a filter paper card, a drop of blood can be spotted directly on the filter paper or 
with the aid of a precision capillary [32]. In our previous study, we used the second sample 
collection technique, and spotted a drop of blood with a fixed volume onto the filter paper card, 
followed by analysis of the complete DBS [52]. However, as correct sampling in this case ideally 
requires the presence of trained staff and in routine practice it is more convenient to collect the 
drop of blood directly on the filter paper cards, we modified our procedure accordingly. As we did 
not wish this simplification to be at the expense of sensitivity (lower limit of quantification or LLOQ 
of 2 µg/ml), we re-adjusted several sample pre-treatment steps. Furthermore, the analysis of DBS 
punches rather than of complete DBS also requires the evaluation of the impact of various blood 
sample properties [51]. In this study, the influence of the punch localization, of the volume spotted 
on the filter paper card and of the hematocrit value (Ht) was evaluated in terms of precision and 
accuracy of the GHB concentration measured in DBS samples [51]. Following method validation 
including the generally accepted parameters for bio-analytical methods, we demonstrated 
applicability by analyzing DBS collected from patients presenting at the emergency department 
with a suspected GHB-intoxication. The results obtained from capillary sampling and those 
obtained by conventional blood collection (venepuncture) were compared in order to evaluate the 
DBS sampling technique. 
 
II.C.3.2 MATERIALS AND METHODS 
 
II.C.3.2.1 Reagents  
GHB (sodium salt, powder) and a 1-mg/ml solution in methanol of the internal standard (IS) GHB-
d6 (sodium salt) were purchased from LCG standards (Molsheim, France). The derivatization 
reagents trifluoroacetic acid anhydride (TFAA) and heptafluorobutanol (HFB-OH) were obtained 
from Sigma Aldrich (Bornem, Belgium). Methanol and ethylacetate, both of suprasolve quality 
suitable for GC-analysis, were delivered by Merck (Darmstadt, Germany). 
 
Stock and working solutions to prepare calibration solutions of GHB were prepared by dissolving 
10 mg of the base in 1 ml methanol, followed by appropriate dilution to obtain 1 and 0.1 mg 
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base/ml. To prepare quality controls (QC’s), a second, independent, stock solution was used. For 
the IS, a 25 µg/ml methanolic solution of GHB-d6 was prepared by appropriate dilution of the 
commercially available stock solution of 1-mg Na-GHB-d6/ml in methanol. All solutions were 
stored at -20 °C.  
 
II.C.3.2.2 DBS sampling  
In the procedure to obtain DBS, the hand is first cleaned and held down or warmed for a few 
minutes. With the help of an automatic lancet (Becton Dickinson ref n
o 
VAC366594, Franklin Lakes, 
USA), the fingertip is pricked. While the first drop of blood is wiped off with a sterile piece of cloth 
because of the presence of tissue fluid, the following drops are collected on a Whatman 903 filter 
paper card (ref n
o
 10334885, Dassel, Germany) with pre-printed circles. The circle (8 mm diameter) 
must be entirely filled with blood and although the blood is spot on just one side, both sides of the 
filter paper must be coloured [32].  
 
For method development and validation, we used venous whole blood from healthy non-user 
volunteers with endogenous GHB concentration below the established LLOQ, collected in EDTA 
tubes and preserved for maximum one week at 4 °C. No significant difference (α=0.05, 95% 
confidence interval) was observed between the mean GHB concentration measured (nominal 
value 5 and 100 µg/ml, n=5) when 25 µl of blood was either directly applied with a calibrated 
pipette or by allowing the drops to fall from the pipette tip onto the filter paper card. So from the 
whole blood samples, 25-µl spots were applied with a calibrated pipette directly onto the 
Whatman filter paper. The resulting spots were dried for minimum 2 hours at ambient 
temperature and subsequently analyzed or preserved in a zip-closure plastic bag with desiccant at 
room temperature until analysis. 
 
II.C.3.2.3 Sample preparation and analytical procedure 
Instead of using the whole DBS, only a 6-mm (diameter) disc (corresponding to ± 10 µl) was 
punched out from the centre of a DBS. This influences the sample pre-treatment procedure, thus 
each step from our previous procedure [52] was re-evaluated (data not shown). The most 
important adjustments included addition of the IS (5 µl of a 25 µg/ml solution) to the punched 
disc, halving of the amount of derivatization reagents, TFAA and HFB-OH (2:1, by volume), and of 
ethylacetate to redissolve the dried derivatized sample. Fig. II.C.14 gives a detailed overview of all 
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adjustments. Derivatized extracts were analyzed by GC-MS as described before, using the ratio of 
GHB to GHB-d6 (IS) for quantification [52]. The following ions were monitored using the selected 
ion monitoring (SIM) mode: m/z 155, 183, 227 and 242 for derivatized GHB and m/z 161, 189, 231 
and 245 for derivatized GHB-d6 (underscored ions represent the quantifier ions, the other ions 
were selected as qualifier ions).  
 
 
Method 1: 50-µl DBS Method 2: 6-mm DBS punch 
Sample collection 
50 µl (capillary) whole blood is spotted onto 
a Whatman 903 filter paper 
 
A drop of blood is collected directly 
onto a Whatman 903 filter paper 
Sample pre-treatment 
The complete DBS is excised 
 
The IS is added (before excising the DBS) 
10 µl of a 0.05-mg/ml methanolic solution 
 
The DBS is left to dry for 15 min 
 
100 µl of the derivatization reagent is added 
 
A 6-mm punch is excised 
 
The IS is added (after punching out) 
5 µl of a 0.025-mg/ml methanolic solution 
 
The punch is dried for 5 min under nitrogen 
 
50 µl of the derivatization reagent is added 
TFAA /HFB-OH (2:1, by volume) freshly prepared mixture 
Sonication (2-5 min) 
Derivatization at 60 °C for 10 min 
 
The DBS is cooled down by centrifugation for 5 min at 4 °C 
 
The sample is dried under a gentle stream of nitrogen at 25 °C 
 
The sample is redissolved in 200 µl ethylacetate 
 
Sonication for 5 min 
 
Centrifugation 5 min at 1.6 x 1000 g (2 times) 
 
The sample is redissolved in 100 µl ethylacetate 
 
Sonication for 2 min 
 
Centrifugation 5 min at 1.6 x 1000 g 
Transfer of the supernatant to a vial 
 
 
Fig. II.C.14 Overview of the sample collection and sample pre-treatment of our previously published method 
(method 1 [52]) and the newly developed method (method 2) for the determination of GHB in DBS with GC-
MS operating in SIM mode (with the most important changes underlined) 
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II.C.3.2.4 DBS method validation 
As suggested by several authors, punching out a disc from a DBS has as a consequence that the 
impact of additional parameters needs to be evaluated, such as the punch localization (at the 
periphery or central in the DBS), the influence of the volume spotted on the filter paper card and 
of the Ht [51,55]. Furthermore, a partial validation was performed based on the FDA and EMA 
guidelines for the validation of bio-analytical methods [39,40]. Therefore, linearity, precision, 
accuracy, limits of detection and quantification, and dilution integrity were evaluated. Also long-
term stability was determined [51]. Short-term stability, stability of stock solutions, and selectivity 
of the method were evaluated during earlier validation experiments [52].  
  
II.C.3.2.4.1 Influence of the punch localization 
Spots of 50 µl (n=5) were prepared at both low and high GHB concentration levels in whole blood 
with low (0.38), intermediate (0.45) and high (0.50) Ht. The difference between the mean GHB 
concentrations obtained when analyzing discs punched out peripherally vs. centrally was 
statistically evaluated using an independent sample T-test (α=0.05, 95% confidence interval) [56].  
 
II.C.3.2.4.2 Influence of the blood spot volume  
Venous whole blood from healthy volunteers with low (0.38), intermediate (0.45) and high (0.50) 
Ht was spiked at both low and high GHB concentration levels (5 and 100 µg/ml). Different volumes 
(20, 35 and 50 µl) were spotted (n=5 or 6) onto the filter paper card, the DBS were dried and 
subsequently analyzed. To calculate accuracy, the obtained GHB concentrations, when using a 
calibration curve prepared in whole blood with intermediate Ht (0.45), were divided by the 
nominal value of 5 or 100 µg/ml and multiplied by 100 %. The average % bias, which is the 
accuracy lowered with 100 %, needed to be within ± 15 %, while the within-volume precision 
needed to be < 15 % relative standard deviation (RSD), calculated by dividing the standard 
deviation (SD) by the mean ratio of GHB to GHB-d6 and multiplying by 100 % [55]. 
 
II.C.3.2.4.3 Influence of the hematocrit  
To investigate the effect of increasing Ht on the GHB concentration, both low and high GHB 
concentration solutions were prepared in six whole blood samples with increasing Ht (0.34, 0.39, 
0.44, 0.46, 0.51, and 0.56) and 25-µl spots were made (n=5). Therefore, we started from a whole 
blood sample, and after centrifugation, plasma was added or withdrawn to obtain whole blood 
samples with increasing Ht. The DBS were analyzed as described above, and the sample with a Ht 
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of 0.44 was normalized, as this is the theoretical average value of our patient population, including 
healthy women and men (Ht reference range of 0.37-0.47 and 0.41-0.51, respectively) [57].  
 
II.C.3.2.4.4 Validation  
To obtain the calibration data, on 4 non-consecutive days fresh calibration solutions were 
prepared in venous whole blood with intermediate Ht (0.45) and the resulting DBS were analyzed 
in duplicate. To ensure the independency of the result to the blood matrix properties, QC samples 
(2, 10 and 100 µg/ml) were prepared in venous whole blood samples with low (0.38), intermediate 
(0.45) and high (0.50) Ht values, obtained from different individuals [51]. For each day, a 6-point 
calibration curve was constructed by plotting the ratio (mean of the duplicates) of the area of GHB 
to GHB-d6 in function of the concentration (2, 5, 10, 25, 50, and 100 µg/ml). The resulting data 
were statistically evaluated by performing weighting if necessary. Therefore, the sum % relative 
error (RE) was calculated and the % RE versus concentration was plotted, where % RE is the 
concentration found lowered with the nominal concentration, divided by the nominal 
concentration and multiplied by 100 %. Linearity was assessed by performing Fisher’s test [41].  
 
Intra- and interbatch precision were evaluated by analyzing QC solutions prepared in blood with 
low, intermediate and high Ht on 5 separate days in duplicate. The RSD was calculated using one-
way-ANOVA as recently described by Wille et al., and needed to be < 15 and < 20 % at LLOQ [43]. 
Accuracy needed to be within 85 to 115 % of the nominal value and within 80 to 120 % at LLOQ 
level (expressed as % bias).  
 
To evaluate sensitivity, the limit of detection (LOD) was estimated as the minimum GHB 
concentration with a signal-to-noise ratio equal to or larger than 3. Furthermore, the LLOQ was 
defined as the lowest GHB concentration still measured with % RSD < 20 % and accuracy between 
80 and 120 %. 
 
The possibility to dilute the final derivatized extract of samples with a GHB concentration higher 
than the highest point of  the calibration curve (100 µg/ml), was assessed by spiking venous whole 
blood with low (0.38), intermediate (0.45) and high (0.50) Ht at 200 µg/ml and 25-µl spots were 
made (3 days, n=2). The spots were analyzed as described and 10 µl of the final derivatized extract 
was diluted to 100 µl with ethylacetate (as a result, also the derivatized internal standard is diluted 
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10-fold). The mean GHB concentration was back-calculated by using the daily calibration curve, 
and was corrected for by the dilution factor. Inter-batch precision (% RSD) and accuracy were 
evaluated as described above and needed to be < 15 % and within 85-115 %, respectively.  
 
Finally, drying times of 30 min to 2h and of 72 h at room temperature or 4 °C in a study box were 
investigated (n=3 for each condition at 5 and 100 µg/ml). Long-term stability at room temperature 
was investigated by analyzing DBS (n=6) at both low and high GHB concentration levels (5 and 100 
µg/ml) at time point zero, and after 14, 48 and 148 days of storage. The mean concentration 
measured must be within ± 15 % of the nominal concentration, when using a freshly prepared 
calibration curve.   
 
II.C.3.2.5 Determination of GHB in DBS collected at the emergency 
department 
In a first study (approved by the local medical ethical boards), patients transported to the 
emergency room of the cooperating hospitals (Ghent and Antwerp), and  with moderate to severe 
loss of consciousness and/or with indications of a GHB-ingestion were included. A venepuncture 
was performed (EDTA as anti-coagulant) and within 10 minutes capillary DBS were obtained as 
described above, in order to compare the GHB concentration in the venous and capillary whole 
blood sample [55]. Within 30 minutes after collection of the venous whole blood sample, DBS 
were prepared (so called venous DBS) by applying 25 µl onto the filter paper card with a calibrated 
pipette. The collected DBS were left to dry for minimum 2 hours at room temperature and were 
then placed in a zip-closure plastic bag with desiccant until analysis, while the venous whole blood 
samples were stored at 4 °C until analysis. The venous whole blood samples were analyzed in 
accordance with the routine procedure of toxicological analysis, while the DBS were analyzed as 
described above in order to confirm a possible GHB-intoxication. If the GHB concentration was 
found to be above the highest calibration level, the derivatized extract was diluted as described. In 
addition, an aliquot of a GHB-positive venous whole blood sample was analyzed according to the 
procedure of Van hee et al. [2]. Briefly, 20 µl of the whole blood sample was directly derivatized to 
obtain the di-trimethylsilyl derivative of GHB, which was analyzed by GC-MS in the SIM mode.  
 
In a second study, capillary DBS and venous whole blood were collected at the same time from 
patients with a suspected GHB-intoxication in the emergency department of Guy’s and St Thomas’ 
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hospital, London, in collaboration with the Clinical Toxicology Service. First, 4 drops of capillary 
whole blood were collected using a single-use lancet and then, venous samples were taken, of 
which 4 drops of 25 µl were spot onto a DBS card. Once dry, the DBS were placed in zip-closure 
plastic bags and samples were sent to the laboratory in batches by regular mail (see study flow 
diagram: Fig II.C.15). At the laboratory, samples were treated as described above.  
 
 
Fig. II.C.15 Comparison of capillary and venous blood analysis for GHB in patients with acute GHB-
intoxication. Study flow diagram formulated by the clinical toxicology department of Guy’s and St Thomas’ 
hospital, London 
 
 
The % difference between the various GHB measurements was calculated from the following 
concentration ratios: [venous DBS]/[capillary DBS] and [venous whole blood]/[venous DBS]. These 
respective ratios were used to evaluate whether there were consistent differences in GHB 
concentrations between DBS obtained from capillary vs. venous blood and between venous blood 
analyzed as such or as DBS. For method comparison, cross-validation was performed by analyzing 
an aliquot of the venous whole blood samples at the Laboratory of Toxicology of ZNA Stuivenberg 
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Hospital in Antwerp, using the method of Van hee et al. [2] and by analyzing venous DBS using the 
developed DBS method. The difference between the measured GHB concentratios in the venous 
DBS obtained by the newly developed DBS method and those obtained by analyzing venous whole 
blood with the method of van hee et al. [2] should be within 20 % of the mean for at least 67 % of 
the samples [40]. Furthermore, to evaluate if capillary GHB concentrations are a true reflection of 
venous GHB concentrations, the concentrations obtained from capillary and venous DBS were 
compared using Bland-Altman plot, Mountain plot and Passing-Bablok regression [54,58-62].   
 
II.C.3.3 RESULTS AND DISCUSSION 
Following DBS collection and drying (for a minimum of 2 hours at room temperature), a 6-mm-
(diameter)-disc was punched out. After applying the IS, “on spot” derivatization was performed 
with a mixture of TFAA and HFB-OH (50 µl, 2:1 by volume) at 60 °C for 10 min. The derivatized 
sample was then centrifuged, dried under a gentle stream of nitrogen and the dried extract was 
redissolved in 100 µl ethylacetate. Following brief sonication and centrifugation, 1 µl of the 
derivatized extract was analyzed by GC-MS. Besides modification of the sample preparation, the 
impact of additional parameters was investigated. Finally, the procedure was validated and 
applicability was demonstrated using samples obtained at the emergency department of 
cooperating hospitals.  
 
II.C.3.3.1 DBS method validation 
 
II.C.3.3.1.1 Influence of the punch localization  
Several publications have pointed out that the site of punching may have an effect on the 
measured concentration. This has been shown for both macromolecules (proteins) as for small 
molecules, with higher concentrations observed at the peripheral or at the central punching site, 
depending on the molecule under investigation. This effect, which is also influenced by the Ht, is 
likely owing to chromatographic effects, which are determined by interaction of the compound 
with both the paper and the blood [63-65]. To investigate whether the site of punching out a disc 
from a DBS influences the result of our analyses, discs punched out peripherally and centrally were 
analyzed. Irrespective of the Ht, this revealed no significant difference between the mean GHB 
concentrations at a confidence level of 95 %, demonstrating a homogenous GHB distribution in 
DBS [56].  
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II.C.3.3.1.2 Influence of the blood spot volume 
The influence of the volume spotted on the measured analyte concentration was evaluated by 
replicate analysis of discs punched out in the centre of DBS with different blood volumes. Fig. 
II.C.15 summarizes the results and shows that the average % bias was overall within the 
predefined acceptance limits of ± 15 %, except for the analysis of discs punched out from 50-µl 
spots (5 µg/ml GHB) at the low and high Ht. The latter is probably due to an overload of the filter 
paper, negatively influencing the spread and the homogenous distribution of the blood drop. The 
within-volume precision (% RSD) was overall < 15 %. So, based upon our results, the best blood 
volume spotted was between 20 and 35 µl, regardless of the Ht of the blood sample. This is also 
the volume required for filling the pre-printed circles in the case of DBS from patients (8-mm 
diameter, containing ± 20 µl).  
 
 
       
Fig. II.C.15 Average % bias vs. blood volume spotted for the determination of GHB in DBS. The DBS (n=5 or 6, 
at low and high nominal value) were analyzed using “on spot” derivatization and GC-MS, operating in the 
SIM-mode. Dotted lines indicate the ± 15 % (bias) limits. 
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II.C.3.3.1.3 Influence of the hematocrit  
Although not unequivocally demonstrated, an equal distribution of GHB between plasma/serum 
and blood is assumed, which, similar to ethanol, is expected to result in a concentration ratio of 
blood to plasma or serum of about 0.87 (this figure being slightly lower than 1 because of the solid 
constituents of blood) [30,66]. As this implies an even partitioning between plasma/serum and 
erythrocytes, no effect of the Ht on the GHB concentration in blood per se is expected [67]. 
However, still, the influence of the Ht requires special attention, especially in the analysis of DBS, 
as the Ht is directly proportional to the blood viscosity, affecting flux and diffusion of the blood 
that is spotted on the filter paper card [68]. The Ht values in healthy women and men range from 
0.37 to 0.47 and from 0.41 to 0.51, respectively [57]. Using a calibration curve obtained by 
analyzing DBS prepared of blood with intermediate Ht (0.45), we determined the GHB 
concentration (low and high nominal value) in DBS from whole blood solutions with increasing Ht. 
The results are summarized in Table II.C.4, presenting the % deviation from the normalized sample 
with average Ht [57].  
Table II.C.4 Influence of the hematocrit on the GHB concentration measured in DBS samples, using GC-MS, 
operating in  SIM mode. Values indicate the mean % deviation from the GHB concentration obtained for the 
sample with a hematocrit of 0.44, which was used for normalization, given the reference interval of 0.37 to 
0.51 for healthy women and men. 
Hematocrit Low GHB concentration 
(5 µg/ml, n=5) 
High GHB concentration 
(100 µg/ml, n=5) 
0.34 -15.0 -5.17 
0.39 -3.45 -2.73 
0.44 Normalized Normalized 
0.46 -2.32 3.85 
0.51 -0.910 1.18 
0.56 11.1 10.9 
 
 
Overall, we observed little or negligible influence in the Ht range of 0.39 to 0.51, covering the 
expected range of Ht in our patient population. Analysis of DBS prepared from whole blood with 
Ht deviating from the reference range may no longer result in accurate measurements. Therefore, 
based upon this experiment and in agreement with other reports, for quantification purposes, it is 
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recommended to prepare calibration and QC samples in whole blood with a Ht within the 
reference range and most preferably with an intermediate Ht, and this to minimize its effect on 
accuracy [32,51].  
 
II.C.3.3.1.4 Validation  
The obtained calibration data were statistically evaluated as described in the experimental section, 
and a weighting factor of 1/x
2
 was applied. The resulting calibration and sensitivity data are 
summarized in Table II.C.5. Fig. II.C.16 shows a representative chromatogram for the LLOQ sample 
(2 µg/ml). Linearity was demonstrated within the working range using Fisher’s test. 
 
 
Fig. II.C.16 Representative chromatogram obtained after analysis of a 6-mm disc punched out from a DBS 
prepared from blood spiked with GHB at 2 µg/ml (LLOQ). Five µl of a 25 µg/ml IS solution was added to the 
punch before derivatization and analysis with GC-MS operating in SIM mode. 
 
 
Table II.C.5 Calibration and sensitivity data for the determination of GHB in 6-mm punches using GC-MS in 
SIM mode 
 Slope 
Mean ±SD  
(95 % CI) 
(n=4 x 2) 
Intercept 
Mean ±SD  
(95 % CI) 
(n=4 x 2) 
Working 
range 
(µg/ml) 
LLOQ 
(µg/ml) 
R
2 
(n=4 x 2) 
Weighting 
factor 
6-mm 
punch  
0.044 ± 0.003 
(0.040; 0.047) 
0.000 ± 0.007 
(-0.007; 0.007) 
2-100 2.0 0.999 1/x
2
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As shown in Table II.C.6, precision and accuracy were within the predefined acceptance limits (< 15 
% RSD and bias). Results of the dilution experiment are also summarized in Table II.C.6. Precision 
and accuracy were acceptable, so the derivatized extract of samples with a GHB concentration of 
more than 100 µg/ml can be diluted 1 to 10 with ethylacetate prior to GC-MS analysis.  
 
Table II.C.6 Intra- and interbatch precision and accuracy data for the QC’s prepared in whole blood with low, 
intermediate and high Ht 
 Nominal GHB 
concentration 
(µg/ml) 
Measured GHB 
concentration 
(µg/ml) 
Intra-batch 
precision 
(% RSD, n=5 x 2) 
Inter-batch 
precision 
(%RSD, n=5 x 2) 
Accuracy 
(Bias %) 
Low Ht (0.38) 
QC low 2 1.99 5.3 7.9 -0.6 
QC mid 10 9.07 6.7 14.6 -9.2 
QC high 100 97.17 5.2 12.5 -2.8 
2 x ULOQ 200 191.30 6.0 9.5 -4.4 
Intermediate Ht (0.45) 
QC low 2 2.10 11.6 11.6 5.1 
QC mid 10 9.65 3.7 5.5 -3.5 
QC high 100 103.02 4.9 14.7 3.0 
2 x ULOQ 200 209.94 4.5 11.1 5.0 
High Ht (0.50) 
QC low 2 2.12 6.0 10.3 6.0 
QC mid 10 10.10 6.3 12.5 1.0 
QC high 100 106.60 7.3 8.0 6.6 
2 x ULOQ 200 206.50 4.1 6.8 3.3 
  
 
Furthermore, 2 h drying at room temperature was required to obtain completely dry DBS suitable 
for punching out a 6-mm disc. Drying DBS for 72 h was possible at room temperature or 4 °C in a 
study box with desiccant, before placing the DBS card in a sealable plastic bag for storage at room 
temperature. Finally, DBS appeared to be stable when stored at room temperature in a zip-closure 
plastic bag with desiccant for at least 148 days, as the average calculated GHB concentration 
deviated less than 15 % from the nominal value (Fig. II.C.17).  
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Fig. II.C.17 Long-term stability of GHB in DBS (n=6, low and high GHB concentration level) stored at room 
temperature in a zip-closure plastic bag with desiccant up to 148 days. The average % bias vs. time point of 
DBS analysis (days) is plotted and needed to be within the ± 15 % limits, indicated by the dotted lines. T0 
refers to time point zero (DBS analysis after 2 hours of drying).  
 
 
II.C.3.3.2 Determination of GHB in DBS collected in the emergency room 
Given the required drying time of minimum 2 h at room temperature, the DBS analyses will most 
likely have no influence on clinical patient management in an emergency department setting. This 
also holds true for the majority of methods used to determine GHB, given the rapid onset and 
disappearance of (side-) effects. Because of the availability of presumed GHB positive patients at 
emergency departments, we chose to collect DBS samples from these patients, to demonstrate 
the applicability of our procedure. So, two separate studies were conducted to evaluate the DBS 
sampling technique in a real-life setting, as well as to make a first comparison between the GHB 
concentrations measured in venous vs. capillary whole blood. In the first study, a total of 14 
patients (between 18 and 35 years old, 13 men and 1 woman) were included. They were brought 
to the emergency department with unknown cause of coma and/or signs of drug intoxication. 
Blood sample analysis confirmed 7 GHB intoxications (Table II.C.7, patients 1-7). Consistent with 
other reports describing GHB abuse in the context of multi-drug use, we found GHB to be 
combined in all cases with other drugs such as alcohol, cocaine and cannabinoids [20]. We 
previously demonstrated that these do not interfere with the GC-MS determination [52]. Within 
the same study, also during one dance festival and one techno party, we collected samples at a 
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first aid post. Also here, 2 samples were GHB-positive, consistent with the clinical diagnosis (Table 
II.C.7, patients 8-9).  
 
From the study in collaboration with Guy’s and St Thomas’ hospital in London, we received 15 
paired samples (Table II.C.7, patients 10-24). Broad toxicological screening of corresponding 
plasma samples using time-of-flight mass spectrometry was performed [68]. Only 3 samples were 
negative for additional recreational drugs (N° 13,22 and 24). All other samples screened positive 
for mephedrone (4-methylmethcathinone, 4-MMC) and its metabolites. In addition, other 
commonly abused recreational drugs were also present (e.g. synthetic cathinone, ketamine and 
amphetamines). Other detected drugs were benzodiazepines, antidepressants, antibiotics, 
antiretroviral drugs and over-the-counter medications such as antihistamines. Furthermore, 
patient 13 and 19 had a blood alcohol concentration of 1.1 and 0.27 ‰, respectively; the rest of 
these patients (10 to 24) were negative (for alcohol ingestion).  
Fig. II.C.18 shows representative chromatograms (overlay) obtained by GC-MS analysis of a 
derivatized extract of a capillary and venous DBS collected from the first GHB-positive patient (case 
N
o
1, in Table II.C.7). The measured GHB concentrations in the collected DBS and whole blood are 
summarized in Table II.C.7.  
 
 
Fig. II.C.18 Overlay of representative chromatograms obtained by analyzing the derivatized extract of the 
capillary and venous DBS, collected from the first patient who tested positive for GHB use (GHB-positive case 
N
o
 1 in Table II.C.7), by using “on spot” derivatization and GC-MS, operating in the SIM-mode 
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Table II.C.7 GHB level (µg/ml) in paired venous and capillary DBS, and venous whole blood samples in 24 
patients presenting at emergency departments with a suspected GHB-intoxication. A DBS (single analysis) was 
analyzed using “on spot” derivatization and GC-MS, operating in SIM mode, while venous whole blood (in 
duplicate, average of duplicate measurements is shown) was analyzed according to the procedure of Van hee 
et al. [2]  
GHB-positive case N° Venous DBS 
(µg/ml GHB) 
Capillary DBS 
(µg/ml GHB) 
Venous whole blood 
(µg/ml GHB) 
1 81 79 89 
2 170 150 173 
3 153 169 154 
4 56 92* 44 
5 118 142 126 
6 107 116 91 
7 127 132 97 
8 121 137 125 
9 170 163 145 
10 275 269 261 
11 121 135 145 
12 113 91 85 
13 100 102 102 
14 98 89 85.0 
15 624 580 526 
16 131 127 128 
17 130 140 121 
18 142 120 118 
19 101 128 109 
20 121 126 96.7 
21 225 218 229 
22 163 142 136 
23 123 112 100 
24 201 170 166 
* We suspect this higher value to be due to contamination of the fingertip 
 
 
To ensure that no consistent change in GHB concentration occurred during drying of the DBS, an 
aliquot of the GHB-positive samples was also analyzed using the procedure of Van hee et al. [2]. 
Overall, as shown in Table II.C.7, analyzing a venous whole blood sample directly or after it has 
been spotted onto a filter paper card yielded similar analyte concentrations (mean difference of 
Chapter II.C Determination of GHB in DBS using “on spot” derivatization and GC-MS 
 
 
168 
 
8.5 %) with a ratio [venous whole blood]/[venous DBS] equal to 0.93. According to the general 
guidelines for cross-validation, for more than two-thirds of the samples the difference between a 
repeated measurement and the mean of the first and repeat measurement should be less than 20 
% [40]. This requirement was fulfilled when calculating the % difference in GHB concentrations 
obtained with the 2 methods.  
 
Comparing the measured GHB concentrations in capillary and venous DBS using Bland-Altman 
analysis revealed no systematic difference, with the zero value included in the 95 % CI of the mean 
difference in GHB concentration. Passing-Bablok regression resulted in a linear model to fit the 
data, with an intercept of 17.91 (95 % CI ranging from -5.94; 36.17) and a slope of 0.89 (95 % CI 
ranging from 0.75; 1.03), so with 1 and zero value included in the respective CI. This suggests that 
there are no systematic differences between GHB concentrations measured in capillary vs. venous 
DBS (Fig. C.II.19). The average ratio [venous DBS]/[capillary DBS] was 0.99, suggesting that capillary 
GHB concentrations can be used as an alternative for venous GHB concentrations. Since the 
analyses mentioned above were conducted with mere 24 paired samples, a more extensive paired 
sample analysis is recommended to confirm these preliminary findings. 
 
In addition, re-analysis of a subset of capillary DBS (n=6) and venous DBS (n=4) was performed 
after at least 3 weeks of storage of the DBS at room temperature in a plastic bag with dessicant 
(incurred sample re-analysis, ISR). The requirement that for more than two-thirds of the samples 
the initial concentration and that obtained by reanalysis should be within 20 % of their mean for at 
least 67 % of the repeats [40], was fulfilled, with all the percentages below 15 %. Concerning the 
sampling technique, collecting the drops of blood directly on the filter paper card was generally 
experienced as easy and quick. Also, thorough cleaning of the fingertips before sampling appeared 
to be very important to exclude contamination [32]. For example, since there were only 2 min 
between collection of venous whole blood and capillary DBS in case N
o
 4, with the venous whole 
blood being collected first, we suspect the higher concentration found in the capillary DBS in this 
case to be due to contamination of the fingertip. Nevertheless, the advantages of DBS sampling 
make this technique highly suitable for drug determination in a real-life setting, as it is less invasive 
than a venepuncture, the obtained DBS can be collected fast and only little sample volume is 
needed.  
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II.C.3.4 CONCLUSION 
A method for the determination of GHB in DBS samples, previously developed in our laboratory, 
was successfully adjusted in order to collect drops of blood directly on filter paper cards. 
Consequently, no longer a fixed volume of blood was analyzed, but only a 6-mm (diameter) disc 
punched out of the obtained DBS. This report includes the re-evaluation of the sample pre-
treatment steps, to maintain a LLOQ of 2 µg/ml, as well as the evaluation of the impact of various 
blood sample properties and method validation. We applied this procedure on DBS from 
intoxicated patients from collaborating emergency departments. Collecting the drops of blood 
directly on the filter paper card can be considered as a more convenient technique than the use of 
a precision capillary in a real-life setting. Moreover, GHB in DBS was found to be stable for at least 
148 days stored at room temperature in a zip-closure plastic bag with desiccant, so the DBS matrix 
overcomes the reported possibility of in vitro production by storage of whole blood samples at 
temperatures above 2 to 8 °C [30]. To conclude, the collection and analysis of DBS may be a useful 
tool to confirm a suspected GHB ingestion, even outside a hospital environment, because of the 
general advantages coupled to this sampling technique.  
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II.C.4 DETERMINATION OF GHB IN DBS COLLECTED BY PATIENTS WHO USE XYREM® 
(SODIUM OXYBATE) FOR THE TREATMENT OF NARCOLEPSY WITH CATAPLEXY 
 
(Based on Feasibility of Following up Gamma-Hydroxybutyric Acid Concentrations in Sodium Oxybate 
(Xyrem®)-Treated Narcoleptic Patients Using Dried Blood Spot Sampling at Home. An Exploratory Study. CNS 
Drugs. 27(3):233-237 (2013). Ann-Sofie M.E. Ingels, Katrien B. Hertegonne, Willy E. Lambert and Christophe P. 
Stove.) 
 
II.C.4.1 INTRODUCTION 
Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid synthesized in the early 1960s as a 
structural analogue of gamma-aminobutyric acid. GHB is also naturally present in blood, urine and 
peripheral and brain tissue [19,30]. The sodium salt of GHB, which is a popular club drug, is used as 
an orphan drug (sodium oxybate, Xyrem
®
) in the treatment of narcolepsy (with cataplexy or with 
excessive daytime sleepiness [EDS]), a chronic neurological sleep disorder [7]. This orphan disease 
is characterized by EDS, cataplexy (a sudden loss of muscle tone provoked by emotional stimuli), 
disturbed nocturnal sleep, hypnagogic hallucinations and sleep paralysis. It has been demonstrated 
that GHB administration in narcoleptic patients with cataplexy increases slow-wave sleep duration, 
improves EDS and reduces the number of awakenings at night [69-71].
  
 
Therefore, sodium oxybate has been approved in 2002 by the US Food and Drug Administration 
(FDA) for the treatment of cataplexy in narcolepsy patients, and subsequently in 2005 for the 
treatment of EDS in narcolepsy patients. Also, in 2005, the European Medicines Agency (EMA) 
approved sodium oxybate for the treatment of narcolepsy with cataplexy. A maximum of 9 g can 
be administered each night, split in two equal doses because of the short half-life (plasma and 
whole blood half-life less than 1 h). The first dose should be taken at bedtime and the second 2.5–
4 h later [69-71].
 
Intra- and interindividual variation in clinical effect has been seen with sodium 
oxybate; however, it is not known whether this correlates with variation in obtained GHB 
concentrations. Therefore, the DBS sampling technique, stated to be easy and minimally invasive, 
may be useful to obtain patient samples in a non-hospital-based setting.   
 
The present study was designed to determine the GHB blood concentration obtained after the first 
intake of sodium oxybate by the use of the DBS sampling technique. The first objective was to 
evaluate the applicability of a recently developed and validated DBS-based GC-MS method [72]. 
Chapter II.C Determination of GHB in DBS using “on spot” derivatization and GC-MS 
 
 
171 
 
Whereas DBS sampling has been used for decades in newborn screening, more recently, this 
alternative sampling strategy is increasingly gaining interest in the context of therapeutic drug 
monitoring, (pre-) clinical studies and toxicology. Having advantages such as being easy to perform 
and minimally invasive, DBS sampling renders blood sampling by the patient at home a feasible 
option, allowing better insight to be gained into GHB concentrations following sodium oxybate 
administration [32,50,51,73]. However, only a few studies have evaluated true home-based 
sampling; therefore, a second objective was to evaluate DBS collection in a real-life setting [74,75]. 
 
II.C.4.2 METHODS  
Since narcolepsy with cataplexy is an orphan disease and sodium oxybate may only be prescribed 
in selected cases, there is very limited access to patients. In Belgium, around 80 of the 
approximately 200 patients diagnosed with narcolepsy are currently using sodium oxybate 
(Xyrem
®
; UCB Pharma Ltd, Brussels, Belgium), of whom 7 are treated in the Department for 
Respiratory Diseases of Ghent University Hospital. Those 7 patients were included in this study, 
approved by the local medical ethical board.  
 
The patients, taking sodium oxybate on a daily basis, were asked to fill a maximum of four pre-
printed circles (8-mm diameter) on a DBS card approximately 20 min after the first sodium oxybate 
intake on 7 consecutive days. They received DBS cards (Whatman 903 filter paper; reference no. 
WHA10334885, Dassel, Germany), single-use automatic lancets for capillary blood collection 
(Becton Dickinson; reference no. VAC366594, Franklin Lakes, NJ, USA), disinfection tissues, zip-
closure plastic bags to store the DBS cards and a pre-paid envelope to send the material back to 
the laboratory. Each patient provided informed consent and was given a 30-min explanation 
concerning the aim of the study and the DBS collection, together with an illustrating folder. Also, a 
logbook (Fig. II.C.20) and a questionnaire, with questions concerning ease of sample collection and 
pain, as well as inconvenience experienced with this collection technique, were provided. Patients 
were asked to complete and return this form and questionnaire at the end of the collection period. 
 
Fig. II.C.20  Patients were asked to fill this logbook in correctly for each day they participated to the study  
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II.C.4.2.1 Dried blood spot (DBS) collection 
To obtain a DBS, the hand was first cleaned and held down or warmed for a few minutes. With the 
help of an automatic lancet, the fingertip was pricked. While the first drop was wiped off with a 
sterile piece of cloth because of the presence of tissue fluid, the subsequent drops were collected 
on the DBS card [32]. After overnight drying (horizontal on a clean and empty glass), the card was 
placed in a zip-closure plastic bag and, finally, all the cards were sent to the laboratory by regular 
mail. Fig. II.C.21 gives an overview of the DBS collection (part of the illustration folder provided to 
the patients). 
 
Fig. II.C.21 Schematic overview of how to collect DBS at home, information supplied to the participating 
patients using an illustrating folder 
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II.C.4.2.2 DBS analysis 
Upon arrival at the laboratory, DBS were visually inspected according to Edelbroek et al. [32]. DBS 
were considered of acceptable quality when these were large enough, symmetrically spread on 
the filter paper and had even colouration on both sides of the filter paper [32]. Fig. II.C.22 shows 
examples of well and not well collected DBS. The number of well collected DBS for each day was 
recorded and DBS analysis was performed in duplicate, if possible, using a previously developed 
and fully validated GC-MS method. Briefly, a 6-mm disc was punched out from a DBS and placed in 
a test tube. The internal standard GHB-d6 was added directly on the punch (5 µL of a 25-µg/mL 
methanolic solution), and subsequently dried under nitrogen at 25°C. Derivatization took place by 
adding ‘on spot’ 50 µl of a freshly prepared mixture of trifluoroacetic acid anhydride and 
heptafluorobutanol, and by placing the test tube in a heating block at 60°C for 10 min. The sample 
was cooled down during centrifugation, dried under nitrogen and then redissolved in 100 µl of 
ethylacetate. Finally, after centrifugation, the supernatant was transferred to a vial. One µL of the 
derivatized extract was injected into the GC-MS, operating in selected ion monitoring (SIM) mode 
for quantification [72].  
 
                                                              
Fig. II.C.22 Overview of well (a) and not well (b, c, d) collected DBS. Sometimes, DBS are too small (b), both 
sides of the filter paper are not evenly coloured (c) or the DBS are not spread symmetrically on the filter 
paper (d). 
 
 
The method used has a lower and upper limit of quantification of 2 and 100 µg/ml GHB, 
respectively. Of those DBS with a GHB concentration above 100 µg/ml, the final ethylacetate 
extracts were diluted ten-fold according to the previously validated dilution technique.
 
Furthermore, in our previous work we demonstrated that similar GHB concentrations are found in 
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capillary DBS, in DBS prepared from venous blood and in venous blood, collected simultaneously 
from GHB-intoxicated patients. Based on that study, it can be concluded that DBS from capillary 
blood can be used as a suitable alternative for venous blood [72]. 
 
II.C.4.3 RESULTS AND DISCUSSION 
In total, five series of DBS were collected by three different patients. One patient sent back a single 
series, the two other patients two series. An overview of the GHB concentrations (µg/ml) in DBS 
collected by the three patients is depicted in Fig. II.C.23. Appendix 2 gives a detailed overview of 
the sodium oxybate dose, which was taken at bedtime, the measured GHB concentrations, the 
time between sodium oxybate intake and DBS collection, the number of usable DBS and remarks.  
 
 
 
 
Fig. II.C.23 Overview of the measured GHB concentrations (µg/ml, analysis of 1 spot (  ) or mean of analysis of 
2 spots (  ) on one card) in DBS collected by three narcoleptic patients approximately 20 min after the intake 
of their sodium oxybate dose during a maximum period of 7 days. Patients 2 and 3 collected two series with 
an interval of 5 and 9 months between series, respectively. DBS analysis was performed using a GC-MS 
method with ‘on spot’ derivatization. b.w. bodyweight, * DBS collected after the second dose of Xyrem® 
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Table II.C.8 gives an overview of the within-card precision, which was calculated as the percentage 
relative standard deviation (% RSD, standard deviation/mean × 100) of two DBS, obtained at the 
same time points. Upon evaluation of the day-to-day GHB concentrations found in the collected 
DBS (Fig. II.C.23), it becomes clear that patient 2 had more intra-individual variation than patients 
1 and 3. When this patient performed a second sampling 5 months later, day-to-day variation was 
again observed. On the other hand, analysis of DBS of the second series of patient 3 resulted in 
similar GHB concentrations as compared with series 1, with the exception of one day. To rule out 
variation in analytical performance as a cause for this exception, the two remaining DBS were also 
analyzed, resulting in similar GHB concentrations (mean: 8.8 µg/ml, % RSD: 5.9 %, n = 2 × 2).  
 
Table II.C.8 Within-DBS card precision (% RSD), calculated for each duplicate measurement; a
 
indicates two 
usable DBS, but only one was analyzed, together with one DBS collected in the morning 
       
 
 
                     
 
 
 
 
 
                                            ND:  no duplicate measurements possible, - indicates no DBS collected 
 
Concerning the DBS sampling technique, the three patients reported that DBS were easy or quite 
easy to obtain. According to the first and third volunteer, no pain or inconvenience was 
experienced; patient 2 reported inconvenience of the finger prick itself. Despite the positive 
evaluation, visual inspection at the laboratory (using guidelines from Edelbroek et al. [32] revealed 
that not all DBS fulfilled the requirements (Fig. II.C.24). Since a maximum of four DBS was 
requested, DBS cards with at least two suitable DBS were considered to have acceptable quality 
Day Patient 1 Patient 2 Patient 3 
  Series 1 Series 2 Series 1 Series 2 
1 5.4 ND 11.0 ND 7.7 
2 1.7 ND 2.0 4.5 11.4 
3 3.2 ND ND 2.2 0.1 
4 24.6 ND 8.5 2.2 1.0 
5 a ND 7.9 - 7.6 
6 7.5 ND 10.1 5.6 6.5 
7 10.4 ND ND 1.4 - 
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[76]. For the first collection period, this criterion was fulfilled by 100 % of total cards collected by 
patient 1, none of the cards by patient 2 (analysis of single spots was however possible on 6 out of 
7 days) and 83 % of the cards by patient 3. When repeating the study (series 2), the number of well 
collected DBS increased, to 71 % by patient 2 and to 100 % by patient 3 (Fig. II.C.24).  
 
 
Fig. II.C.24 Overview of the number of well collected dried blood spots (DBS) per day per patient 
 
 
Of the 7 patients, one patient decided to cease participation after 3 days because of nausea, one 
was lost in follow-up and two stated falling asleep almost immediately after the intake of sodium 
oxybate. The GHB concentrations found in the three patients that completed the study are in line 
with those previously reported in pharmacokinetic studies using plasma samples of narcoleptic 
patients ingesting twice-nightly a 3-g dose [77]. In addition, no interference is to be expected from 
sodium oxybate intake on the previous day, since in all cases there were more than 21 hours 
between the intake of two first doses on subsequent days. Scharf et al. [77] using a dosing scheme 
similar to the one in our report (two doses some 4 h apart), reported a decrease to endogenous 
levels in less than 11 hours, consistent with the reported rapid metabolism of GHB in - and 
elimination from - the human body [14]. 
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With a single exception, the variation in GHB concentrations in DBS collected at the same time 
(within-DBS card precision) was acceptable for all duplicate measurements (< 11.5 % RSD, Table 
II.C.8). Besides confirming the precision of the analytical procedure, this also demonstrates the 
suitability of the collection technique. Patients were able to send back representative and 
independent samples collected in an ambulant setting, leading to valid measurements.  
The intra-individual variation found in the narcoleptic patients of this study is in line with reports 
describing variation of serum levels following ingestion of low GHB doses in healthy subjects 
[78,79]. Also, variation in clinical effects has been reported [78,80]; however, it is not known 
whether this relates to differently obtained GHB concentrations. Although not within the scope of 
this exploratory study, our results demonstrate that in future studies, it may be possible to explore 
the relationship between GHB blood levels and sleep quality in a real-life setting using DBS 
sampling. In addition, although here, we opted for the most challenging scenario, in which 
sampling was performed shortly after the intake of the first dose (which may pose a problem for 
some patients), the sensitivity of our method [72] also renders sampling before or several hours 
after intake of the second dose a feasible option. Introduction of DBS-based sampling at home may 
not only allow to gain better insight to be gained into the intra-individual variations in GHB 
concentration from day-to-day, but may also give relevant information about the concentrations 
attained at a certain time point. Indeed, in addition to sampling shortly after the first sodium 
oxybate dose - as was done here - it may be relevant to know the GHB concentration at the time of 
awakening at night (just before the second dose) or in the morning (e.g. when the patient wakes 
up or leaves to work). Interesting to mention in this respect is the fact that hitherto it is not known 
whether the spontaneous awakening at night of sodium oxybate-treated patients is associated 
with the drop of GHB levels below a certain threshold (and - if so - whether this threshold is similar 
in different patients). The most representative insights into this matter may be obtained in a home 
setting, rather than in a hospital environment. Also, from a legal perspective, it is relevant to know 
whether at the time a sodium oxybate-treated patient gets into a car to drive, the GHB 
concentrations have dropped below 4–5 µg/ml, the cut-off value used in forensic toxicology. 
 
Overall, the sampling technique was positively evaluated by the patients, and when patients 2 and 
3 repeated the collection, improvement in DBS quality was seen. This improvement supports the 
idea that if in future studies adequate training is provided, the DBS collection technique may be 
used as an alternative to venepuncture in an ambulant setting [74-76]. No guidelines are available 
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on the percentage of spots that should fulfill a certain quality standard. As we asked the patients in 
this study to generate 4 DBS and as we wished to perform duplicate analysis (i.e., analysis on two 
different spots on every time point), we put forward an acceptance criterion of 50 % (i.e., there 
should be at least two DBS with acceptable quality: large enough, symmetrically spread on the 
filter paper, both sides of the filter paper being evenly coloured). In fact, for any given DBS-based 
method, we would recommend to strive for at least 2 suitable DBS, in order to allow sample re-
analysis, when deemed necessary. 
 
II.C.4.4 CONCLUSION 
This study shows that the DBS sampling technique may be easily adapted in a real-life setting, 
since DBS cards with acceptable quality are obtained by non-medically trained patients without 
any supervision or aid of a trained person. In addition, our results demonstrate the acceptable 
precision associated with execution of the complete procedure, from patient self-sampling to 
analysis in the laboratory. Given the nature of the medication (requiring intake just before going to 
bed and having a very short half-life), monitoring of GHB concentrations was hitherto only possible 
in a hospital setting. Our study is the first to demonstrate that unsupervised sampling by sodium 
oxybate-treated patients at home is not only feasible, but also leads to samples with acceptable 
quality. Therefore, in future studies, this minimally invasive sampling technique, in which samples 
can be obtained in an easy and convenient way for the patient, may be used to acquire additional 
information on the relationship between GHB blood concentrations, the corresponding effects and 
adverse effects and sleep quality.   
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PART III 
DETERMINATION OF GHB IN BIOFLUIDS 
USING A ONE-STEP PROCEDURE WITH “IN-
VIAL” DERIVATIZATION AND HS-TRAP GC-
MS 
The aim of this part was to evaluate if a relatively new 
commercially available technique, headspace-trap (HS-trap), 
combined with GC-MS may be a valuable alternative for 
existing methods to determine GHB in biofluids. First, in 
Chapter III.A, a brief overview of headspace techniques is 
given, with the focus on headspace-trap and its published 
applications. 
Secondly, Chapter III.B describes the optimization of the 
derivatization reaction, as well as of the headspace-trap GC-MS 
method to determine GHB in urine, plasma, serum and whole 
blood. Using a (HS-) trap for sample introduction should 
decrease sample treatment and increase method sensitivity. 
Indeed, sample treatment only consists of the addition of salt 
and derivatization reagents to an aliquot of the sample, 
followed by proper sealing of the vial which is subsequently 
placed in the HS oven. Different parameters such as sample 
volume, amount of salt added, the derivatization procedure, 
the HS oven temperature, time to reach equilibrium, trap 
  
 
settings and GC-MS parameters were optimized to determine 
low levels of GHB in only 100 µl of various biofluids. Since GHB 
requires derivatization, we opted for an “in-vial” derivatization 
reaction, which, when combined with HS-trap, extends the 
application range of this technique to non-volatile analytes, 
with a negligible increase in workload. Finally, validation has 
been performed and the applicability of the method was 
demonstrated by the analysis of samples collected from 
suspected GHB-intoxicated patients. 
 
 
 
 
 
 
 
 
CHAPTER III.A 
HEADSPACE INJECTION TECHNIQUES: FOCUS ON HEADSPACE- 
TRAP 
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III.A.1 INTRODUCTION 
Extraction of various body fluids or tissue samples to separate analytes of interest (e.g. toxic 
compounds or their metabolites in forensic and clinical toxicology) from the complex biological 
matrix is an important step of almost every analysis. Hereby, one of the aims is to minimize the 
disturbing response of interferences caused by matrix constituents during subsequent 
chromatographic-spectrometric analysis [1]. If the analytes of interest are volatile enough, 
headspace (HS) techniques may be of interest as they combine extraction and injection in a single 
step. When applying static headspace, volatile analytes are extracted from a solid or liquid sample 
and injected onto a gas chromatographic (GC)-column as a gaseous phase. Only those analytes 
that are volatile enough will reach the GC-column, and can thus be analyzed without the 
interference of the non-volatile matrix [2]. Modifications of the classical procedure may involve 
adsorption of the analytes of interest on or in surfaces of fibers, inside an injection needle or inside 
a capillary, followed by desorption by evaporation at high injector temperatures (GC) or by 
dissolution in the mobile phase (liquid chromatography, LC) [1] .  
 
III.A.2 STATIC AND DYNAMIC HEADSPACE 
When analyzing samples with static or classical headspace, a liquid or solid sample is placed in a HS 
vial, the vial is sealed properly and subsequently placed in the HS oven (Fig. III.A.1). Volatile 
components will partition between the gas phase and the sample, until equilibrium has been 
reached. Next, an aliquot of the headspace is brought onto the GC column [2].  
 
          
Fig. III.A.1 Principle of static headspace: by heating the vial, volatile components will partition between the 
gas phase and the sample until equilibrium has been reached.  
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The peak area is proportional to the concentration of the analyte in the gas phase: 
A  ~  Cg= Co / K + β 
Where  A = peak area 
 Cg = concentration in the gas phase (mg/l) 
 Co = original concentration in the sample (mg/l) 
 K = partition coefficient 
 β = Vg/Vs = phase ratio 
 
To improve the sensitivity of a HS method for a given sample with concentration Co of the analyte 
of interest, K and β can be optimized. The partition coefficient or K can be influenced by changing 
the HS oven temperature (equilibration temperature), while by changing the sample volume (Vs) 
the phase ratio or β can be optimized. The influence of K and β is analyte-specific and should be 
evaluated separately in each case. The HS oven temperature is limited by the sample matrix (e.g. 
for aqueous samples, the oven temperature should not exceed 100 °C) and by the developed 
pressure when heating the sample vial. Also the sample volume (Vs) is limited: the needle may not 
enter the sample phase and there should be enough gas phase that can be transferred to the 
analytical column [2].  
 
Furthermore: 
K  ~  1 / pi x γi 
With  pi = pressure 
 γi = activation coefficient 
 
Ideally, the analyte(s) of interest should resolve better in the gaseous phase than in the matrix. For 
aqueous samples with polar compounds, sensitivity may be improved substantially by adjusting 
the matrix, so by influencing K by adjusting γi. This can be accomplished by the addition of 
electrolytes or by salting out, thereby decreasing the solubility of the analytes in the matrix and 
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increasing the concentration in the gaseous phase. In addition, β is changed via an additional 
volume-effect. Finally, besides matrix adjustments, the chemical properties of the analytes of 
interest can also be modified by derivatization, resulting in less polar and more volatile analytes 
more suitable for headspace analysis [2].  
 
Furthermore, dissolving inorganic salts may improve sample-to-sample reproducibility. For this 
reason, the liquid sample can also be diluted with a solvent reducing the influence of the sample 
matrix on the analyte distribution or the sample can be evaporated completely no longer requiring 
partitioning between the 2 phases (total or full vaporization technique) [2]. Also the addition of an 
internal standard can eliminate the effect of small variations in the matrix.  
 
A second headspace technique is dynamic headspace or purge and trap, based on a continuous gas 
extraction by a continuous flow of new carrier gas in or through the sample, to remove all volatile 
analytes from the sample matrix. The analytes in the gas phase are first collected onto a trap, 
where they are concentrated. At the end of the extraction, the trap is heated to release the 
analytes of interest (desorption), which are then brought onto the analytical column for analysis 
[2]. This technique mostly has a better sensitivity than when using static headspace, but may suffer 
from carry-over and may have difficulties to eliminate water before injection [3].  
 
A modification allowing miniaturization, sample enrichment and sample transfer is solid-phase 
micro-extraction (SPME). Here, the analytes of interest are extracted from a gas or liquid sample 
by adsorption in or on coated surfaces of fibers, inside needles or inside capillaries. In the case of 
HS extraction, a fiber or needle is placed in the gas phase, allowing analytes in the gas phase to 
adsorb and to concentrate before desorption. Besides the general advantage of SPME, being a 
solvent-free and fully automatable technique, headspace SPME has as an additional advantage 
over classical HS that it provides cleaner extracts, since it allows injection without excess of air. 
Furthermore, when compared to SPME where the fiber or needle is placed in the liquid sample, 
headspace SPME also minimizes fiber damage by aggressive or irreversibly adsorbed matrix 
components [1].  
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III.A.3 HS-TRAP 
A relatively new commercialized technique, HS-trap, encompasses an enhanced static HS system 
covering both static and dynamic HS properties (Fig. III.A.2). The principle of the HS-trap method 
has been illustrated by Barani et al. [3] and Schulz et al. [4]. A brief description of the procedure is 
given below (variables are given in italics) and shown in Fig. III.A.2.  
 
A vial is heated (thermostat time and oven temperature) and when the analytes reach equilibrium 
between headspace and sample matrix, an aliquot of the headspace is withdrawn. To this end, the 
vial is pressurized (vial pressure and pressurization time), followed by trap loading until the 
pressure in the HS vial reaches atmospheric pressure (decay time). The trap is maintained at lower 
temperature (trap low temperature), just above ambient, leading to condensation of the gas 
phase, while water can be removed by purging helium through the trap (dry purge time and 
pressure). Then, the trap is heated (trap high temperature) and backflushed, leading to desorption 
of the analytes that enter the chromatographic system (desorption time and pressure) [5].  
 
As mentioned above, an advantage of this technique is the possibility to eliminate water before 
injection (dry purge) by purging helium through the trap. This is important since injection of large 
amounts of water may disturb flame ionization detection (FID) or mass spectrometric (MS) signal 
stability, resulting in peak broadening and in higher background. Furthermore, similar to dynamic 
HS, a larger fraction of the HS can be analyzed compared to static HS, since the analytes are first 
concentrated on the trap before desorption, enhancing sensitivity. To further increase sensitivity, 
without excessively increasing analysis time, loading of the trap can be repeated up to 4 times 
(trap load) [3,4].  
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 (a) 
 
(b)                                                 
 
Fig. III.A.2 A headspace (HS)-trap system from PerkinElmer (a), together with a schematic overview of the principle of 
sample preparation using HS-trap (b, figure modified from Schulz et al. [4]) 
 
A. Trap loading is accomplished by pressurizing the sample vial and allowing the pressure to decay through the 
cooled adsorbent trap 
B. A drying step removes moisture from the trap 
C. After thermal desorption, the analytes are transported by the carrier gas into the GC column for separation  
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The HS-trap technique has already been successfully applied to determine various volatile 
compounds in water [3,5], spirits [4], soil [6], apple juices [7] and plant matrices [8] (Table III.A.1) 
in combination with GC-FID or GC-MS analysis. 
 
Table III.A.1 Overview of other published methods using headspace-trap  
Reference Analytes of 
interest 
Matrix Analytical column 
 
(run time) 
Equilibration 
time and 
temperature 
Trap Mode/ 
Type of 
injection 
Barani et 
al.; 2006 
[3] 
Volatile 
organic 
compounds 
(VOCs) 
Water 6 % cyanopropylphenyl 
- 94 % dimethyl-
polysiloxane 
 
60 m x 0.32 mm; 1.8 
µm (GC-FID) 
60 m x 0.25 mm; 1.4 
µm (GC-MS) 
 
(12 min) 
20 min at 70 °C 
 
Shaker ON 
Air 
Toxic® 
Constant pressure 
mode  
33 psi/  
 
NS 
Schulz et 
al.; 2007 
[4] 
Volatile 
constituents 
Spirits  6 % cyanopropylphenyl 
- 94 % dimethyl-
polysiloxane 
 
60 m x 0.53 mm; 1.5 
µm 
 
(45 min) 
20 min at 80 °C 
 
Air 
Toxic® 
Constant pressure 
mode  
13 psi/ 
 
Splitless injection 
Røen et al.; 
2010a and 
b 
[5,6] 
Sulphur 
mustard and 
related 
compounds 
Water 
Soil 
5 % diphenyl - 95 % 
dimethyl-polysiloxane  
 
30 m x 0.25 mm; 0.25 
µm  
 
(20 min) 
15 min at 80 °C  
 
Shaker ON 
TenaxTM Constant pressure 
mode 
15 psi/  
 
Direct connection 
Nikfardjam 
and Maier; 
2011 
[7] 
Aldehydes  
Ketones 
Aroma’s 
Alcohols 
Apple 
juices 
6 % cyanopropylphenyl 
- 94 % dimethyl-
polysiloxane 
 
30 m x 0.25 mm; 1.4 
µm 
 
(45 min) 
20 min at 80 °C 
 
Air 
Toxic® 
Constant pressure 
mode  
40 psi/  
 
NS 
 
Aberl and 
Coelhan; 
2012 
[8] 
Volatile 
constituents 
in hops 
Plant 
matrices 
5 % diphenyl - 95 % 
dimethyl-polysiloxane  
 
60 m x 0.25 mm; 0.25 
µm  
 
(38.5 min) 
45 min at 85 °C Air 
Toxic® 
Constant pressure 
mode 22 psi/ 
 
NS 
NS: not specified  
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There are currently 2 traps (fused silica capillaries filled with adsorbent material) commercially 
available by PerkinElmer, Air Toxic
©
 and Tenax
TM
. According to the manufacturer, Air Toxic
©
 
contains graphitized carbon, a relatively weak adsorbent for very volatile analytes, and a molecular 
sieve with strong adsorbing material. This trap is typically used for the determination of volatile 
organic components (VOC) such as aromatics and volatile alkanes. On the other hand, the 
turbomatrix thermal desorber trap packed with Tenax
TM
 consists of a porous polymer of 2,6-
diphenyl oxide and shows better results for volatile analytes, with little or no retention of the very 
volatile components. The highest recommended working temperatures for Air Toxic
©
 and Tenax
TM
 
are 375 and 280 °C, respectively [4,5]. 
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III.B.1 INTRODUCTION 
In numerous analytical methods to detect and quantify drugs in biological matrices, sample 
preparation is regarded as the most laborious and time-consuming step [1,2]. Hence, a tendency 
towards less demanding procedures has been noted, such as automated solid phase extraction 
(SPE), dilution or filtration of the samples prior to injection, thereby reducing manual operations, 
often with a simultaneous reduction of the initial sample size [1,2]. Moreover, if the analytes of 
interest are volatile enough, headspace (HS) extraction techniques can be used as these combine 
extraction and injection in a single step. Only relatively recently, a new HS technique has been 
commercialized: HS-trap, encompassing an enhanced static headspace system covering both static 
and dynamic HS properties. This technique, already successfully applied to determine various 
volatile compounds in water [3], spirits [4], soil [5], apple juices [6] and plant matrices [7], was 
evaluated for its possibility to determine gamma-hydroxybutyric acid (GHB), a low molecular 
weight compound and drug of abuse, in biofluids such as urine, plasma, serum and whole blood. 
As mentioned earlier, detection and quantification of GHB in biological matrices is of interest in 
toxicological cases, since recreational use with limited awareness of the possibility to suddenly fall 
into a coma has resulted in an increase in GHB intoxications at raves or other dance parties [8,9].  
 
Reported procedures, mostly using gas chromatography (GC) -although liquid chromatography (LC) 
and capillary zone electrophoresis have been applied as well- often include laborious sample 
preparation steps. While in a UHPLC-MS/MS method mere filtration and dilution prior to injection 
was shown to suffice as sample preparation for urine samples, extraction with SPE was required 
for whole blood samples [10]. For GC analysis, either derivatization to a more volatile derivative or 
conversion to the more volatile lactone-form gamma-butyrolactone (GBL) is required [11].  
 
Several options have been described that allow reducing the work-load associated with GC-MS-
based GHB determination in biological fluids. These include the addition of excess derivatization 
reagents directly to biological samples, thus omitting the extraction step [12-15], the use of HS 
injection after conversion of GHB to gamma-butyrolactone (GBL) [16-18] or “in-vial” derivatization 
with for example hexylchloroformate prior to solid-phase microextraction (SPME) [19] or HS 
injection [20]. The available HS-based methods, either ‘classical’ static HS [16], SPME [17,20], or 
solid-phase dynamic extraction (SPDE) [18], all start from 0.5-1 ml of biofluid (water, urine, plasma, 
serum or whole blood), providing sufficient sensitivity (LLOQ from 0.1 to 5.0 µg/ml). In this study, 
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we evaluated whether the combination of two advantageous options, “in-vial” 
derivatization/conversion and headspace injection, may represent a valuable alternative for 
existing methods. A third advantage is that smaller sample volumes may be analyzed, while still 
providing enough sensitivity. This is because, when compared to SPME or SPDE, the trap described 
here allows sampling of a larger headspace fraction, since its adsorptive capacity (having a solid 
sorbent volume of 160 mm
3
) is much larger than that of the small fibers or coated capillaries 
(having volumes of 0.94-5.99 mm
3
) used in SPME or SPDE [4]. Furthermore, by combining “in-vial” 
derivatization and HS-trap, the application range can be extended to non-volatile analytes, with a 
negligible increase in workload [21].  
 
The aim of this study was to develop a HS-trap GC-MS procedure to determine GHB in a small 
sample volume (100 µl) of biofluids with minimal sample handling: sample handling is limited to 
the addition of a sample and reagents to a single vial, followed by closing the vial. Method 
validation was performed and applicability was demonstrated by analysis of samples from 
suspected GHB-intoxicated patients. 
 
III.B.2 MATERIALS AND METHODS 
 
III.B.2.1 CHEMICALS AND REAGENTS 
Na-GHB and its internal standard (IS) Na-GHB-d6 were supplied by LGC standards (Molsheim, 
France). Dimethyl sulphate (DMS) and tetrabutylammonium-hydrogensulphate (TBA-HSO4) were 
delivered by Sigma-Aldrich (Steinheim, Germany), while anhydrous sodium sulphate (Na2SO4) and 
methanol (MeOH) of analytical grade were supplied by Merck (Darmstadt, Germany). Sodium 
hydroxide (NaOH) was supplied by VWR (Stockholm, Sweden). Ultrapure water from a Synergy 
ultrapure water purification system (Millipore, Brussels, Belgium) was used in the experiments.  
 
III.B.2.2 PREPARATION OF STOCK AND WORKING SOLUTIONS 
A 10 mg/ml stock solution of GHB was prepared by dissolving 12.2 mg Na-GHB powder in 1 ml 
MeOH. Working solutions of GHB of 1 and 0.1 mg/ml were prepared by appropriate dilution of the 
stock solution in MeOH. From a second, separately prepared 10 mg/ml stock solution of GHB, 1 
and 0.1 mg/ml working solutions were prepared for quality control (QC) samples.  
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Similar to the preparation of the GHB stock solutions, a 10 mg/ml stock solution of GHB-d6 was 
prepared in MeOH. By appropriate dilution of this stock solution in water, a 0.30 mg/ml GHB-d6 
working solution was freshly prepared each week or as needed, and stored at -20 °C.  
 
III.B.2.3 HEADSPACE-TRAP SETTINGS 
A PerkinElmer Turbomatrix HS-40 trap automatic headspace sampler with trap enrichment 
(Shelton, CT, USA) was used. There are currently 2 traps commercially available by PerkinElmer, Air 
Toxic
©
 and Tenax
TM
. Both packing materials were tested and based on preliminary results Tenax
TM
 
was used in further experiments, providing a signal for methylated GHB in the chromatogram.  HS 
vials of 22 ml with polytetrafluoroethylene (PTFE)/silicone septa (delivered by PerkinElmer), were 
used once, as recommended by the manufacturer; the derivatization reagent required caution and 
proper sample handling and waste removal [22]. The HS oven can thermostat several vials at the 
same time, the period from injection to injection was automatically calculated by the HS system 
and was set at 30 min.  
HS-trap conditions were optimized to determine GHB in urine, plasma and whole blood. To 
optimize trap parameters and vial pressure and pressurization time, water samples spiked with 
GHB were analyzed. Other parameters were optimized using spiked biofluids, as described below 
and more into detail in the results and discussion section. Table III.B.1 gives an overview of all the 
parameters that need to be optimized.  
 
Table III.B.1 Overview of HS and trap variables 
Headspace conditions 
Oven temperature 
Needle temperature 
Thermostat time  
Vial pressurization time 
Decay time = Trap load time 
Column pressure 
Vial pressure 
Trap settings 
Trap low temperature 
Trap high temperature 
Dry purge time 
Desorption time 
Trap hold time 
Desorption pressure  
(same pressure during dry 
purge: Dry purge pressure) 
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III.B.2.3.1 Effect of salting out 
The effect of adding anhydrous Na2SO4 to the sample matrix was evaluated by analyzing samples 
with increasing amounts of salt. Therefore, to 100 µl of biofluid spiked with 10 (urine) or 25 
(plasma and whole blood) µg/ml GHB, no salt, 50, 100, 120 or 150 mg Na2SO4 (n=3) was added. 
Fifteen µl of a 5-M NaOH solution and 30 µl DMS were added to derivatize GHB to its 
corresponding di-methyl derivative. The vials were closed immediately and analyzed within 24 h. 
Resulting peak areas of GHB were compared (n=3 for each condition) and significance of 
differences was checked at 0.05 significance level using one-way ANOVA with post hoc Bonferroni 
correction. 
 
III.B.2.3.2 Equilibration time and temperature 
To determine the equilibration time, 100 µl of biofluid was spiked with 25 µg/ml GHB; 100 or 50 
mg (whole blood) Na2SO4, 15 µl NaOH 5 M and 30 µl DMS were added and the HS vial was closed. 
Analysis was performed in triplicate and the time to reach equilibrium was varied from 10 to 60 
min. The resulting peak areas of GHB were plotted in function of time; when the signal reaches a 
plateau, this indicates that equilibrium is reached [23]. 
 
III.B.2.4 GC-MS ANALYSIS 
The HS-trap was connected to a 6890 Agilent gas chromatographic system and a 5973 mass 
spectrometer (Agilent, Avondale, PA, USA). The GC-MS procedure was optimized to selectively 
determine GHB in biofluids using HS-trap as injection technique. During preliminary experiments, 
better results were obtained when using a capillary GC column with a stationary phase consisting 
of 94 % dimethyl 6 % cyanopropylphenyl polysiloxane (DB-624; Agilent, Avondale, PA, USA; Fig. 
III.B.1) instead of the commonly used 95 % methyl 5 % phenyl polysiloxane (30 m x 0.25 mm i.d., 
0.25 µm film thickness). The column used had a length of 30 m, a 0.25 mm internal diameter with 
a 1.4 µm film thickness. Helium was used as carrier gas, at constant column inlet pressure of 15 
psi. To separate derivatized GHB from interfering components, various temperature programs 
were evaluated, and finally, the following temperature program was chosen: The GC temperature 
program started at 40 °C, which was maintained for 2 min, then ramped at 10 °C/min to 170 °C, 
resulting in a total run time of 15 min. Solvent delay was set at 9 min, and derivatized GHB-d6 and 
GHB eluted at 11.82 and 11.88 min, respectively. The HS transfer line was directly coupled to the 
analytical column using a butt connector, and was maintained at 150 °C, as recommended by the 
manufacturer, to avoid condensation on possible cold spots [3].  
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Fig. III.B.1 Structure of poly(dimethylcyanopropylphenyl)siloxane 
 
 
The mass spectrometer operated in the electron impact (EI) mode with ionization energy of 70 eV. 
The transfer line temperature was set at 210 °C, the ion source at 230 °C, and the quadrupole 
temperature at 150 °C. Following the initial acquisition of the mass spectra in SCAN mode, 
selective m/z fragments were selected of derivatized GHB and its IS (Fig. III.B.2). For GHB 
quantification in various biological matrices, the mass spectrometer operated in the selected ion 
monitoring (SIM) mode. The following m/z ions were chosen for GHB: 117, 101, 74 and 59 (Fig. 
III.B.3); and for GHB-d6: 123, 107, 77 and 63. Underscored ions represent quantifier ions, which 
are not the most abundant but the most selective for GHB and GHB-d6. As GHB is a low molecular 
weight compound, and methylation does not result in the formation of high mass fragments, 
quantifier and qualifier ions were not chosen based on relative intensities, but on being selective 
for GHB and GHB-d6 [13]. Fragment m/z 117 is formed by the loss of the neutral group CH3, and 
the other proposed fragments are presented in Fig. III.B.3. Data acquisition and integration were 
carried out with Chemstation software MSDChem (Agilent, Avondale, PA, USA). 
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Fig. III.B.2 Mass spectrum of GHB derivatized with dimethylsulphate (bold ions were chosen to be monitored 
in SIM, underscored ion was used for quantification) 
 
 
Fig. III.B.3 Proposed fragments of GHB derivatized with dimethylsulphate 
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III.B.2.5 “IN-VIAL” DERIVATIZATION 
The “in-vial” derivatization is a modification of the procedure recently published by Rasanen et al. 
[22]. Briefly, different volumes of the methylation reagent DMS, 5 M NaOH and TBA-HSO4 (0.1M), 
were added to 0.1 ml of sample. Fig. III.B.4 shows the reaction scheme for GHB. TBA-HSO4 is an ion 
pairing agent, which may activate the analytes during derivatization, thereby increasing 
esterification yields, thus improving the sensitivity of a derivatization procedure. Preliminary 
experiments in water and biofluids showed no improvement of derivatization and extraction yield 
of GHB using the ion-pairing agent (data not shown), so TBA-HSO4 was no longer added to a HS vial 
during further experiments. Furthermore, during further optimization (see III.B.3.1 “In-vial” 
derivatization), we evaluated various volumes of NaOH (15, 30 and 60 µl). To this end, we spiked 
100 µl of urine, plasma and whole blood with 25 µg/ml GHB and compared the resulting peak 
areas of GHB (mean ± st dev, n=3). 
 
 
Fig. III.B.4 Reaction scheme of the applied “in-vial” derivatization reaction of GHB with dimethylsulphate in 
biofluids 
 
 
III.B.2.6 SAMPLE PREPARATION 
One hundred µl sample was added to a 22 ml HS vial. Ten µl of a 0.30 mg/ml solution in water of 
the IS GHB-d6 was added, followed by addition of 100 mg anhydrous Na2SO4, 30 µl 5 M NaOH and 
30 µl DMS.  The vial was properly sealed and in the case of whole blood and plasma, samples were 
vortexed for 10 sec before placing the vial in the HS autosampler. To conduct method 
development and validation, healthy drug-free volunteers donated EDTA-anticoagulated whole 
blood and urine.  
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III.B.2.7 ANALYTICAL PERFORMANCE AND APPLICATION  
The analytical performance of the optimized method was evaluated based on guidelines of the 
European Medicines Agency (EMA) for validation of bioanalytical methods [24]. To determine 
inter- and intra-batch precision, QC’s (LLOQ, low, medium, high, 2 x ULOQ) were analyzed in 
duplicate on 4 different days, and precision was calculated using one-way ANOVA [25]. Accuracy 
(% bias) was determined by dividing the difference between the measured mean and the nominal 
value by the nominal value and multiplying it with 100 %.  Bias and imprecision should be < 15 % 
for all QC’s, except at LLOQ, where it should be < 20 % [24].   
 
To evaluate if plasma calibrators can be used for quantification of GHB in serum samples, QC 
samples prepared in serum were also measured together with calibration samples prepared in 
plasma. Similarly, to evaluate if calibrators prepared in whole blood are suitable for quantification 
of GHB in lyzed blood samples such as postmortem blood samples, QC samples were prepared in 
fresh whole blood (stored for a maximum of 7 days at 4 °C after collection) and lyzed blood 
(submitted to 2 freeze-thaw cycles before spiking). Also linearity, sensitivity, stability of processed 
samples, selectivity and carry-over were evaluated, as described more into detail below (III.B.3.5 
Analytical performance). It was defined that no carry-over was seen if in a blank sample injected 
after a 200 µg/ml GHB water sample, the area at the retention time of GHB was < 20 % of the area 
of the LLOQ [24]. 
 
The applicability of the HS-trap injection technique was demonstrated using patient samples. To 
this end, we analyzed urine and serum samples (anonymous leftovers) from suspected GHB-
intoxicated patients, kindly provided by the Laboratory of Toxicology of Ghent University Hospital 
and by the AZ St-Jan Hospital in Bruges, and a whole blood sample received in our own laboratory. 
To evaluate assay reproducibility, incurred sample reanalysis (ISR) was performed after a minimum 
of 7 days of storage at -20 °C. The initial concentration and that obtained by reanalysis should be 
within 20 % of their mean for at least 67 % of the repeats [24]. Furthermore, for method 
comparison, we performed a cross-validation by analyzing an aliquot of the samples at the 
Laboratory of Toxicology of ZNA Stuivenberg Hospital in Antwerp, using the method of Van hee et 
al. [12]. The difference between the result obtained by the newly developed HS-trap method and 
that obtained by the previously published method for the determination of GHB should be within 
20 % of the mean for at least 67 % of the samples [24]. 
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III.B.3 RESULTS AND DISCUSSION  
 
III.B.3.1 “IN-VIAL” DERIVATIZATION 
Using HS injection techniques, only volatile compounds will partition between the sample matrix 
and the headspace. Consequently, an aliquot of the sample can be brought directly into the HS 
vial, requiring a minimum of sample preparation [23]. “In-vial” or “in-situ” derivatization 
techniques are compatible with this general advantage The HS vial is then used as reaction vessel 
to perform derivatization reactions of the analytes of interest. However, one should bear in mind 
that derivatization reagents added directly to the HS vial, if they are volatile and added in excess, 
that they can also enter the chromatographic system and may interfere in the chromatogram. 
Furthermore, non-volatile impurities from the sample matrix may also be derivatized and generate 
peaks in the chromatogram, with additional increase of the vial pressure. Finally, most 
derivatization reagents require water-free conditions for the derivatization reaction to occur, 
restricting their use to derivatize samples in real practice. Reagents suitable for “in-situ” or “in-
vial” derivatization are therefore preferentially combined with headspace techniques. Examples of 
those reagents are alkylchloroformates and methylation reagents such as dimethylsulphate [23]. 
 
In literature, “in-situ” hexylchloroformation of GHB has been reported in urine samples, followed 
by SPME [19, 20]. However, when applying this derivatization reagent to water samples spiked 
with GHB, we had difficulties to desorb hexyl-GHB from the trap (preliminary results, data not 
shown). Furthermore, only two fragments were formed using the MS in EI mode, requiring 
background substraction to properly identify the presence of hexyl-GHB. Therefore, methylation 
was considered, as also used by Rasanen et al. [22] for “in-vial” derivatization of hydroxylic 
analytes, including GHB, in urine and extracted blood samples. Safety measures should be taken 
into account, and excess reagent should be avoided, as it can enter the gaseous phase and 
interfere with the chromatographic detection of di-methyl GHB [26]. We evaluated this “in-vial” 
methylation reaction on 100 µl of urine, plasma and whole blood, spiked at 25 µg/ml GHB. 
Comparison of the resulting peak areas of derivatized GHB led us to choose a 1:1 ratio of NaOH 
(5M) and DMS (30 µl for both) in the final procedure (Fig. III.B.5).  
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Fig. III.B.5 Optimization of the “in-vial” derivatization: 
NaOH 5M-solution and dimethylsulphate were added to 100 µl urine, plasma and whole blood spiked with 25 
µg/ml GHB in three different ratio’s: 0.5:1.0, 1.0:1.0, 2.0:1.0 (v:v). Samples were analyzed using a HS-trap GC-
MS method and resulting peak areas of GHB for each ratio (mean ± SD; n=3) were plotted for each matrix.  
 
 
III.B.3.2 EFFECT OF SALTING OUT 
Adding salt to a HS vial may decrease analyte solubility in a water-based matrix and result in an 
additional volume-effect, facilitating the transfer of the analyte from the sample matrix to the 
headspace [23]. As shown in Fig. III.B.6, the addition of salt indeed increased the amount of 
derivatized GHB in the vapour phase, the difference between no salt and salt added being 
significant in all matrices, with no significant difference between the different salt concentrations 
added (one-way ANOVA with Bonferroni correction, α=0.05, n=3). Based upon these results, we 
opted to add 100 mg (± 5 mg) of anhydrous Na2SO4 to each HS vial in the final procedure.  
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Fig. III.B.6 Effect of salting out:  
To 100 µl urine, plasma and whole blood, spiked with 10 (urine) or 25 (plasma and whole blood) µg/ml GHB, 
varying amounts of anhydrous Na2SO4 
were added. Samples were analyzed using a HS-trap-GC-MS method. 
The resulting peak areas of GHB (mean ± SD; n=3) for the various amounts of salt added were plotted for each 
matrix.  
 
 
III.B.3.3 TRAP SETTINGS 
Trap parameters (overview Table III.B.2) such as trap temperature during trap load and trap 
desorption were optimized to retain the analytes of interest and to maximize sample transfer to 
the GC-MS system [4]. In addition, when dealing with aqueous matrices, water removal prior to 
GC-MS analysis needs special consideration. The latter was achieved by dry purging the trap 
between its loading and desorption [3]. Conditions of the dry purging step were selected to obtain 
a maximum of water loss accompanied by a minimum of analyte loss from the trap [4]. For 100 µl 
water samples thermostatted for 50 min at 90 °C, a dry purge time of 10 min at a trap low 
temperature of 50 °C was required to efficiently remove water from the trap. To evaluate possible 
losses during this drying step, we compared the extraction yields obtained under these conditions 
with those obtained by a 5 min dry purge at 40 °C, the latter being associated with incomplete 
drying of the trap (as measured by following m/z 18, corresponding to H2O). Comparing the means 
of the resulting peak areas using a t-test revealed no significant difference at the 0.05 significance 
level (n=3; relative standard deviations or RSDs < 3 %) [3]. 
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Table III.B.2 Evaluated HS and trap settings  for the determination of GHB in 100 µl urine, serum, plasma and 
whole blood samples (22 ml vial) using “in-vial” derivatization and GC-MS. Underlined values indicate the 
initially tested settings; bold values indicate the optimal setting chosen for the final method. * Decay time= 
Trap load time; 
$
 Desorption pressure= Dry purge pressure 
 
 
A well-known point of attention with any trapping technique is the potential of carry-over 
between samples. To prevent this, complete desorption of analytes from the trap is required [3]. 
We could minimize carry-over by setting a trap high temperature of 265 °C, desorption time of 2 
min at a pressure of 30 psi, and a trap hold time of 10 min. This was evaluated by injecting a 200 
µg/ml GHB spiked water sample, followed by injection of 3 blank water samples. Carry-over was 
no longer seen after injection of one blank sample following injection of the high concentrated 
GHB sample. Furthermore, analysis of blank water samples following injection of the highest 
calibrator prepared in matrix (urine, plasma and whole blood) also demonstrated lack of carry-over 
in the 2
nd
 blank sample. Higher trap temperatures and higher desorption pressures are not 
recommended for routine practice, respectively to extend trap life-time and to efficiently remove 
water during analysis (the same pressure is also used during dry purge, negatively influencing 
water removal with higher pressures) [3]. Therefore, since carry-over could not be excluded 
completely using these mild trap settings, blank samples were analyzed between higher 
concentrated samples. Also, the trap can be re-used for at least 500 injections and if upon 
progressive use, carry-over would be seen between samples, it can be re-conditioned by heating it 
at 280 °C for 30 to 60 min. 
Chapter III.B Determination of GHB in biofluids using “in-vial” derivatization and HS-trap GC-MS 
 
 
211 
 
III.B.3.4 HEADSPACE CONDITIONS 
 
III.B.3.4.1 Equilibration time and temperature 
Preferably, an aliquot of the vapour phase is sampled when the analytes of interest have reached 
equilibrium between the sample matrix and the vapour phase. The time needed to reach 
equilibrium depends on the sample volume, the properties of the analyte of interest and the oven 
temperature [23]. Preliminary experiments showed that oven temperatures of 70 °C or lower 
resulted in a low GHB signal (data not shown). Since the matrices of interest are water-based, the 
HS oven temperature may not exceed 100 °C. Therefore, 90 °C was selected for further 
experiments. Plotting the resulting peak areas of GHB in function of equilibration time at 90 °C, as 
presented in Fig. III.B.7, shows that the di-methyl derivative of GHB reaches equilibrium after 20-
25 minutes in 100 µl urine, plasma and whole blood. For maximum sample throughput, the period 
from injection to injection should be as short as possible. The latter is calculated by the 
instrument, based on the optimized HS parameters. For the determination of GHB in biofluids, this 
calculation resulted in a minimum interval of 30 min between injections. Therefore, an 
equilibration time of 30 min was set, being slightly longer than the minimum required equilibration 
times of 20 or 25 min.  
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Fig. III.B.7 Time to reach equilibrium for GHB in 100 µl urine, plasma and whole blood, spiked at 25 µg/ml 
GHB, at 90 °C without shaking: the peak areas of GHB (mean ± SD; n=3) are plotted in function of equilibration 
time for each matrix 
 
 
III.B.3.4.2 Sample shaking 
Shaking of the sample vial during thermostatting may reduce the time needed to reach equilibrium 
[23]. However, for derivatized GHB no reduction in equilibration time was seen, with shaking 
rather introducing more variation (Fig. III.B.8). Consequently, samples were not shaken during 
further experiments. 
 
 
 
 
 
 
Chapter III.B Determination of GHB in biofluids using “in-vial” derivatization and HS-trap GC-MS 
 
 
213 
 
(a)      
  (b)  
                
            (c) 
                        
Fig. III.B.8 Equilibration time required for GHB (spiked at 25 µg/ml) in 100 µl urine (a) plasma (b) and WB (c) 
samples in 22 ml HS vials at 90 °C with (   ) and without (   ) shaking during thermostatting (n=3, mean ± SD) 
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III.B.3.4.3 Vial pressure, vial pressurization time and decay time 
The vial pressure was optimized to give the highest sample transfer onto the trap, without risk of 
vial leakage at the septum or septum puncture [3]. Vial pressure was varied from 20 to 35 psi. An 
increase in vial pressure from 20 to 30 psi resulted in an approximate 14 % increase in GHB peak 
area (n=3). A pressure of 35 psi gave lower peak areas (approximate 50 % decrease in peak area, 
n=3). Subsequently, vial pressurization time was varied from 1 to 3 min for a vial pressure of 20 
and 30 psi and it was seen that vial pressurization for 1 or 2 min at 30 psi gave highest peak areas 
with the lowest RSDs (< 1 %, n=3). Therefore, 1 min vial pressurization with 30 psi was chosen. 
Decay time or the time needed to decrease the vial pressure to atmospheric pressure after vial 
pressurization, was calibrated using a blank sample and was set to 1.2 min [3].  
 
III.B.3.4.4 Repeated vial extraction  
Vial pressurization followed by trap load can be repeated up to 4 times, to almost completely 
extract the vapour phase of the HS vial (pulse extraction). On the other hand, with each successive 
extraction, a larger amount of water vapour is introduced on the trap, possibly requiring 
adjustment of the dry purge step and prolonging analysis time. Furthermore, higher variation in 
measurement may be seen if equilibrium is no longer reached [3]. For 100 µl urine and plasma 
samples spiked at 10 and 5 µg/ml GHB, respectively, the mean GHB peak area (n=3) increased with 
approximately 75 % using a second extraction, with acceptable RSDs (< 5 %). A second extraction 
of 100 µl whole blood samples spiked at 5 µg/ml GHB, resulted in a 34 % mean increase of the 
peak area of GHB, as compared to a single vial extraction (Fig. III.B.9). Despite the increase in GHB 
peak area observed with a second vial extraction, we opted for a single vial extraction since that 
already resulted in sufficient sensitivity. However, it should be noted that two cycles can be used if 
lower detection limits would be desired. 
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Fig. III.B.9 Repeated vial extraction: The peak areas of GHB (mean ± SD; n=3) after one and two trap load 
cycles are plotted for 100 µl urine (spiked at 10 µg/ml GHB), plasma (spiked at 5 µg/ml GHB) and whole blood 
(spiked at 5 µg/ml GHB). 
 
 
III.B.3.5 ANALYTICAL PERFORMANCE 
The resulting optimized HS-trap GC-MS method was validated based on EMA guidelines [24] to 
determine GHB in biofluids: to 100 µl sample, 10 µl 0.30 mg/ml GHB-d6, 100 mg anhydrous 
Na2SO4, 30 µl 5M NaOH and 30 µl DMS were added. Subsequently, the vial was properly sealed 
and placed in the HS autosampler. The sample was equilibrated for 30 min at 90 °C, before 
transferring an aliquot of the HS to the Tenax trap (50 °C) after vial pressurization (30 psi for 1 
min). Water was removed during dry purge (30 psi for 10 min), followed by desorption (30 psi for 2 
min) of di-methylated GHB by heating the trap (265 °C). The GC-MS operated in SIM mode for GHB 
quantification.  
 
III.B.3.5.1 Selectivity 
To evaluate selectivity, 6 different sources were analyzed for each matrix (urine, plasma, serum 
and whole blood). Blank (GHB-free) matrices are unavailable since GHB is naturally present in 
biofluids, and small elevations of m/z ions 59, 74, 101 and 117 at the retention time of GHB were 
sometimes seen when analyzing these non-spiked samples. To evaluate the interference of matrix 
compounds and structural analogues such as beta-hydroxybutyric acid, alpha-hydroxybutyric acid, 
gamma-aminobutyric acid, 1,4-butanediol, ethyleneglycol, diethyleneglycol, glycolic acid, lactic 
acid, urea (urine samples), succinic semi-aldehyde and hydroxy-isovaleric acid, the latter 
compounds were spiked at 100 µg/ml, together with GHB at 10 µg/ml (urine) or 5 µg/ml (plasma, 
Chapter III.B Determination of GHB in biofluids using “in-vial” derivatization and HS-trap GC-MS 
 
 
216 
 
serum and whole blood) and GHB-d6, and analysis was performed as described above (n=1 for 
each matrix). Since at all instances the measured GHB concentration was within ± 15 % of the 
nominal value, we concluded that no interference with the GHB determination was seen.  
 
Also the possible interference by common drugs of abuse, such as ketamine, flunitrazepam, 
amphetamine, 3,4-methylenedioxy-N-methylamphetamine (MDMA), cocaine, benzoylecgonine, 
tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC, and ethanol was evaluated. Therefore, 100 µl 
spiked urine (10 µg/ml GHB), plasma (5 µg/ml GHB) and whole blood (5 µg/ml GHB) samples 
containing these interferences in concentrations above therapeutic or toxic range were analyzed 
(n=1 for each matrix). Also here, GHB measurements were within ± 15 % of the nominal value in all 
cases, meaning that there was no interference with the GHB determination.  
 
Since derivatization occurs in an alkaline environment, reported to favour hydrolysis of the lactone 
GBL to GHB in aqueous matrices [27], samples were spiked at 100 µg/ml GBL (n=6) to evaluate 
GBL-GHB conversion. In the urine samples 109 ± 3.3 µg/ml GHB was measured and 111 ± 7.0 µg/ml 
GHB in the plasma samples, 103 ± 9.0 µg/ml GHB in the serum samples, 113 ± 4.9 µg/ml GHB in 
the whole blood samples, and finally 98 ± 12.0 µg/ml GHB in the lyzed blood samples, meaning 
that GBL had been completely converted to GHB during analysis. Therefore, this method 
determines total GHB (GHB+GBL) in biofluids. Since GBL is converted to GHB within minutes after 
oral ingestion, GHB is the analyte of choice to search for in samples collected from suspected 
GBL/GHB-intoxicated patients [17,28,29]. 
 
III.B.3.5.2 Linearity, precision, accuracy, dilution integrity and sensitivity  
To evaluate the calibration model for determining GHB in 100 µl of biofluid using HS-trap, in total 8 
curves were constructed in the different biofluids, by preparing and analyzing on 4 different days, 
a blank (non-spiked), a zero (blank + IS) and 2 x 9 calibrators (2, 5, 10, 25, 50, 100, 150, 200 and 
250 µg/ml GHB in urine and plasma; 2, 3.5, 5, 10, 25, 50, 100, 150 and 200 µg/ml GHB in whole 
blood). Sensitivity and calibration data are summarized in Table III.B.3.  
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Table III.B.3 Sensitivity and calibration data: HS-trap GC-MS analysis of 100 µl of urine, plasma or whole blood 
samples using “in-vial” derivatization 
 Slope 
Mean ±SD  
(95 % CI) 
(n=4 x 2) 
Intercept 
Mean ±SD  
(95 % CI) 
(n=4 x 2) 
Working 
range 
(µg/ml) 
LLOQ 
(µg/ml) 
R
2 
(n=4 x2) 
Weighting 
factor 
Urine 0.0505 ± 0.005 
(0.0470; 0.0539) 
0.0178 ± 0.0306 
(-0.003; 0.0389) 
5.0-150 5.0 0.999 1/x
2
 
Plasma 0.0477 ± 0.002 
(0.0461; 0.0493) 
0.0035 ± 0.0107 
(-0.004; 0.0110) 
2.0-150 2.0 0.996 1/x
2
 
Whole 
blood 
0.0420 ± 0.003 
(0.0398; 0.0442) 
0.0063 ± 0.0066 
(0.002; 0.0109) 
3.5-200 3.5 1.000 1/y
2
 
 
 
Only for urine samples, calibrator ratios were lowered with the blank signal (ratio GHB/GHB-d6) 
and the calibration curve was found to be linear (using Fisher’s test) from 2 to 150 µg/ml GHB. A 
working range of 5 to 150 µg/ml was selected for accuracy and precision experiments. The latter 
range includes the proposed cut-off level for GHB in urine (6 or 10 µg/ml) [30-33] and can be 
extended to 1500 µg/ml using a 10-fold dilution technique. Fig. III.B.10 shows representative 
chromatograms of a blank and zero urine sample, as well as of a urine sample spiked at LLOQ and 
a patient sample positive for GHB. For plasma samples, the calibration curve was also found to be 
linear from 2 to 150 µg/ml, and this range was also selected as working range (using the following 
6 calibrators: 2, 5, 25, 50, 100 and 150 µg/ml). Furthermore, the calibration curve was linear from 
2 to 200 µg/ml GHB for whole blood samples, and a working range of 3.5 to 200 µg/ml was chosen 
(using the following 6 calibrators: 3.5, 10, 50, 100, 150 and 200 µg/ml). The lower limit of this 
range is below the proposed cut-off level for GHB in blood, 4 or 5 µg/ml, used to distinguish 
between endo- and exogenous GHB [32,33]. Upon evaluation of the resulting data, 
heteroscedasticity was observed in all matrices and 1/x
2
 was chosen as weighting factor for urine 
and plasma, while for whole blood 1/y
2
 was chosen.  
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Fig. III.B.10 Representative chromatograms of a blank (a), a zero (b) and a 5 µg/ml-GHB-spiked (LLOQ) (c) 
urine sample, as well as a positive urine sample (1/10 dilution with water) containing 596 µg/ml GHB (sample 
U5, see Table III.B.6)  
 
 
As shown in Table III.B.4, where precision and accuracy data are summarized, requirements were 
fulfilled for all QC samples, prepared in the different biofluids and analyzed using the method 
described above. Importantly, the results for the QC’s prepared in serum and lyzed blood 
demonstrate that calibration curves prepared in respectively plasma and whole blood can be used 
for quantification in these matrices. As to method sensitivity, as mentioned above, no blank (GHB-
free) matrices are available. Therefore, the lower limit of quantification was arbitrarily set at the 
lowest point of the calibration curve (5 µg/ml for urine, 2 µg/ml for plasma and serum, and 3.5 
µg/ml for whole blood). Samples with a GHB concentration above the upper limit of quantification 
can be diluted 10-fold with ultrapure water and in the case of plasma, serum and whole blood, 
also with non-spiked matrix, and can be analyzed as described above with acceptable precision 
and accuracy (see Table III.B.4, QC 2 x ULOQ).  
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Table III.B.4 Precision and accuracy data of the quality control samples (100 µl urine, plasma, serum, whole 
and lyzed blood) analyzed with HS-trap GC-MS in combination with “in-vial” derivatization (n=4 x 2). 
 Nominal GHB 
concentration 
(µg/ml) 
Measured GHB 
concentration 
(µg/ml) 
Intra-batch 
precision 
(% RSD) 
Inter-batch 
precision 
(%RSD) 
Accuracy 
(Bias %) 
Urine 
LLOQ 5 4.7 1.3 9.6 -6.7 
QC low 10 9.9 3.1 4.6 -1.4 
QC mid 75 71.9 1.9 6.1 -4.1 
QC high 125 125.4 8.5 12.6 0.3 
2 x ULOQ 300 296.1 1.5 4.6 -1.3 
Plasma 
LLOQ 2 1.8 4.3 9.9 -10.4 
QC low 5 5.0 3.5 8.9 0.1 
QC mid 75 67.5 2.1 4.3 -10.0 
QC high 125 117.0 0.5 6.4 -6.4 
2 x ULOQ 300 273.1 2.9 5.4 -9.0 
2 x ULOQ (matrix)a 300 310.8 5.6 11.0 3.6 
Serum 
LLOQ 2 1.8 4.4 10.6 -9.2 
QC low 5 4.9 2.3 9.0 -1.1 
QC mid 75 69.4 2.3 8.5 -7.5 
QC high 125 114.1 3.6 5.2 -8.7 
2 x ULOQ 300 266.6 3.3 4.7 -11.2 
2 x ULOQ (matrix)a 300 313.6 4.6 8.4 4.5 
Whole blood 
LLOQ 3.5 3.4 4.3 11.8 -1.7 
QC low 7.5 7.8 3.9 4.7 4.3 
QC mid 75 75.8 4.9 7.8 1.0 
QC high 160 158.3 5.0 7.6 -1.1 
2 x ULOQ 400 360.0 3.3 9.5 -10.0 
2 x ULOQ (matrix)
a
 400 388.3 4.5 11.1 -2.9 
Lyzed blood 
LLOQ 3.5 3.9b 6.4b 7.7b 10.4b 
QC low 7.5 7.8 4.5 6.6 4.2 
QC mid 75 71.6 6.7 8.2 -4.6 
QC high 160 159.8 6.4 8.6 -0.1 
2 x ULOQ 400 375.0 6.1 10.3 -6.3 
2 x ULOQ (matrix)a 400 379.3 2.8 8.2 -5.2 
a 10-fold dilution with blank matrix, b 1 outlier (Grubbs test for outliers) 
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III.B.3.5.3 Processed sample stability 
Low and high QC samples prepared in the different matrices, with all reagents added in a closed 
vial, were stored for at least 24 h at RT and for one week at 4 °C (n=3). The measured GHB 
concentration was within 15 % deviation from the original concentration in all cases. Thus, 
processed samples are stable under these storage conditions (Table III.B.5), which further 
contributes to the convenience of the developed procedure. 
 
Table III.B.5 Processed sample stability: The average % deviation from the original concentration (T0) is given 
for low and high processed QC samples (n=3) stored for at least 24h at room temperature and for at least 7 
days at 4 °C. 
 
 
Nominal GHB 
concentration  
(µg/ml) 
Room temperature 
24 h 
 
% deviation from T0 
concentration 
4 °C 
7 days 
 
% deviation from T0 
concentration 
QC low 
Urine 10 2.2 0.6 
Plasma 5 1.7 -12.4 
Serum 5 13.9 -14.8 
Whole blood 7.5 7.2 -9.1 
Lyzed blood 7.5 7.0 -5.1 
QC high 
Urine 125 -0.5 -4.1 
Plasma 125 -8.2 -6.3 
Serum 125 1.8 -0.7 
Whole blood 160 13.7 -12.2 
Lyzed blood 160 4.6 -10.8 
                                        
 
 
III.B.3.6 APPLICATION  
The applicability of the validated method using HS-trap as injection technique in combination with 
GC-MS for the determination of GHB in patient samples was demonstrated by analyzing 5 urine, 5 
serum, and 1 whole blood sample collected from suspected GHB-intoxicated patients. An aliquot 
of these samples was also analyzed using the method of Van hee et al. [12]. Results are 
Chapter III.B Determination of GHB in biofluids using “in-vial” derivatization and HS-trap GC-MS 
 
 
221 
 
summarized in Table III.B.6. Both the initial concentration and the concentration obtained by 
reanalysis using our described method varied from -4 to 4 % from their mean, well in line with the 
above mentioned requirement for ISR. Furthermore, analyzing the study samples by the use of HS-
trap and by the use of the method by Van hee et al. [12] led to similar GHB concentrations for the 
same sample. The difference between the two obtained results was within -9.4 to 16.7 % from the 
mean, calculated by dividing the difference between the two results (separately obtained by the 
two above-mentioned methods for the same sample), by the mean of those two results and 
multiplying this quotient with 100. 
 
Table III.B.6 Measured GHB concentrations (µg/ml) in real samples using the HS-trap GC-MS method (HS-
trap) and the method of Van hee et al. [12]. Urine samples (U) were frozen at -20 °C before reanalysis after 14 
days; serum samples (S) were frozen at -20 °C before reanalysis after 30 days; whole blood sample (WB) was 
frozen at -20°C before reanalysis after 7 days.       
 GHB concentration 
(µg/ml) 
Sample HS-trap HS-trap (ISR) Van hee et al. 
U1 546 555 600 
U2 991 1024 1052 
U3 385 393 387 
U4 58 59 57 
U5 596 587 531 
S1 13 12 11 
S2 70 68 69 
S3 128 124 134 
S4 259 247 224 
S5 220 231 220 
WB1 183 176 186 
ISR: incurred sample re-analysis 
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III.B.4 CONCLUSION  
In the study presented here, “in-vial” derivatization and HS-trap injection are combined into an 
application with minimal hands-on time. This combination has resulted in a simple and accurate 
GC-MS method for determination of total GHB (GHB+GBL) in urine, plasma, serum, whole blood 
and lyzed blood. In contrast to other published methods, no extra sample pretreatment step is 
required for quantitative determination of GHB in e.g. blood: the same procedure can be applied 
to all biofluids, which can simply be added to the HS vial together with the reagents, followed by 
closure of the vial. Moreover, the fact that these samples can be stored for at least 24 h at RT or 7 
days at 4 °C further adds to the convenience of the procedure.  
 
Besides the simplicity of the sample preparation, requiring a minimum of technical time, an 
important reduction of sample volume was accomplished in comparison to other HS-based 
methods, as a result of the trap and its associated gain in sensitivity. A sample volume of only 100 
µl is used, which is markedly lower than previously reported HS-based methods for GHB 
determination, which require 0.5 to 1 ml sample volume. In conclusion, the use of HS-trap as 
injection technique results in a quick, simple and universal sample preparation protocol, only 
including the addition of salt and derivatization reagents directly to a given biological matrix.  
 
The method was shown to be selective and sensitive enough to quantify GHB in samples collected 
from suspected GHB-intoxicated patients with LLOQ’s below the proposed cut-off levels. In 
addition, incurred sample reanalysis demonstrated good assay reproducibility, while cross-
validation with another method demonstrated comparable results. Furthermore, according to 
preliminary experiments, this method shows great potential to determine other compounds of 
interest in emergency toxicology or post-mortem cases, such as GBL itself, as well as 1,4-BD, beta-
hydroxybutyric acid, diethylene glycol, glycolic acid and ethylene glycol, derivatized to their 
corresponding (di)-methyl derivatives.  
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In this work, several new methods to determine gamma-hydroxybutyric acid (GHB) in 
microvolumes (≤ 100 µl) of biofluids have been successfully developed, validated and applied. The 
polar nature of GHB renders derivatization necessary prior to analysis by gas chromatography-
mass spectrometry (GC-MS). This is generally seen as laborious, so we opted to use direct 
derivatization approaches. Applying derivatization reagents directly to biological matrices, thereby 
combining derivatization and extraction, resulted in efficient and minimal sample treatment 
procedures.  
First, GC-MS-based methods to determine GHB in dried blood spots (DBS) were successfully 
developed and validated. This included a method for the analysis of GHB in 50-µl DBS, where a 
fixed volume is applied on a filter paper, as well as a procedure to analyze 6-mm discs punched out 
of complete DBS. The latter offers the possibility to directly apply the drops of blood on the filter 
paper, which is useful and practical in real-life settings. Method sensitivity allowed for the 
discrimination between endogenous GHB concentrations and concentrations arising from 
exogenous intake, with a lower limit of quantification below the current cut-off value of  5 µg/ml 
GHB in blood samples. Moreover, the second method has been used to determine GHB in DBS 
collected from suspected GHB-intoxicated patients brought to the emergency room. Results 
demonstrated that combining “on spot” derivatization, followed by analysis with GC-MS, led to a 
reliable procedure applicable in routine toxicology. Also, a first comparison could be made 
between GHB concentrations measured in the collected capillary DBS, in the DBS prepared from 
the venous whole blood sample, and in the venous blood, collected simultaneously from the same 
patient (not self-sampling by the patients). In the 24 samples (each consisting of venous and 
capillary DBS and venous blood), we found similar GHB concentrations. Although more patients 
samples should be collected, these findings suggest that for GHB determination in blood, DBS from 
capillary blood could be a suitable alternative for venous blood.  
Furthermore, in a second study that was set-up to evaluate the feasibility of the DBS sampling 
technique at home, acceptable precision of the complete procedure - from sampling at home to 
quantitative analysis in the laboratory - has been demonstrated. Given the intra- and inter-
individual variability in clinical effects seen with GHB/sodium oxybate, the possibility of DBS 
sampling via a fingerprick may allow a better follow-up of GHB concentrations in future studies. 
Conclusions and future perspectives 
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These can be set-up in e.g. patients discontinuing chronic use of GHB (to explore the correlation 
between GHB concentration and withdrawal symptoms) or in patients using sodium oxybate in 
real-life settings, e.g. to measure GHB concentrations after awakening in the morning.  
Secondly, another one-step procedure has been successfully developed and validated to 
determine GHB in various biofluids using a relatively recently commercialized HS technique, HS-
trap. Here, “in-vial” methylation was chosen to directly derivatize GHB, allowing for a 
straightforward approach. The developed procedure only included the addition of salt and 
derivatization reagents to a 100-µl sample in a HS-vial, and could be used for all tested biofluids 
(urine, plasma, serum, whole blood or lyzed blood). The implementation of the trap and its 
associated gain in sensitivity led to a reduction of the required sample volume compared to 
previously reported HS-based methods for GHB determination (which require 0.5 to 1 ml sample 
volume). For all biofluids, the method was shown to be selective and sensitive enough to 
discriminate between exo- and endogenous GHB concentrations with LLOQ’s below proposed cut-
off values.  
Comparable results were obtained when analyzing samples (collected from suspected GHB-
intoxicated patients) using the novel method and using another GC-MS method, implying that our 
method is a valuable alternative for GHB determination in toxicological samples. Moreover, re-
analysis of these samples led to similar results, showing assay reproducibility. Finally, according to 
preliminary experiments, this method shows great potential to determine other compounds of 
interest in emergency toxicology or post-mortem cases, such as GBL itself, as well as 1,4-BD, beta-
hydroxybutyric acid, diethylene glycol, glycolic acid and ethylene glycol, derivatized to their 
corresponding (di)-methyl derivatives. 
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Appendix 1 Overview of the drugs of abuse determined in DBS, as discussed in Table II.A.1. Update until July 2013. 
Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Amphetamine Jantos & Skopp, 
2011 
LC-MS/MS 3.0 ng/ml 
5-50 ng/ml 
C: 100 µl (18 mm  punch covers 
complete spot) 
PAPER: Whatman 903 
EXTR: 1 ml 0.01M NaOH  LLE 
(ethylacetate) 
Intra- and 
interassay 
precision  
Linearity 
No carry-over 
Yes (venous DBS) 
(DRUID study) 
Cross-comparison 
with whole blood 
NS 
 Langel et al., 2011 GC-MS 20-2000 ng/ml C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 89.2% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ±40 ng/ml C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
LC-MS/MS 5-200 ng/ml P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: 97.4% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
Yes (venous DBS) 
(DUID) 
Cross-comparison 
with whole blood 
6 months at -20°C 
6 months at 4°C: ± 40% ↓ 
 Ambach et al., 2013 LC-MS/MS NS  
Screening technique  
LOD 5.0 ng/ ml 
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
RECOV: 95.2% 
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
LOD, extraction 
efficiency, 
stability 
Yes  
(venous DBS) 
2 w RT and 4°C  
MDMA, MDA Skopp et al., 2007 LC-MS/MS NS C: 100 µl 
PAPER: Whatman 903 
EXTR: 0.1M NaOH  LLE 
 
 
Precision 
Linearity 
No ion 
suppression 
Yes (venous) NS 
 Jantos & Skopp, 
2011 
Jantos et al., 2011a 
LC-MS/MS 5-40 & 50-400 ng/ml 
5.7 ng/ml (MDMA) 
0.25-3 & 2.5-30 ng/ml 
0.40 ng/ml (MDA) 
C: 100µl (18 mm  punch covers complete 
spot) 
PAPER: Whatman 903 
EXTR: 1 ml 0.01M NaOH  LLE 
(ethylacetate) 
RECOV: >85% (MDMA)     >95% (MDA) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
Yes (venous DBS) 
(DRUID study) 
Cross-comparison 
with whole blood 
NS 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
MDMA, MDA 
continued 
Langel et al., 2011 GC-MS 20-2000 ng/ml C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 90.9% (MDMA)     98.6% (MDA) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 2 ng/ml (MDMA) 
± 20 ng/ml (MDA) 
C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
LC-MS/MS 5-200 ng/ml P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: 101.6% (MDMA)     121.6% (MDA) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No 6 months at -20°C 
6 months at 4°C: ±25-30% ↓ 
 Thomas et al., 2012 LC-HRMS (0.5-20 ng/ml) 
(qualitative) 
C: 20 µl 
PAPER: Sartorius TFN 
EXTR: 100 µl MeOH + 400 µl TBME 
           300 µl acetone 
RECOV: 62% (MDMA)     78% (MDA) 
Precision 
Linearity 
No 7d at 4°C 
 Ambach et al., 2013 LC-MS/MS NS  
Screening technique  
LOD 2.5 ng/ ml 
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
RECOV: 87.6% (MDA) 
              96.4 % (MDMA) 
 
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
LOD, extraction 
efficiency, 
stability 
Yes  
(venous DBS) 
2 w RT and 4°C  
MDEA Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 2 ng/ml (MDEA) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
 5-200 ng/ml P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: NS 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No NS 
 
 
 
 
 
Ambach et al., 2013 
 
 
 
 
LC-MS/MS NS  
Screening technique  
LOD 1.0 ng/ ml 
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
               
 
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
Yes  
(venous DBS) 
2 w RT and 4°C  
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
MDEA 
continued 
Ambach et al., 2013 
continued 
 
LOD, extraction 
efficiency, 
stability 
Methamphetamine Langel et al., 2011 GC-MS 20-2000 ng/ml C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 87.3% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 50 ng/ml C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
LC-MS/MS 5 ng/ml 
5-200 ng/ml 
P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: 88.6% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
 
No 6 months at -20°C 
6 months at 4°C: ±40-50% ↓  
 Ambach et al., 2013 LC-MS/MS NS  
Screening technique  
LOD 1.0 ng/ ml 
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
RECOV: 98.3%  
        
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
LOD, extraction 
efficiency, 
stability 
Yes  
(venous DBS) 
2 w RT and 4°C  
Novel psychoactive 
substances (64) 
e.g. amphetamine and 
tryptamine derivatives, 
phenethylamines such as 
cathinones, piperazine 
derivatives 
Ambach et al., 2013 LC-MS/MS NS  
Screening technique  
LOD’s included for each 
compound  
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
 
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
LOD, extraction 
efficiency, 
stability 
Yes  
(venous blood) 
2 w RT and 4°C  
Cocaine, benzoylecgonine 
(BE), cocaethylene (CE) & 
ecgonine methylester 
(EME) 
Henderson et al., 
1993 
RIA 10-600 ng/ml (BE) P: 6.4 mm  
PAPER: Whatman 903 
EXTR: 18h in 200µl PBS:Tween20 
RECOV: >95% (BE) 
Intra- and 
interassay 
precision 
 
Yes 
(autopsy samples & 
newborn DBS) 
>1024h at 25, 45, 55°C (BE) 
108h at 45°C (cocaine) 
 Sosnoff et al., 1996 LC-MS/MS ± 2 -166 ng/ml (BE) P: 6.4 mm  (reconstituted blood) 
PAPER: NS 
EXTR: 200 µl 2mM CH3COONH4 
Linearity Yes (fingerprick from 
drug abusers) (DBS 
from new-borns & 
mothers) 
NS 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Cocaine, benzoylecgonine 
(BE), cocaethylene (CE) & 
ecgonine methylester 
(EME) continued 
Henderson et al., 
1997 
RIA, LC-MS / (BE) P: 6.4 mm  
Procedures of Henderson et al., 1993 & 
Sosnoff et al., 1996 
/ Yes 
(newborn DBS) 
/ 
 Alfazil & Anderson, 
2008 
LC-MS/MS 24.6 ng/ml 
50-2000 ng/ml 
(cocaine) 
C: 100 µl of reconstituted blood 
PAPER: Whatman 903 
EXTR: phosphate buffer (3.5 ml, pH6) 
RECOV: 90-97% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
 
No 1 month at -20°C & 4°C 
1 month at RT: 19.9% ↓ 
(DBS from spiked blood) 
 Mercolini et al., 
2010 
LC-FLUO 20-1000 ng/ml (cocaine & 
BE) 
12-1000 ng/ml 
(cocaethylene) 
C: 10 µl 
PAPER: Whatman 903 
EXTR: 500 µl methanol 
RECOV: 92-93%  
Intra- and 
interassay 
precision 
Linearity 
Selectivity 
Yes (fingerprick) 
(drug abusers) 
NS 
 Langel et al., 2011 GC-MS 50-1000 ng/ml (cocaine) C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 83.2% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 1 ng/ml 
(cocaine & BE) 
C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
LC-MS/MS 5-200 ng/ml 
(cocaine, BE, CE, EME) 
P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: 100% (cocaine), 99.4% (BE), 85.9% 
(EME) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
 
Yes (venous) (BE) 
(DUID) 
Cross-comparison 
with whole blood 
6 months at: 
-20°C (cocaine, BE, EME) 
4°C (BE) 
4°C: ±55% ↓ (cocaine) 
4°C: ±90% ↓ (EME) 
 Thomas et al., 2012 LC-HRMS 0.25 ng/ml 
(cocaine) 
C: 20 µl 
PAPER: Sartorius TFN 
EXTR: 100 µl MeOH + 400 µl TBME 
           300 µl acetone 
RECOV: 67% 
Precision 
Linearity 
No 7d at 4°C (cocaine) 
Benzodiazepines 
 
 
 
 
 
 
Alfazil & Anderson, 
2008 
 
 
 
 
 
LC-MS/MS 9.9 ng/ml (diazepam) 
15.8 ng/ml 
(flunitrazepam) 
11 ng/ml (lorazepam) 
18 ng/ml (nitrazepam) 
20.6 ng/ml (oxazepam) 
10.8 ng/ml (temazepam) 
C: 100 µl of reconstituted blood 
PAPER: Whatman 903 
EXTR: phosphate buffer (3.5 ml, pH6) 
RECOV: 83-99% (diazepam) 
             89-103% (flunitrazepam) 
               81-88% (lorazepam) 
               90-100% (nitrazepam) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No (DBS from spiked blood) 
1 month at -20°C 
1 month at 4°C 
1 month at RT: 
Diazepam: 12.3% ↓        
Flunitrazepam: 15% ↓ 
Lorazepam: 11% ↓; 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Benzodiazepines 
continued 
Alfazil & Anderson, 
2008 continued 
 
50-2000 ng/ml                95-106% (oxazepam) 
               89-94% (temazepam) 
Nitrazepam:  15.5% ↓ 
Oxazepam: 12% ↓ 
Temazepam: 15% ↓ 
 Havard et al., 2010 LC-MS/MS 100 pg/ml 
(midazolam) 
P: 4 mm  of 20 µl DBS Interassay 
precision 
No 1d at RT 
 Thomas et al, 2010  NS 
(diazepam, nordiaze-pam, 
oxazepam, oxa-zepam 
glucuronide) 
C: 5 µl (10 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: on-line extraction with ACN : 15 mM 
CH3COONH4 (97:3) 
No ion 
suppression 
No NS 
 Jantos & Skopp, 
2011 
 0.7 ng/ml 
2.5-50 ng/ml 
(alprazolam) 
C: 100µl (18 mm  punch covers complete 
spot) 
PAPER: Whatman 903 
EXTR: 1ml borate buffer (pH 8.5)  LLE 
Intra- and 
interassay 
precision  
Linearity 
No carry-over 
Yes (venous DBS) 
(DUID study) 
Cross-comparison 
with whole blood 
NS 
 Langel et al., 2011 GC-MS 5-250 ng/ml (lorazepam) 
5-500 ng/ml (alprazolam 
& clonazepam) 
10-1000 ng/ml 
(midazolam & 
nitrazepam) 
20-1000 ng/ml 
(phenazepam) 
20-2000 ng/ml 
(nordiazepam) 
50-1250 ng/ml 
(oxazepam) 
50-2500 ng/ml (diazepam) 
50-5000 ng/ml 
(temazepam) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV:   96.1% (alprazolam) 
92.3% (clonazepam) 
95.1% (diazepam) 
94.4% (lorazepam) 
92.0% (midazolam) 
88.2% (nitrazepam) 
96.6% (nordiazepam) 
94.3% (oxazepam) 
87.4% (phenazepam) 
96.4% (temazepam) 
 
Intra- and 
interassay 
Precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
 ± 0.1 ng/ml (prazepam) 
± 0.5 ng/ml (clobazam, 
flurazepam, midazolam, 
triazolam); ± 1 ng/ml 
(alprazolam, 7-
aminoflunitraze-pam, 
nitrazepam, nordiazepam, 
temazepam), ± 2 ng/ml 
(hydroxy-midazolam) 
± 5 ng/ml (flunitrazepam, 
lorazepam) 
± 10 ng/ml (clonazepam, 
diazepam, oxazepam) 
C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Benzodiazepines 
continued 
Déglon et al., 2012b LC-MS/MS 1ng/ml 
0.5-100 ng/ml 
(desmethylflunitraze-
pam, flurazepam, 
lormetazepam, triazolam) 
4 ng/ml 
2-500 ng/ml 
(alprazolam, hydroxy-
alprazolam, clonaze-pam, 
7-aminoclonazepam, 
desalkylflurazepam, 
flunitrazepam, 7-
aminofluitrazepam, 
lorazepam, midazo-lam, 
hydroxy-midazo-lam) 
40 ng/ml 
20-5000 ng/ml 
(clobazam, diazepam, 
nitrazepam, nordiaze-
pam, oxazepam, pra-
zepam, temazepam) 
C: 5 µl (6 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: 100 µl MeOH (in-vial extraction) 
RECOV:   79.6-85.3% (alprazolam) 
68.7-76.2% (hydroxyalprazolam) 
70.1-90.2% (clobazam) 
79.1-83.7% (clonazepam) 
58.6-61.9% (7-
aminoclonazepam) 
67.7-89.3% (diazepam) 
72.3-86.5% (flunitrazepam) 
56.3-68.8% (7-
aminoflunitrazepam) 
82.2-91.4% 
(desmethylflunitrazepam) 
51.9-70.2% (flurazepam) 
71.9-81.0% 
(desalkylflurazepam) 
69.2-78.0% (lorazepam) 
78.6-78.7% (lormetazepam) 
71.2-85.7% (midazolam) 
68.7-76.2% (hydroxymidazolam) 
72.2-93.4% (nitrazepam) 
76.6-88.4% (nordiazepam) 
72.2-93.4% (oxazepam) 
63.0-98.0% (prazepam) 
74.8-95.7% (temazepam) 
73.3-73.9% (triazolam) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
Ion suppression 
overall < 15% 
No carry-over 
Yes (venous DBS) 
DUID 
30d at -20°C & RT 
Zolpidem Hudson et al., 2011 LC-MS/MS (0.1-500 ng/ml) P: 3 mm  of 15 µl DBS 
PAPER: Bond Elut DMS 
EXTR: 300µl of 0.1% HCOOH in 80% MeOH 
RECOV: 102-110% 
 
Linearity No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 1 ng/ml (zolpidem) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Déglon et al., 2012b LC-MS/MS 4 ng/ml 
2-500 ng/ml (zolpidem) 
C: 5 µl (6 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: 100 µl MeOH (in-vial extraction) 
RECOV: 66.4-81.6% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No carry-over 
Yes (venous DBS) 
DUID 
30d at -20°C & RT 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Zopiclone and ACP (2-
amino-5-chloropyridine) 
Langel et al., 2011 GC-MS 10-1000 ng/ml 
(zopiclone) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 79.3% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 2 ng/ml (zopiclone) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Jantos and Skopp, 
2011 
Jantos et al., 2012 
LC-MS/MS 6.4 ng/ml 
(zopiclone) 
0.14 ng/ml 
(ACP) 
 
C: 100 µl 
PAPER: Whatman 903 
EXTR: 1 ml borate buffer (pH 8.5)  LLE 
RECOV: 67.1-79.7% (zopiclone) 
               80.4-83.8% (ACP) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
Yes (venous DBS) 
(DRUID study) 
Cross-comparison 
with whole blood 
Authentic & spiked DBS 
30d at -20°C 
22d at 4°C 
8d-30d at 20°C 
3d at 40°C 
 Déglon et al., 2012b LC-MS/MS 4 ng/ml C: 5 µl (6 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: 100 µl MeOH (in-vial extraction) 
RECOV: 61.6-67.2% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No carry-over 
No 30d at -20°C & RT 
Zaleplon Déglon et al., 2012b LC-MS/MS 4 ng/ml C: 5 µl (6 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: 100 µl MeOH (in-vial extraction) 
RECOV: 77.4-89.8% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No carry-over 
No 30d at -20°C & RT 
Ketamine and 
norketamine 
Moll et al., 2009 LC-MS/MS 5-2500 ng/ml 
5 ng/ml 
(ketamine & 
norketamine) 
P: 3.2 mm  from 19 µl spot 
PAPER: NS 
EXTR: MeOH/0.2M ZnSO4 (7:3)  dilute 
with H2O 
Precision & 
Accuracy 
No matrix 
interferences 
No carry-over 
No NS 
 Ambach et al., 2013 
(ketamine) 
LC-MS/MS NS  
Screening technique  
LOD 1.0 ng/ ml 
C: 10 mm  punch, 10 µl spotted 
PAPER: Bioanalysis cards 226 
EXTR: 500 µl MeOH 
RECOV: 96.3%  
               
For screening 
purposes: 
selectivity, 
specificity, 
matrix effect, 
LOD, extraction 
efficiency, 
stability 
 
 
Yes  
(venous blood) 
2 w RT and 4°C  
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
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Application 
Stability of DBS 
Gamma-hydroxybutyric 
acid (GHB) 
Forni et al., 2013 LC-MS/MS 1-128 µg/ml P: 3 x4.6 mm  
PAPER: Whatman 903 
EXTR: 200 µl MeOH 
RECOV: > 70 % 
Linearity 
Recovery 
Matrix effect 
Intra- and 
interday 
precision 
Yes 
(newborn DBS) 
NS 
 Ingels et al., 2010 GC-MS 2-100 µg/ml C: 50 µl 
PAPER: Whatman 903 
EXTR: on-spot derivatization with 100 µl 
TFAA  & HFB-OH (2:1) 
RECOV: / 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No carry-over 
 
Yes (venous DBS) 
(drug abuser) 
> 7d at RT 
> 14d at -20°C 
 Ingels et al., 2011 GC-MS 2-100 µg/ml P: 6 mm  
PAPER: Whatman 903 
EXTR: on-spot derivatization with 50 µl 
TFAA  & HFB-OH (2:1) 
RECOV: / 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
Effect of 
hematocrit, 
volume spotted, 
site of punching 
Yes (fingerprick) 
Cross-comparison 
with venous blood & 
DBS from venous 
blood 
> 148d at RT 
Opiates & metabolites: 
morphine, codeine, 6-
monoacetylmor-phine 
(6MAM), morphine 3-
glucuronide (M3G), 
morphine 6-glucuronide 
(M6G), oxycodone, 
noroxycodone, 
hydromorphone 
Skopp et al., 2007 LC-MS/MS NS C: 100µl 
PAPER: Whatman 903 
EXTR: 0.5% NH4OH  LLE 
NS No 6d at 4°C, RT & 40°C 
 Garcia Boy et al., 
2008 
LC-MS/MS 14 ng/ml (morphine) 
27 ng/ml (6MAM) 
50-500 ng/ml (morphine 
& 6MAM) 
C: 100 µl 
PAPER: Whatman BFC 180 
EXTR: 1ml 0.1M borate buffer (pH 8.5) 
RECOV: 23-37% (morphine) 
               76-86% (6MAM) 
Intra- and 
interassay 
precision 
Linearity 
No ion 
suppression 
No carry-over 
Yes (venous DBS) 
(drug abusers) 
Cross-comparison 
with whole blood 
10% ↓ in both morphine & 6MAM 
upon drying 
Morphine: 7d at 4°C, -20°C; 5d@ 
40°C 
6MAM: 5d at 40°C: ±50% ↓ 
 Thomas et al., 2010 LC-MS/MS NS 
Morphine, codeine and 
their glucuronides 
C: 5 µl (10 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: on-line extraction with ACN : 15 mM 
CH3COONH4 (97:3) 
No ion 
suppression 
No NS 
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Analyte  Analytical 
Technique 
LLOQ 
Assay Range 
Extraction (C = complete DBS / P = DBS 
punch) 
Recovery 
Analytical 
Validation 
Clinical 
Application 
Stability of DBS 
Opiates & metabolites 
continued 
Marin et al., 2010 LC-MS/MS 100 pg/ml 
(oxycodone) 
RECOV: ±85% NS No NS 
 Clavijo et al., 2011a 
 
LC-MS/MS 
 
1-1000 ng/ml (morphine 
& M3G) 
2.5-1000 ng/ml 
(M6G) 
P: 6.4 mm  from 50 µl spot 
PAPER: Whatman 903 
EXTR: 100 µl HPLC-water 
RECOV: 99.6-108.3% (morphine) 
              95.6-102% (M3G) 
              99.7-103.3% (M6G) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
Yes 
(Method used in 
pharmacokinetic 
studies) 
≥ 3 freeze-thaw cycles; 
≥ 3d at RT 
7d at 4°C, -20°C, -80°C 
 Jantos et al., 2011b LC-MS/MS NS (morphine, hydro-
morphone, oxycodo-ne, 
noroxycodone) 
C: 100 µl 
PAPER: Whatman 903 
NS Yes (venous DBS) 
Cross-comparison 
with whole blood 
NS 
 Langel et al., 2011  10-1000 ng/ml (morphine 
& codeine) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 50% (morphine) 
               >75 % (codeine) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ±20 ng/ml (morphine) 
± 5 ng/ml (codeine) 
± 1 ng/ml (6MAM, 
hydrocodone) 
C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Saussereau et al., 
2012 
LC-MS/MS 5-200 ng/ml 
(morphine, codeine) 
10-200 ng/ml 
(M3G & M6G) 
P: 3 mm  of 30 µl DBS 
PAPER: Whatman 903 
EXTR: 150 µl H2O 
RECOV: 90% (morphine) 
               93.2% (codeine) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
Yes (venous DBS) 
Cross-comparison 
with whole blood 
(morphine) 
6 months at -20°C 
 Mommers et al., 
2013 
LC-MS/MS 4-1000 ppb morphine P: 3 mm   
PAPER: Whatman 903 
EXTR: 100 µl MeOH-H2O (1:9) 
 
Linearity 
Precision 
Accuracy 
No NS 
Buprenorphine and 
metabolites 
Thomas et al., 2010 
 
LC-MS/MS NS 
Buprenorphine, 
norbuprenorphine and 
their glucuronides 
C: 5 µl (10 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: on-line extraction with ACN : 15 mM 
CH3COONH4 (97:3) 
No ion 
suppression 
Yes 
(animal study) 
 
NS 
 Marin et al., 2010 LC-MS/MS NS (>25 pg/ml) RECOV: ±45% NS No NS 
 
 
 
Langel et al., 2011 
 
 
GC-MS 5-100 ng/ml 
(buprenorphine) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
Inter- and 
intraday 
precision 
No NS 
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Buprenorphine and 
metabolites continued 
Langel et al., 2011 
continued 
2 ml Butylacetate 
RECOV: 49.8% 
Accuracy 
Linearity 
 Lauer et al., 2011 LC-MS/MS NS C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
Methadone and 
metabolites 
Clavijo et al., 2010 LC-MS/MS 0.1-100 ng/ml 
(methadone, EDDP, 
EMDP) 
P: 6.4 mm  from X µl spot 
PAPER: Whatman 903 
EXTR: 100 µl HPLC water  PP 
RECOV: NS 
Precision & 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
No NS 
 Langel et al., 2011 GC-MS 10-1000 ng/ml 
(methadone) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 78.5% 
Inter- and 
intraday 
precision 
Accuracy 
Linearity 
No NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 1 ng/ml (methadone) 
± 5 ng/ml (EDDP) 
C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS NS NS 
 Addolorata 
Saracino et al., 
2012 
LC-
Coulometry 
4-500 ng/ml (on-column 
concentration) 
C: Theoretical volume calculated from  
PAPER: Whatman FTA® classic 
EXTR: 250 µl phosphate buffer: CH3CN 
(20:80) & 250 µl phosphate buffer 
RECOV: 90.1-94.8% 
Inter- and 
intraday Prec 
Linearity 
Yes (fingerprick) 
(methadone 
maintenance 
patients) 
Cross-comparison 
with plasma 
1 month at RT (methadone) 
(patient samples) 
Fentanyl and metabolites Clavijo et al., 2011b LC-MS/MS 0.1 - 100 ng/ml (fentanyl) 
0.25-100 ng/ml 
(norfentanyl & 
despropionylfentanyl) 
P: 6.4 mm  from 50 µl spot 
PAPER: Whatman 903 
EXTR: 100 µl HPLC-water 
RECOV: 78, 75, 77% for resp. fentanyl, 
norfentanyl and despropionylfentanyl 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
Yes 
(pharmacokinetic 
study in neonates & 
children) 
DBS from spiked blood 
6d at -20°C & -80°C 
3d at RT (all 3 analytes) 
5d at RT (fentanyl) 
 
 Jantos et al., 2011b LC-MS/MS NS (fentanyl & 
norfentanyl) 
C: 100 µl 
PAPER: Whatman 903 
NS Yes (venous DBS) 
Cross-comparison 
with whole blood 
NS 
 Lauer et al., 2011 
Déglon et al., 2012a 
LC-MS/MS ± 0.2 ng/ml (fentanyl) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS NS NS 
Tramadol 
 
 
 
Langel et al., 2011 
 
 
 
GC-MS 50-5000 ng/ml C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
Inter- and 
intraday 
precision 
Accuracy 
No NS 
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Tramadol 
continued 
Langel et al., 2011 
continued 
RECOV: 78% Linearity 
 Déglon et al., 2012a LC-MS/MS ± 0.5 ng/ml (Tramadol) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS NS NS 
Tetrahydrocannabinol and 
metabolites 
Thomas et al., 2010 LC-MS/MS NS 
THC, carboxy-THC and its 
glucuronide, 11-OH-THC 
C: 5 µl (10 mm  punch covers complete 
spot) 
PAPER:Whatman 903 
EXTR: on-line extraction with ACN : 15 mM 
CH3COONH4 (97:3) 
No ion 
suppression 
No NS 
 Langel et al., 2011 GC-MS 5-100 ng/ml (THC) 
5-500 ng/ml (THC-COOH) 
C: 100 µl 
PAPER: NS 
EXTR: saturated borate buffer (pH 10) and 
2 ml Butylacetate 
RECOV: 41.2% (THC) 
              32.2% (THC-COOH) 
Inter- and 
intraday 
precision 
Accuracy 
Linearity 
No NS 
 Déglon et al., 2012a LC-MS/MS ± 50 ng/ml (THC) C: 5 µl 
PAPER: NS 
EXTR: 100% MeOH (on-line extraction) 
NS No NS 
 Thomas et al., 2012 LC-HRMS 1 ng/ml (THC & THC-
COOH) 
C: 20 µl 
PAPER: Sartorius TFN 
EXTR: 100 µl MeOH + 400 µl TBME 
           300 µl acetone 
RECOV: 19% (THC) 
               36% (THC-COOH) 
Precision & 
Accuracy 
Linearity 
No 7d at 4°C 
 Mercolini et al., 
2013 
LC-MS/MS 2.5-2000 ng/ml (THC) 
5-2000 ng/ml (THC-OH & 
THC-COOH) 
!! [ ]’s are those in a 
MeOH solution spiked to 
the DBS 
C: 10 mm  punch 
PAPER: Whatman 903 
EXTR: 1 ml MeOH 
RECOV: 81-86% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
Yes (venous DBS) 3 months at RT 
Cotinine Spector et al., 2007 GC-MS NS ¼ of filled (± 200 µl) circle  ± 50 µl 
EXTR: 500 µl 0.2 M NaOH 
NS Yes 
(newborn DBS) 
NS 
 Murphy et al., 2013 
(cotinine and trans 
3’-hydroxycotinine) 
LC-MS/MS 0.3-102 ng/g cotinine P: 3.2 or 4.6 mm   
PAPER: Ahlstrom 226 
EXTR: 400 µl HPLC-water 
SPE: Oasis MCX 96-well plate 
Linearity 
Intra-day 
precision 
Yes  
(plasma) 
NS 
Ethylglucuronide – 
ethylsulfate 
 
 
Hernàndez 
Redondo et al., 
2011 
 
LC-MS/MS 0.1-10 µg/ml P: 5 mm  
PAPER: NS 
EXTR: methanol 
Intra- and 
interassay 
precision 
Accuracy 
No 3 weeks at 4°C 
3 weeks at RT: ± 20% ↓ 
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Ethylglucuronide – 
ethylsulfate  
continued 
Hernàndez 
Redondo et al., 
2011 continued 
Linearity 
Effect of volume 
spotted, site of 
punching 
Phosphatidylethanol 
(Peth) 
Faller et al., 2011 
Faller et al., 2012 
 
LC-MS/MS 22.7 ng/ml (PEth 
18:1/18:1) 
87.3 ng/ml (PEth 
16:0/18:1) 
50-5000 ng/ml 
C: 100 µl 
PAPER: Whatman 903 
EXTR: 400 µl 0.5M CH3COONa (pH5) + 600 
µl isopropanol + 700 µl n-hexane  LLE 
RECOV: 26.6-42.5% (PEth 18:1/18:1) 
              68.9-90.7% (PEth 16:0/18:1) 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
No ion 
suppression 
No carry-over 
 
Yes 
(subjects in alco-hol 
detoxification 
program) 
Cross-comparison 
with whole blood 
> 30d at -20°C & 20°C 
 Jones et al., 2011 LC-MS/MS 8 ng/ml (PEth 16:0/18:1) P: 3 X 3.2 mm  
PAPER: Whatman 903 
EXTR: 50 µl 2mM CH3COONH4/CH3CN 
/Isopropanol (20:58:22) + 500 µl MeOH 
RECOV: 56.0-82.9% 
Intra- and 
interassay 
precision 
Accuracy 
Linearity 
Significant 
matrix effect 
(>40%) 
No carry-over 
Yes 
Cross-comparison 
with whole blood 
No ex vivo de novo formation 
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Appendix 2 Overview per patient of the sodium oxybate dose which was taken at bedtime, the measured 
GHB concentrations, the time between sodium oxybate intake and DBS collection, the number of usable DBS 
and remarks. If at least 2 DBS on a DBS card had acceptable quality (№ usable DBS ≥ 2), analysis was 
performed in duplicate (n= 2 DBS) and the result of the 2 measurements is reported (table GHB conc (µg/ml)). 
The remaining DBS were kept for eventual re-analysis. If only one DBS was considered suitable for analysis (№ 
usable DBS =1), that DBS was analyzed, and only that single result is given (table GHB conc (µg/ml)). If there 
were no DBS with acceptable quality provided (№ usable DBS =0), no analysis could be performed.  
 
 
 
Patient 1 
4.50 g 
(53.6 mg/kg b.w.) 
GHB conc 
(µg/ml) 
Δ time (min) 
sodium oxybate 
intake-DBS 
collection 
№ usable DBS Remarks 
Day 1 
 
32.6 
35.2 
20 
 
4  
Day 2 
 
42.9 
41.9 
15 3  
Day 3 
 
39.1 
40.9 
20 4  
Day 4 
 
19.9 
28.3 
30 4  
Day 5 
 
25.7 
 
20 2 
 
At morning: 20.2 µg/ml 
Day 6 
 
68.1 
61.2 
20 4  
Day 7 
 
51.0 
44.0 
20 4  
Patient 2 
 
GHB conc 
(µg/ml) 
Δ time (min) 
sodium oxybate 
intake-DBS 
collection 
№ usable DBS  Remarks 
Series 1 
3.75 g   
 (75.0 mg/kg b.w.) 
Day 1 
 
54.9 17 1  
Day 2 
 
20.7 25 1  
Day 3 
 
103.8 20 1  
Day 4 
 
  0  
Day 5 
 
49.1 17 1  
Day 6 
 
19.2 15 1  
Day 7 112.7 18 1  
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Series 2 
3.75 g 
(75.0 mg/kg b.w.) 
Day 1 
 
49.2 
57.5 
20 
 
4 Long sleep, slept well 
1.16 am until 4.53 am 
Day 2 
 
48.7 
50.1 
25 4 Slept normal 
0.30 am until 3.25 am 
Day 3 201 15 1 Short sleep, tired again shortly after – 
5.00 am until 6.30 am 
DBS collected after 2nd dose 
Day 4 
 
132 
117 
20 3 Slept not enough and badly 
0.20 am until 2.45 am 
Day 5 
 
152 
136 
20 3 
 
Slept not enough and badly 
1.10 am until 3.50 am 
Day 6 
 
150 
173 
20 2 Slept not enough and badly 
0.05 am until 2.30 am 
Day 7 
 
55.5 15 1 Slept not long, but good 
3.50 am until 6.30 am 
DBS collected after 2nd dose 
Patient 3 
 
 
GHB conc 
(µg/ml) 
Δ time (min) 
sodium oxybate 
intake-DBS 
collection 
 
№ usable DBS 
 
Remarks 
Series 1 
4.50 g 
(41.3 mg/kg b.w.) 
Day 1 86.7 30 1  
Day 2 
 
88.1 
82.7 
30 
 
2 
 
 
Day 3 
 
51.8 
53.4 
30 
 
4  
Day 4 
 
43.0 
41.7 
30 4  
Day 5    Stayed unexpectedly with his parents 
Day 6 
 
68.2 
63.0 
30 
 
3  
Day 7 
 
56.4 
57.5 
30 
 
4  
Series 2 
4.50 g 
(40.9 mg/kg b.w.) 
Day 1 
 
82.7 
74.2 
20 
 
3  
Day 2 
 
64.0 
54.5 
20 3  
Day 3 
 
81.8 
81.7 
20 4  
Day 4 
 
61.9 
61.1 
20 4  
Day 5 
 
9.10 
8.17 
20 4 
 
Unexplainable low GHB conc 
Day 6 
 
86.5 
94.9 
20 4  
Day 7    Used all the material   
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SUMMARY 
 
The aim of this work was to quantify the low molecular weight compound and drug of abuse 
gamma-hydroxybutyric acid (GHB) in various biological matrices using gas-chromatography 
coupled to mass spectrometry (GC-MS). The structure of GHB requires chemical modification and 
we chose to derivatize GHB to enhance volatility, to improve the chromatographic properties and 
to increase detection sensitivity. Since derivatization typically results in an additional step during 
sample treatment, we aimed to develop one-step sample preparation procedures based on direct 
derivatization techniques.  
In PART I of this thesis, a brief background on GHB is provided, including an overview of its 
chemical properties, metabolization, use, abuse, effects, adverse effects and current legal status 
(Chapter I.A). Chapter I.B provides an in-depth overview of screening and confirmation techniques 
used for GHB in biofluids.  
In the second part (PART II) of this work, the development of an accurate and sensitive method for 
the GC-MS-based determination of GHB in dried whole blood samples is presented. A dried blood 
spot (DBS) is capillary whole blood obtained by a finger or heel prick and collected on a filter paper. 
DBS sampling has generally been used for newborn screening. However, more recently this 
alternative sampling strategy is increasingly receiving interest in the context of e.g. therapeutic 
drug monitoring (TDM), (pre)clinical studies, pharmacokinetics and toxicology. An overview of the 
use of DBS in toxicology, with a focus on the determination of drugs of abuse, is presented in 
Chapter II.A. The DBS sampling technique ensures an easy and rapid collection of a representative 
sample without specific handling or storage requirements. This is of interest for GHB, which is 
rapidly metabolized following ingestion (hence, rapid sampling is an advantage) and which is 
subject to storage issues (de novo formation).  
Since GHB requires chemical modification prior to GC analysis and derivatization is generally 
experienced as laborious and tedious, we opted to directly derivatize GHB in DBS, setting-up a 
quick and efficient sample treatment procedure. As summarized in Chapter II.B, if derivatization of 
the DBS sample is necessary, a DBS sample treatment procedure generally starts with extraction, 
followed by evaporation of (an aliquot of) the extraction solvent under a stream of nitrogen before 
adding the derivatization reagent(s). Then, the excess reagent is removed and finally the 
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redissolved or reconstituted derivatized extract is ready to be injected. Modifications of this 
general scheme have been described, e.g. the sample can be injected directly after the 
derivatization step. Another convenient DBS treatment procedure is obtained by direct 
derivatization, thus by applying extraction solvents and derivatization reagents simultaneously to 
the DBS, or even by adding only the derivatization reagents “on spot” without the use of any 
extraction solvent. The latter approach was chosen for method development. 
Chapter II.C.1 and II.C.2 describe the optimization of the complete procedure for quantitative 
analysis of GHB in DBS, with special attention to the sample treatment, followed by method 
validation. First, DBS of 50 µl were prepared and, after addition of internal standard GHB-d6, these 
were directly derivatized (“on spot”) using 100 µl of a freshly prepared mixture of trifluoroacetic 
acid anhydride (TFAA) and heptafluorobutanol (HFB-OH) (2:1). Following drying and reconstitution 
in ethylacetate, the derivatized extract was injected into a GC-MS, operating in the electron impact 
mode (EI), with a total run time of 12.3 min. Method validation included the evaluation of linearity, 
precision, accuracy, sensitivity, selectivity and stability. A weighting factor of 1/x
2
 was chosen and 
acceptable intra-batch precision, inter-batch precision and accuracy were seen. The linear 
calibration curve ranged from 2 to 100 µg/ml, with a limit of detection of 1 µg/ml.  
As we also wished to collect DBS in a real-life setting, a more convenient approach than the use of 
precision capillaries is the collection of the drops of blood directly on the filter paper. The 
adjustment of the first method to enable the analysis of a fixed area (6-mm DBS punch) instead of 
a fixed volume (50-µl DBS) is presented in Chapter II.C.3. Punching out a disc requires the 
investigation of the impact of additional parameters such as the influence of the volume spotted, 
of the punch localization and of the hematocrit (Ht). Method validation included the evaluation of 
linearity, precision, accuracy, sensitivity, dilution integrity, selectivity and stability. The best blood 
volume spotted was between 20 and 35 µl, regardless of the Ht of the blood sample. Furthermore, 
a homogenous distribution of GHB in DBS was demonstrated. The 6-point calibration curve ranged 
from 2 to 100 µg/ml with a limit of detection of 1 µg/ml. QC samples (2, 10 and 100 µg/ml) were 
prepared separately in whole blood with low (0.38), intermediate (0.45) and high (0.50) Ht. A 
weighting factor of 1/x
2
 was chosen and overall acceptable precision (% RSD between 3.8 and 14.8) 
and accuracy were obtained (% bias between 1.2 and 12.2). GHB appeared to be stable in DBS 
stored at RT for at least 148 days. In 24 cases, a suspected GHB-intoxication was successfully 
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confirmed by DBS analysis, suggesting the routine applicability of the DBS sampling technique for 
GHB analysis in toxicological cases.   
Chapter II.C.4 presents an exploratory study set up to measure GHB concentrations in DBS 
collected by narcoleptic patients who use the sodium salt of GHB (sodium oxybate, Xyrem®). The 
applicability of the developed DBS-based GC-MS method was evaluated, as well as the feasibility of 
the sampling technique in an ambulant setting. Therefore, 7 narcoleptic patients being treated 
with sodium oxybate at the department for Respiratory Diseases of Ghent University Hospital were 
asked to collect DBS approximately 20 min after the first sodium oxybate intake during a maximum 
of 7 consecutive days. Using an automatic lancet, patients pricked their fingertip and collected 
blood drops on a DBS card. The DBS cards were sent to the laboratory by regular mail and, before 
analysis, were visually inspected to record DBS quality (large enough, symmetrically spread on the 
filter paper with even coloration on both sides of the filter paper). In total, 5 series of DBS were 
obtained from 3 patients. Analyzing the DBS in duplicate resulted in acceptable within-DBS card 
precision and DBS with acceptable quality were obtained by patients without supervision.  
 
The third part of this work (PART III) describes the development of a headspace-trap (HS-trap) GC-
MS method to determine GHB in various biological fluids. Following a brief description of 
headspace injection techniques, with a focus on headspace-trap and its applications found in 
literature (Chapter III.A), the development of the HS-trap method is presented (Chapter III.B). 
Following optimization of headspace conditions and trap settings, validation was performed. 
Although sample preparation only consists of the addition of salt and derivatization reagents 
directly to a 100 µl-sample in a HS-vial, adequate method sensitivity and selectivity was obtained. 
Calibration curves ranged from 5 to 150 µg/ml GHB for urine, from 2 to 150 µg/ml for plasma, and 
from 3.5 to 200 µg/ml for whole blood. Acceptable precision and accuracy (<13 % bias and 
imprecision) were seen for all quality controls (lower limit of quantification-level, low, medium, 
high), including for the supplementary serum- and lyzed blood-based QC’s, using calibration curves 
prepared in plasma or whole blood, respectively.  
 
To conclude (PART IV), procedures to determine GHB in microvolumes (≤ 100 µl) of biofluids have 
successfully been developed, validated and applied. The novel approach of direct “on spot” 
derivatization, followed by analysis with GC-MS, proved to be reliable, fast and applicable in 
routine toxicology for the analysis of both volumetrically applied DBS as for analysis of discs 
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punched out from DBS. Furthermore, results of an exploratory study in patients treated with 
Xyrem® (the sodium salt of GHB, sodium oxybate) demonstrated the acceptable precision of the 
complete procedure, from sampling at home to quantitative analysis in the laboratory. Given the 
intra- and inter-individual variability in clinical effects seen with sodium oxybate, the easy 
adaptation of DBS sampling opens the possibility of following up GHB concentrations in patients in 
real-life settings in future studies. A second one-step procedure, using HS-trap, has been 
successfully developed and validated to determine GHB in various biofluids. Combining this 
relatively novel and fully automated headspace technique with “in-vial” methylation of GHB 
allowed for a straightforward approach. One single method could be used for all biofluids (urine, 
plasma, serum, whole blood or lyzed blood). Moreover, our approach involves mere addition of all 
reagents and sample into one vial. Incurred sample reanalysis demonstrated assay reproducibility, 
while cross-validation with another GC-MS method demonstrated that our method is a valuable 
alternative for GHB determination in toxicological samples, with the advantage of requiring only 
100 µl and minimal hands-on time, as sample preparation is easy and injection automated. 
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SAMENVATTING 
 
Dit werk had als doel om gamma-hydroxyboterzuur (GHB), een laag-moleculair-
gewichtscomponent die misbruikt wordt als drug, op te sporen en te kwantificeren in 
verscheidene biologische matrices, hierbij gebruik makend van gas chromatografie gekoppeld aan 
massa spectrometrie (GC-MS). Gezien GHB chemisch gemodificeerd dient te worden om de 
vluchtigheid, chromatografische eigenschappen en detectiegevoeligheid te verbeteren, kozen we 
voor derivatisatie van GHB. Het includeren van een derivatisatiestap betekent echter veelal een 
verlenging van de staalvoorbereiding. Daarom was het ook onze doelstelling één-staps 
staalvoorbereidingsprocedures te ontwikkelen door het gebruik van directe derivatisatie.  
 
In het eerste deel van dit werk, PART I, wordt algemene informatie omtrent GHB weergegeven. 
Meer bepaald worden in Chapter I.A. de chemische eigenschappen, metabolisatie, gebruik, 
misbruik, effecten en neveneffecten kort beschreven. Vervolgens wordt informatie gegeven over 
de wetgeving omtrent GHB. Het tweede hoofdstuk van dit deel, Chapter I.B, geeft een 
gedetailleerd overzicht van screenings- en bevestigingstechnieken toegepast voor GHB in 
biologische vloeistoffen.  
 
Het tweede deel, PART II, beschrijft de ontwikkeling van een accurate en gevoelige methode voor 
de bepaling van GHB in gedroogde bloedspots (DBS) gebruik makend van GC-MS. Een gedroogde 
bloedspot is capillair bloed verkregen door de vingertip of de hiel te prikken en de bloeddruppels 
te verzamelen op een filterpapier. Deze manier van staalafname wordt reeds een 50-tal jaar 
gebruikt voor de screening bij pasgeborenen op zeldzame metabolische stoornissen (newborn 
screening). Meer recent is er een toegenomen interesse om deze alternatieve staalafname ook te 
gebruiken in bijvoorbeeld therapeutische drug monitoring, in (pre)klinische studies, voor 
farmacokinetiek en in de toxicologie. Een overzicht van het gebruik van DBS in het domein van de 
toxicologie, met bijzondere aandacht voor de bepaling van drugs in DBS, wordt gegeven in Chapter 
II.A. Deze wijze van staalafname maakt een eenvoudige en snelle afname van een representatief 
staal mogelijk, vaak zonder specifieke behandelings- of bewaringsvereisten. Dit is in het bijzonder 
van belang voor GHB. Het wordt snel gemetaboliseerd na orale inname en bijgevolg biedt een 
snelle en eenvoudige staalafname voordelen. Bovendien is GHB gevoelig voor wijzigingen in 
concentratie tijdens bewaring (de novo vorming).  
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Zoals vermeld vereist de structuur van GHB een chemische modificatie om GC analyse mogelijk te 
maken. Omdat implementatie van derivatisatie bij staalvoorbereiding in het algemeen een 
significante verhoging van de werklast met zich meebrengt, kozen we voor een directe 
derivatisatie van GHB in DBS. Deze aanpak resulteerde in een snelle en efficiënte 
staalvoorbereiding. Zoals beschreven in Chapter II.B begint, indien derivatisatie van de 
componenten die men wenst te bepalen in DBS nodig is, de staalvoorbereiding in het algemeen 
met een extractie, gevolgd door het droogdampen van (een deel van) het extractiesolvent m.b.v. 
stikstof alvorens de gewenste derivatisatiereagentia toe te voegen. Vervolgens wordt de overmaat 
reagens verwijderd en kan het staal, na (her)oplossen van het residu in een geschikt solvent, 
geïnjecteerd worden. Verschillende wijzigingen van deze algemene procedure zijn beschreven, 
zoals o.a. directe injectie van het staal na derivatisatie. Ook het simultaan toevoegen van 
extractiesolventen en derivatisatiereagentia aan de DBS of zelfs van de derivatisatiereagentia 
alleen (“on spot” zonder het gebruik van extractiesolventen), vereenvoudigt de staalvoorbereiding. 
Deze laatste strategie werd gevolgd bij onze methodeontwikkeling  
 
Chapter II.C.1 en II.C.2 beschrijven de optimalisatie van de volledige procedure voor de 
kwantitatieve bepaling van GHB in DBS, met speciale aandacht voor de staalvoorbereiding, gevolgd 
door methode validatie. Eerst werden DBS van 50 µl bereid en na de toevoeging van de interne 
standaard GHB-d6, werden deze direct gederivatiseerd (“on spot”) m.b.v. 100 µl van een vers 
bereid mengsel van trifluoroazijnzuur anhydride (TFAA) en heptafluorobutanol (HFB-OH) (2:1). Na 
drogen en (her)oplossen in ethylacetaat werd het gederivatiseerde extract geanalyseerd met GC-
MS, in de elektron impact mode (EI), met een totale looptijd van 12,3 min. Voor methode validatie 
werden lineariteit, precisie, accuraatheid, gevoeligheid, selectiviteit en stabiliteit geëvalueerd. Een 
weegfactor van 1/x
2
 werd gekozen en aanvaardbare intra- en inter-batch precisie werden 
bekomen samen met voldoende accuraatheid. De lineaire calibratiecurve had een bereik van 2 tot 
100 µg/ml, met een detectielimiet van 1 µg/ml.  
 
Omdat we ook op een meer praktische manier DBS wilden verzamelen, werd de eerste methode 
aangepast om ook bloeddruppels (rechtstreeks verzameld van de vingertip op een filterpapier) te 
kunnen analyseren op de aanwezigheid van GHB. Bijgevolg diende onze methode aangepast te 
worden zodat een bepaalde oppervlakte (schijfje met 6 mm diameter) geanalyseerd kon worden in 
plaats van een vast volume (50 µl). Dit wordt beschreven in Chapter II.C.3. Analyse van een schijfje 
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uit een volledige DBS vereist bijkomend de evaluatie van de impact van parameters zoals de 
invloed van het DBS volume, de plaats van afzonderen en het hematocriet (Ht) op het bekomen 
resultaat. Voor methode validatie werden lineariteit, precisie, accuraatheid, mogelijkheid tot 
verdunnen, gevoeligheid, selectiviteit en stabiliteit geëvalueerd. Het optimale volume bloed 
aangebracht op het filterpapier ligt tussen 20 en 35 µl, ongeacht de hematocrietwaarde van het 
staal. Bovendien werd een homogene verdeling van GHB in DBS aangetoond. De calibratiecurve, 
opgebouwd uit 6 punten, had een bereik van 2 tot 100 µg/ml met een detectielimiet van 1 µg/ml. 
Stalen voor de kwaliteitscontrole (QC stalen) (2, 10 en 100 µg/ml) werden afzonderlijk 
klaargemaakt in bloed met laag (0,38), intermediair (0,45) en hoog (0,50) Ht. Een weegfactor van 
1/x
2
 werd gekozen en in het algemeen werden een aanvaardbare intra- en inter-batch precisie en 
accuraatheid bekomen. GHB was stabiel in DBS bewaard bij kamertemperatuur gedurende 148 
dagen. Tevens werd een vermoedelijke GHB-intoxicatie bevestigd in 24 patiënten gebruik 
makende van DBS analyse, wat de routinematige toepasbaarheid van een DBS staalafname voor 
de analyse van GHB in toxicologische casussen aantoont.  
 
Chapter II.C.4 beschrijft een exploratieve studie die werd opgezet om GHB concentraties te 
bepalen in DBS aangemaakt door patiënten die het natrium zout van GHB (natrium oxybaat, 
Xyrem®) gebruiken voor de behandeling van narcolepsie met kataplexie. De toepasbaarheid van 
onze nieuw ontwikkelde GC-MS methode en de geschiktheid van de DBS staalafnametechniek in 
ambulante omstandigheden werden geëvalueerd. Aan 7 patiënten behandeld op de afdeling 
longaandoeningen van het UZ Gent werd gevraagd DBS aan te maken ongeveer 20 min na de 
eerste inname van natrium oxybaat en dit gedurende maximum 7 opeenvolgende dagen. M.b.v. 
een automatisch lancet konden de patiënten hun vingertip prikken om vervolgens bloeddruppels 
te verzamelen op een DBS kaart. Deze DBS kaarten werden verstuurd naar het laboratorium en 
werden vóór analyse geïnspecteerd op kwaliteit (groot genoeg, symmetrische spreiding en 
roodkleuring aan beide zijden van het papier). In totaal werden 5 reeksen DBS verkregen van 3 
patiënten. Het analyseren van de DBS in duplicaat resulteerde in aanvaardbare binnen-DBS kaart 
precisie en DBS met aanvaardbare kwaliteit werden aangemaakt door de patiënten zonder enige 
supervisie. 
 
Het derde deel van dit werk (PART III) beschrijft de ontwikkeling van een headspace-trap (HS-trap) 
GC-MS methode voor de bepaling van GHB in verschillende biologische vloeistoffen. Na een korte 
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beschrijving van de bestaande HS injectie technieken, met de focus op HS-trap en diens 
gepubliceerde toepassingen (Chapter III.A), wordt de ontwikkeling van de HS-trap methode 
beschreven (Chapter III.B). Na optimalisatie van de HS condities en trap instellingen werd de 
methode gevalideerd. Hoewel de staalvoorbereiding enkel de directe toevoeging van zout en 
derivatisatiereagentia aan 100 µl van een staal in een HS-vial omvat, werden adequate methode 
gevoeligheid en selectiviteit verkregen. Calibratiecurves hadden een bereik van 5 tot 150 µg/ml 
GHB voor urine, van 2 tot 150 µg/ml voor plasma, en van 3,5 tot 200 µg/ml voor bloed. 
Aanvaardbare precisie en accuraatheid werden verkregen voor alle QC stalen (niveau van de 
kwantificatielimiet, laag, medium, hoog), inclusief voor QC stalen bereid in serum en gelyseerd 
bloed, waarvoor calibratiecurves aangemaakt in respectievelijk plasma of bloed werden toegepast.  
 
Tot slot (PART IV) kan er geconcludeerd worden dat in dit werk procedures voor de bepaling van 
GHB in microvolumes (≤ 100 µl) van biologische vloeistoffen werden ontwikkeld en gevalideerd. De 
nieuwe aanpak van “on spot” derivatisatie, gevolgd door analyse met GC-MS, bleek betrouwbaar, 
snel en toepasbaar in routine toxicologie voor de analyse van GHB in zowel volumetrisch 
aangemaakte DBS als in 6-mm schijfjes uit DBS. Daarenboven tonen de resultaten aan dat de 
volledige procedure – van de staalafname thuis tot en met de kwantitatieve analyse in het 
laboratorium – met aanvaardbare precisie kan worden uitgevoerd. Gezien de intra- en inter-
individuele variatie in klinische effecten bij het gebruik van natrium oxybaat, zou de introductie 
van staalafname via de DBS techniek in de toekomst de opvolging van GHB concentraties mogelijk 
kunnen maken in ambulante omstandigheden.  
 
Een tweede één-staps procedure voor de bepaling van GHB in verschillende biologische 
vloeistoffen werd succesvol ontwikkeld en gevalideerd gebruik makend van de HS-trap 
injectietechniek. Het combineren van deze relatief nieuwe en volledig automatische HS techniek 
met “in-vial” methylering van GHB, resulteerde in een uiterst eenvoudige procedure. Eenzelfde 
methode kon gebruikt worden voor alle onderzochte biologische vloeistoffen (urine, plasma, 
serum, bloed en gelyseerd bloed). Bovendien houdt onze aanpak enkel de toevoeging in van alle 
reagentia aan één vial. Herhaalde analyse van stalen toonde de reproduceerbaarheid aan van de 
ontwikkelde methodologie, terwijl cross-validatie met een andere GC-MS methode aangaf dat 
onze methode een waardig alternatief is voor de bepaling van GHB in toxicologische stalen. Deze 
methode heeft bovendien als voordelen dat er slechts 100 µl staal nodig is en dat ze minimale 
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manuele handelingen vereist, waarbij eenvoudige staalvoorbereiding en automatische injectie 
mogelijk zijn.  
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